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FUNCTIONAL STUDY OF THE THREONINE PHOSPHORYLATION AND THE
TRANSCRIPTIONAL COACTIVATOR ROLE OF P68 RNA HELICASE

by

HEENA T. DEY

Under the Direction of Zhi-Ren Liu

ABSTRACT

P68 RNA helicase is a RNA helicase and an ATPase belonging to the DEAD-box
family. It is important for the growth of normal cells, and is implicated in diverse
functions ranging from pre-mRNA splicing, transcriptional activation to cell proliferation,
and early organ development. The protein is documented to be phosphorylated at
several amino-acid residues. It was previously demonstrated in several cancer cell-lines
that p68 gets phosphorylated at threonine residues during treatments with TNF-α and

TRAIL. In this study, the role of threonine phosphorylation of p68 under the treatment of
anti-cancer drug, oxaliplatin in the colon cancer cells is characterized. Oxaliplatin
treatment activates p38 MAP-kinase, which subsequently phosphorylates p68 at T564
and/or T446. P68 phosphorylation, at least partially, influences the role of the drug on
apoptosis induction. This study shows an important mechanism of action of the anticancer drug which could be used for improving cancer treatment.
This study also shows that p68 is an important transcriptional regulator regulating
transcription of the cytoskeletal gene TPPP/p25. Previous analyses revealed that p68
RNA helicase could regulate expression of genes responsible for controlling stability
and dynamics of different cytoskeletons. P68 is found to regulate TPPP/p25 gene
transcription by associating with the TPPP/p25 gene promoter. Expression of TPPP/p25
plays an important role in cellular differentiation while the involvement of p68 in the
regulation of TPPP/p25 expression is an important event for neurite outgrowth. Loss of
TPPP expression contributes to the development and progression of gliomas. Thus, our
studies further enhance our understanding of the multiple cellular functions of p68 and
its regulation of the cellular processes.

INDEX WORDS: P68 RNA helicase, DEAD-box, ATPase, threonine phosphorylation,
oxaliplatin, p38 MAP-kinase, transcriptional regulation, TPPP
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CHAPTER 1
GENERAL INTRODUCTION

1.1 RNA HELICASES
RNA is a biologically important molecule that is required in almost all aspects of
genetic expression and biological processes. Biological reactions are highly dynamic,
requiring modulation of RNA, DNA and protein interactions in a specific order and
efficient manner. The abilities to modify these interactions and unwind RNAs have been
the essential functions of RNA helicases. RNA helicases modulate the structure of
RNAs through ATP hydrolysis. Biochemical analysis has revealed that RNA helicases
are ATPases and helicases (Staley and Guthrie 1998; Tanner, Cordin et al. 2003). They
are expressed in almost all biological organisms ranging from bacteria and viruses to
humans where the functions of RNA are involved. They are implicated in diverse
biological processes involving RNA such as transcription, mRNA splicing, nuclear
mRNA export, RNA editing, rRNA biosynthesis/assemby and translation (Luking, Stahl
et al. 1998; Fuller-Pace 1994; Chuang, Weaver et al. 1997; de la Cruz, Kressler et al.
1999; Tanner and Linder 2001).
RNA helicases have a core helicase domain consisting of eight conserved motifs
essential for helicase activity (Linder, Lasko et al. 1989) . They are classified into
different families and superfamilies based on these conserved motifs (Linder, Tanner et
al. 2001). DEAD-box RNA helicases derive their name from the conserved motif: AspGlu-Ala-Asp (DEAD) motif (Wassarman and Steitz 1991). Members of this superfamily
are ubiquitously expressed and are involved in all biological processes requiring RNA
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metabolism. The family includes several members such as eIF-4A and Dbp10 (involved
in ribosome biogenesis), Prp28, Prp5 and Sub2 (pre-mRNA splicing), Dbp5 (mRNA
export), Ded1, eIF4A and Vasa (translation initiation), and Dbp2 and Dhh1 (RNA decay)
(Fuller-Pace 1994; Rocak and Linder 2004) (Figure 1.1). Eukaryotic translation initiation
factor 4A (eIF-4A) is a helicase whose crystal structure has been solved. It has a
dumbbell-like structure made up of two globular domains linked by a flexible linker
(Caruthers, Johnson et al. 2000). It has a function in ribosome biogenesis, and has both
ATPase and RNA-unwinding activities (Rozen, Edery et al. 1990). P68 RNA helicase is
another DEAD-box protein having striking homology to eIF-4A protein (Figure 1.2)
(Ford, Anton et al. 1988; Linder, Lasko et al. 1989).

1.2 P68 RNA HELICASE
1.2.1 P68: a DEAD-box RNA Helicase
P68 is a DEAD-box RNA helicase identified as a result of cross-reaction with
DNA tumor virus nuclear oncogene SV-40 (Simian virus-40) antibody (DL3C4)
(Crawford, Leppard et al. 1982). P68 is the product of the gene DDX5 (DEAD-box
polypeptide 5) that is located on the chromosome 17q21 and consists of 13 exons and
10 introns (Figure 1.3a). The cDNA is 3769bp long while the expressed protein product
consists of 614 amino-acids (Hloch, Schiedner et al. 1990). P68 functions as a RNAdependent ATPase, and also unwinds RNA duplexes in a bi-directional manner. It binds
to dsRNA with stronger affinity than ssRNA (Iggo and Lane 1989; Huang and Liu 2002).
P68 protein has been found to be quite conserved throughout evolution (Lane and
Hoeffler 1980). Human and mouse p68 are 98% conserved (Lemaire and Heinlein
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1993), while the chick homologue shares about 90% homology, being shorter by 19
amino-acids (Jost, Schwarz et al. 1999). S.cerevisiae p68, DBP2, is 55% homologous
to the human protein (Iggo, Jamieson et al. 1991). There are reports of p68 homologues
also in bacteria (E.coli dbpA), Drosophila (DPSE/RM62), and Arabidopsis thaliana
(AtDRH1) (Iggo, Picksley et al. 1990).
P68, like other DEAD-box proteins, has a conserved core region of 296 aminoacids flanked by variable N-terminal (from amino-acids 1-134) and C-terminal (from
amino-acids 430-614) regions that share little sequence homology (Figure 1.3b) (Yang,
Yang et al. 2004). The core region has eight conserved motifs (Figure 1.3b). Both motif I
(GxGKT, Walker A motif) and motif III (DEAD, Walker B motif ), function as an ATPase
responsible for ATP-binding and hydrolysis (Schneider and Hunke 1998). Motif VI
(HRIGRXXR), always found to be together with the DEAD-motif, also binds ATP and is
required for its hydrolysis. Mutations in motif VI affect ATP-hydrolysis (Pause and
Sonenberg 1992). Motif IV (SAT) causes conformational changes linked to ATP-binding
and hydrolysis and harbors helicase activity. Mutations in this motif affect helicase
activity without affecting RNA- and ATP-binding and hydrolysis (Pause and Sonenberg
1992). Functions of the remaining motifs, i.e. motif Ia (PTREL), motif Ib (GG), motif II
(TPGR) and motif V (RGXD), are not very well characterized but may be involved in
RNA-binding (Rocak and Linder 2004). P68 also has a regulatory motif, the IQ motif, in
its C-terminal that is subjected to post-translational modification (Buelt, Glidden et al.
1994). This motif is made up of nine amino-acid residues with a conserved glutamine
important for ATP hydrolysis (Tanner, Cordin et al. 2003).
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1.2.2 Expression of P68
P68 is a predominantly nuclear protein, but shows dramatic variations in nuclear
localization during cell cycle stages. Immunocytochemical studies have demonstrated a
weak granular distribution of p68 exclusively in the nucleus of an interphase cell,
especially in the nucleoplasm, but not in the nucleolus (Lane and Hoeffler 1980; Iggo
and Lane 1989). However, during the end of telophase, p68 transiently associates with
the prenucleolar bodies in the nucleolus (Iggo, Jamieson et al. 1991).
P68 expression is regulated by cell growth and development, and is essential for
normal cell growth (Stevenson, Hamilton et al. 1998). It is ubiquitously expressed in the
developing mouse embryos and embryonic lethality is observed in p68 (DDX5)
knockout mice at day 11.5 (Fukuda, Yamagata et al. 2007). P68 expression co-relates
with its functions in organ maturation and in differentiation during development
(Stevenson, Hamilton et al. 1998). P68 is important for neural and mesodermal
development in the brains of chick, frog, and ascidian chordate embryos (Seufert, Kos
et al. 2000). Differentiation of adipocytes is blocked when p68 is knocked-down in
mouse 3T3-L1 preadipocytes cells, implicating the role of p68 in potentiating the
differentiation of adipocytes.(Kitamura, Nishizuka et al. 2001). Consequently, the
function of p68 in cell growth and development strongly suggests that expression of p68
has a function in cellular proliferation. P68 expression is not seen in quiescent Swiss
3T3 cells, but is observed when induced by serum indicating a functional link to cellular
proliferation. However, the expression levels of p68 do not necessarily match with the
cellular proliferation status in the adult tissues, as p68 mRNA and protein have been
found to be differentially expressed in these tissues regardless of their proliferation
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capability, implying that p68 is regulated in a more complex fashion (Stevenson,
Hamilton et al. 1998). Moreover, p68 expression is induced in developing epithelium in
wound tissues by growth factors and cytokines after transient down-regulation due to
skin injury. Increased p68 expression in keratinocytes leads to an increase in
expression of VEGF (vascular endothelial growth factor) and proliferation in response to
serum driving wounded area re-epithelization, an essential step in wound repair
(Kahlina, Goren et al. 2004).
Higher levels of p68 protein have been found in colorectal adenocarcinomas as
compared to their normal counterparts. The overexpressed p68 is poly-ubiquitylated, a
form of post-translational modification, raising the possibility of defects in proteosomal
degradation and consequent development of tumors (Causevic, Hislop et al. 2001).
Phosphorylation of p68 at Y593 is found to promote PDGF-mediated Epithelial-toMesenchymal Transition (EMT) and to contribute to cell proliferation and tumorigenesis
(Yang, Lin et al. 2006).

1.3 FUNCTIONS OF P68 RNA HELICASE
1.3.1 Function of P68 in mRNA Splicing
Splicing is a mechanism where pre-mRNAs are modified by removal of introns
and joining of protein coding exons to form mature mRNAs. Introns are removed by a
macromolecular structure called a spliceosome made up of U1, U2, U4, U5 and U6
snRNPs (small nuclear ribonucleoprotein particles) and other non-snRNP splicing
factors (Will and Luhrmann 2001). Splicing or spliceosome assembly follows a
sequential stepwise pathway consisting of recognition and binding of 5’-splice site on
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pre-mRNA by U1 snRNP and U2AF recognizing 3’-splice site and the E (early complex)
is formed. U2 snRNP then interacts with the branch-point adenosine (BP) that leads to
pre-spliceosome A complex formation. Next, U4-U6-U5 tri-snRNP enters the prespliceosome to form B complex first and then catalytic C complex. Various RNA and
protein rearrangements take place in the spliceosome resulting in U1 and U4 release
and ultimate intron cleavage and ligation of exon in an ATP-dependent manner (Will
and Luhrmann 2001) (Sanford and Caceres 2004) (Wahl, Will et al. 2009).
Recent studies have identified over 300 putative spliceosomal proteins in the
spliceosome (Jurica and Moore 2003). DExH/D RNA helicases are one such family of
proteins responsible for modulating such interactions using energy derived from ATPhydrolysis (Staley and Guthrie 1998) (Schwer 2001). P68 being a DEAD-box RNA
helicase functions as a crucial splicing factor. It modulates U1 snRNP and 5’-splice site
interaction at the intron-exon junctions and unwinds the transient U1-5’-splice site
complex (Liu, Sargueil et al. 1998; Liu 2002). This step is essential for the conversion of
pre-spliceosome to spliceosome (Staley and Guthrie 1998). Depletion of p68 from the
system does not affect the association of U1 snRNP-5’-splice site, however, the
spliceosome formation is impeded as U1 snRNP cannot dissociate from the 5’-splice
site (Liu, Sargueil et al. 1998; Liu 2002). RNA helicase and ATPase functions of p68 are
found to be crucial for this process. P68 mutants without RNA helicase and ATPase
functions associate with the U1-5’-splice site, but inhibit U1 dissociation from 5’-splice
site thereby preventing spliceosome assembly. P68 also functions in U4.U6/U5
assembly independent of its ATPase and helicase activities. P68 function has also been
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extended in alternative splicing of the oncogene c-H-ras, besides its role in splicing
(Guil, Gattoni et al. 2003).

1.3.2 Function of P68 in Transcriptional Regulation
Gene expression is the fundamental process in which genetic information, the
genotype, is converted to a functional gene product giving rise to the phenotype. Vast
multitude of phenotypic differences that are observed in different cells and tissues of
eukaryotes are largely due to differential gene expression. Gene expression is regulated
in eukaryotic cells at many key points including activation of gene structure,
transcription initiation, termination of elongation, nuclear RNA processing, mRNA
transport, mRNA translation, and mRNA stability. Thus, in response to genetic controls,
environmental factors and tissue specific controls, eukaryotic organisms employ highly
orchestrated and elaborate transcription machinery to turn on and off genes encoding
different proteins (Ogbourne and Antalis 1998).
Before transcription initiation can occur, highly organized and densely packed
chromatin must be activated or opened by chromatin remodeling complexes that are
themselves tightly regulated to inhibit responses to initiation factors and DNA
transcription and allow for transcription. The opening or priming of chromatin may be
regulated by N-terminal phosphorylation, acetylation, or methylation of free aminogroups of lysine residues of histones. Transcription is the process by which mRNA
synthesis occurs from DNA in distinct phases, starting with the binding of DNAdependent RNA polymerase to the gene promoter and ending with the formation of
mRNA. The majority of gene expression regulation occurs at transcriptional initiation,
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that is, regulating the assembly of transcription apparatus and positioning of RNA
Polymerase II at the promoter (Ogbourne and Antalis 1998).
RNA polymerase II (RNA Pol Il) is a 8-14 subunit RNA polymerase involved in
the transcription of protein expressing genes. It is solely dependent on auxiliary
transcription factors (TFs) to help it to initiate transcription. RNA Pol II and auxiliary TFs,
together called basal transcription apparatus or general transcription factors (GTFs),
assemble on the core promoter at a precise site known as the transcription initiation site
to form pre-initiation complex (PIC) in a highly regulated and defined order (Figure 1.4).
In most eukaryotic core promoters, a cis-acting element, called TATA box (5’ TATAAAA
3’), located upstream of the transcription start site (roughly 30 bp), is necessary for
directing the transcription initiation, but not sufficient for promoter activity. Precisely,
RNA Pol II transcription begins with the TATA-binding protein (TBP) association with the
TATA box. Subsequently, TBP-associated factors (TAFs) bind to TBP and form a
complex called transcription factor II D (TFIID) sufficient to complete chromatin priming
in the vicinity of the promoter. TFIIA is then recruited to the TFIID-TATA box complex to
undergo conformational change to allow TFIIB and the remaining GTFs to bind. Binding
of TFIIB causes TFIIF-Pol II complex to associate with the complex. TFIIE and TFIIF
interact with Pol II to complete PIC assembly. Although this complex is the complete
basal transcription machinery to initiate transcription, transcription initiation is further
compounded by different cofactors, gene specific activators or repressors, and
chromatin remodeling (Ghosh and Van Duyne 1996; Orphanides, Lagrange et al. 1996;
Nikolov and Burley 1997; Ogbourne and Antalis 1998).
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Core promoter sequences and basal transcription apparatus are required for
transcriptional initiation of any gene but gene selective transcriptional activities require
activators or repressors that bind to either enhancers or silencers. These transcriptional
regulators further modulate transcriptional regulation of tissue or development specific
genes. Most transcriptional activators function by interacting with GTFs and stabilizing
the association of GTF with core promoter. They have two separable functional
domains: a DNA-binding domain that binds to specific DNA sequences or enhancer
elements and an activation domain that interacts with other proteins to stimulate
transcription (Mitchell and Tjian 1989; Martinez 2002). TFIID is the main target for most
transcriptional activators as it is important for the formation of the transcriptional
initiation complex on all promoters (Buratowski, Hahn et al. 1989).
Transcriptional repressors perform opposite functions of activators. They repress
transcription in two ways: general repression or gene-specific repression. During
general repression, repressors either inhibit basal transcription machinery or block the
activity of transcription factors. Repressors can also modulate chromatin structure or
interact with proteins that remodel chromatin so that it is not available for transcription.
In contrast, a gene-specific repressor controls transcription of genes by affecting the
numbers of functional activators or by decreasing the positive effect of activators on
transcription (Gaston and Jayaraman 2002).
Besides the basal transcriptional machinery and transcriptional activators and
repressors, there is another group of factors that participate in transcriptional regulation.
They are called coactivators or corepressors which are dispensable for basal
transcription and may not directly bind DNA (Figure 1.5). They facilitate transcription by
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either mediating the interaction between activators and GTFs or facilitating chromatin
remodeling. Prototypical classes of co-activators are TAF component of TFIID, SRB
complex, SAGA or other proteins that are involved in histone acetylation and chromatin
remodeling complexes (Hampsey 1998; Martinez 2002).
Numerous studies have shown that p68 functions as a transcriptional co-activator
for numerous transcriptional factors (Figure 1.6) (Endoh, Maruyama et al. 1999).
Coactivator role of p68 was first elucidated in the transcriptional coactivation study of
estrogen receptor alpha (ERα). P68 potentiates the activity of ERα AF-1 (activation
function-1). AF1 activation domain of ERα does not require ligand while AF-2 requires
estrogen to facilitate coregulator recruitment. This co-activator function of p68 for ERα
AF-1 does not require RNA unwinding activity of p68 indicating that the involvement of
p68 in the regulation of transcription is not the same as its function in RNA-splicing
where RNA helicase activity of p68 is indispensable (Endoh, Maruyama et al. 1999).
The ERα transcription machinery contains nuclear receptor AF-2 coactivator complex,
such as CBP/p300, SRC-1/TIF2 steroid receptor coactivator, and SRA (steroid receptor
RNA activator) RNA coactivator, besides p68 (Onate, Tsai et al. 1995; Voegel, Heine et
al. 1996; Torchia, Rose et al. 1997; Lanz, McKenna et al. 1999; Watanabe, Yanagisawa
et al. 2001). P68 binds to the activation domain (AD2) of this AF-2 coactivator complex.
It selectively coactivates ERα-AF-1 by binding to the AD-2 domain of AF-2 complex
allowing SRA and the SRC-1/TIF2 to directly bind to AF-2 of ERα, serving as a bridge
between ERα and SRC/SRA (Watanabe, Yanagisawa et al. 2001). A “transcriptional
clock” concept was defined in another study that showed the sequential assembly of
transcriptional cofactors on the promoter of pS2, an ERα downstream gene, in
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estrogen-dependent manner. P68 interacts with the pS2 promoter along with ERα and
the transcription factors, TBP and TFIIA, demonstrating the role of p68 in transcription
coactivation (Metivier, Penot et al. 2003).
Another independent study confirmed the transcriptional regulation function of
p68 by demonstrating the presence of p68 in a multi-protein transcription complex
containing RNA Pol II, CREB-binding protein (CBP) and p300 and showed how p68
impacts transcription of genes that are regulated by RNA Pol II and CBP/p300 (Rossow
and Janknecht 2003). CBP/p300 is a transcriptional coactivator that modulates
expression of genes essential for cell growth and proliferation (Goodman and Smolik
2000; Janknecht 2002). Within the transcriptional multi-protein complex, p68 interacts
with CBP and RNA Pol II and stimulates CBP/p300 transcriptional activity synergistically
requiring its ATPase-dependent function (Rossow and Janknecht 2003). In another
study demonstrating the role of p68 as a transcriptional coactivator, p68 is identified as
the first RNA helicase to be implicated as an important element in the DNA damage
pathway. P68 functions as a transcriptional coactivator or a possible tumor
cosuppressor by interacting with p53 to stimulate transcription mediated by p53. P68 is
involved in the expression of p53-responsive genes including, p21, mdm2, and PIG3.
Chromatin immunoprecipitation experiments demonstrated the p68 interaction with the
p21 promoter stimulated by the drug, etoposide, further supporting the function of p68 in
transcriptional initiation (Bates, Nicol et al. 2005). Furthermore, p68 also forms a
complex containing Smad 3, p68, and CBP under the stimulation of TGF-β. In this
complex, helicase activity of p68 and histone acetylase activity of CBP enhance TGF-βdependent transcriptional activation (Warner, Bhattacherjee et al. 2004).
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Functional role of p68 in the transcription systems mentioned above can be
extrapolated to transcription activation in muscle cells. P68 associates with SRA to
stimulate MyoD transcriptional activity required for differentiation of skeletal muscle
cells. It serves as a bridge between MyoD and SRA within this complex and its helicase
activity is dispensable for this process. Reduction of p68 levels in this system impairs
the recruitment of TBP, RNA Pol II, Brg-1, and SWI/SNF complex catalytic subunit, and
affects chromatin remodeling. Thus, this study shows that p68 is essential for the
recruitment of the transcription machinery and chromatin remodeling (Caretti, Schiltz et
al. 2006). The link between p68 function and proliferation is demonstrated in
keratinocytes where overexpression of p68 increases keratinocyte proliferation and
VEGF expression, while knockdown of p68 reduces serum-induced proliferation and
VEGF expression (Kahlina, Goren et al. 2004). Interestingly, the phosphorylated form of
p68 also has a role in transcriptional regulation. Activation of the gene expression of
cyclin D1 and c-myc occurs by p68 phosphorylation at Y593, thereby promoting cell
proliferation induced by PDGF. Phospho-p68 is recruited to cyclin D1 and c-myc
promoters by its interaction with β-catenin. The TCF/LEF complex and ATPase/helicase
activities of p68 have been found to be required for this cyclin D1 transcription (Yang,
Lin et al. 2007). Thus, transcriptional regulation by phospho-p68 adds another
dimension to the function of p68 in the transcriptional regulation.
Another report demonstrated a function of p68 besides that of transcriptional
initiation. P68 can also function as a transcriptional corepressor depending on the
transcriptional complex and promoter onto which it is recruited. It associates with
HDAC1 and represses transcriptional regulation mediated by it (Wilson, Bates et al.
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2004). Another study showed that phospho-p68 interacts with HDAC1 and MBD3:Mi2/NuRD in the nuclear remodeling and deacetylation complex and activates the
transcription of Snail1 gene from the Snail promoter. It does so by removing HDAC1
from the MBD3:Mi-2/NuRD complex. The Snail1 transcriptional regulation by p68, in
turn, represses E-cadherin expression indirectly (Carter, Lin et al. 2010). In another
study of the Drosophila homologue, Dmp68, p68 is found to be required for the removal
of mRNA transcripts from transcription sites to shut off active genes and letting
chromatin reset to an inactive state, leading to gene deactivation (Buszczak and
Spradling 2006).
Thus, several lines of evidence have established the roles of p68 as
transcriptional coactivator/ corepressor and in most cases, RNA helicase and ATPase
functions are not required for these functions implying that the function of p68 in
transcription is different from its role in RNA-related processes. It is not a general
transcriptional regulator and functions as a coactivator or corepressor based on the
promoter or transcription complex. It has a function in transcriptional regulation by either
acting as a link between transcription factors/ coactivators, or facilitating the
rearrangement or recruitment of protein complexes at the gene promoter, or by
stabilizing the transcription initiation complex, or by associating with the chromatin
remodeling complexes to repress gene activation. Thus, it is a truly multifunctional
protein with functions in several processes each with specific requirements.
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1.3.3 Role of P68 in Post-transcriptional Processes.
P68 is a pleiotrophic protein with different roles in different cellular processes. A
study demonstrated an important function of p68 in pre-rRNA maturation. P68 and U8
small nucleolar RNA (snoRNA) cleave pre-28S rRNA structure of pre-60S ribosomal
subunit (Jalal, Uhlmann-Schiffler et al. 2007). Mouse Drosha complex contains p68,
where p68 is found to be required for primary miRNA and rRNA processing and is
indispensable for survival in mice (Fukuda, Yamagata et al. 2007). P68 is also found to
be involved in the release of mRNA transcripts after transcription to enable
condensation of chromatin causing gene inactivation (Buszczak and Spradling 2006).
Apart from gene inactivation, p68 involvement in transcript release from the transcription
site is also important in cyclical transcriptional activation processes where there is
combinatorial recruitment of coactivators and corepressors for gene regulation (Metivier,
Penot et al. 2003). Thus, p68 functions as an adaptor molecule that is not only involved
in the transcription initiation but also in post-transcriptional processes of gene
expression, such as elongation and RNA processing.

1.3.4 Role of P68 in Differentiation
Several studies have suggested the role of RNA helicases in cellular
differentiation process. RNA helicases serve as potential regulators of differentiation by
virtue of their ability to modulate RNA structure and interactions and their roles in RNA
processing where a large number of proteins can be expressed from a smaller subset of
genes (Abdelhaleem 2005). The mouse p68 is found to be expressed during organ
differentiation in developing murine embryo (Stevenson, Hamilton et al. 1998). In situ
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hybridization of 5 day old chicken embryos demonstrated a very high number of chick
homologs of p68 transcripts in different embryonic tissues (Jost, Schwarz et al. 1999).
P68 is also involved in embryonic differentiation of vertebrates. Very high embryonic
expression of p68 is observed in neural and mesodermal tissues in the brain and spinal
cord of chordates such as chick and frog. Mesodermal p68 expression is also seen in
ascidian and frog embryos during gastrulation and neurulation (Seufert, Kos et al.
2000). The p68 expression has also been observed in other organs and tissues during
differentiation. Invariably, p68 expression is also seen in murine male germ cells,
particularly pachytene spermatocytes and haploid spermatids (Lemaire and Heinlein
1993). The expression of p68 is regulated in these cells by germ cell-specific proteins
that associate with the highly conserved 3’ UTR of the gene (Sandhu, Lemaire et al.
1995). Interestingly, rck/p54 DEAD–box RNA helicase has a role in gametogenesis
(both oogenesis and spermatogenesis) and embryogenesis (Matsumoto, Kwon et al.
2005). Moreover, p68 expression is important during early adipocyte differentiation. The
in vitro model of adipocyte differentiation demonstrates the role of p68 in partially driving
the differentiation into adipocytes where inhibition of p68 expression partially blocks
adipocyte differentiation and simultaneously decreases expression levels of some
marker genes (Kitamura, Nishizuka et al. 2001). Nonetheless, the exact mechanism by
which p68 plays a role in cellular differentiation is not known. This poses several
questions where future research could be targeted: What is the role of p68 in
differentiation?

Could

p68

engage

in

transcriptional

programs

that

control

differentiation? What are the downstream targets of p68 in its function as differentiation
regulator?
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1.3.5 Role of P68 in Cell Proliferation and Cancer
P68 is essential for growth and proliferation of normal cells (Lane and Hoeffler
1980; Stevenson, Hamilton et al. 1998; Tanner and Linder 2001). P68 shows different
localization patterns in the nucleus during different stages of the cell-cycle. It shows
weak granular distribution in the nucleoplasm but not in the nucleolus during interphase
(Lane and Hoeffler 1980; Iggo and Lane 1989), However, its association with the
prenucleolar bodies in the nucleolus is observed during telophase (Iggo, Jamieson et al.
1991). Strikingly, serum-stimulation of quiescent cell lines increases p68 expression
suggesting that p68 expression is functionally linked to cellular proliferation (Stevenson,
Hamilton et al. 1998). In fact, overexpression of p68 in keratinocytes shows a marked
increase in serum-induced proliferation of cells, whereas downregulation of p68
decreases serum-induced proliferation (Kahlina, Goren et al. 2004).
Many studies have shown that p68 is essential for cellular proliferation, and
abnormal p68 may lead to uncontrolled cell proliferation leading to cancer development.
Two p68 abnormalities have been attributed to cancer. Dubey et al. identified a tumorspecific somatic mutation (C→T) that causes serine to phenylalanine transition in the
coding region of p68 with phosphorylation and calmodulin-binding sites leading to a
unique tumor antigen being expressed on murine UV-induced sarcoma. However, it is
still not clear whether this mutation has any effect on the function of p68 or on the
tumorigenesis process (Dubey, Hendrickson et al. 1997). The second type of p68
abnormality is the overexpression and post-translational modifications of p68 (Causevic,
Hislop et al. 2001; Yang, Lin et al. 2005; Shin, Rossow et al. 2007). Overexpression of
p68 is observed in colorectal tumors at the protein level, as compared with normal
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tissues with the expression of p68 increasing with the progression of the disease from
hyperplastic polyps to adenomas and adenocarcinoma (Causevic, Hislop et al. 2001;
Shin, Rossow et al. 2007). Moreover, p68 in tumor tissues is different from the p68
found in normal tissues. It is poly-ubiquitylated suggesting tumor-associated posttranslational modification affected proteasome-mediated degradation in tumor tissues
implying that deregulation of p68 expression/ ubiquitylation leads to tumor development
(Causevic, Hislop et al. 2001). Phosphorylation of p68 is yet another post-translational
modification implicated in tumor development and cellular transformation. P68 is found
to be phosphorylated in six different cancer cells in comparison to normal cell
counterparts and this tyrosine phosphorylation of p68 is associated with abnormal cell
proliferation and cancer development (Yang, Lin et al. 2005). So the overarching
question is how does overexpression and phosphorylation of p68 contribute to tumor
formation? An important phenomenon during colon tumor formation is the abnormal
activation and β-catenin accumulation. Almost 80% of human colorectal carcinomas
show abnormal β-catenin accumulation (Mirabelli-Primdahl, Gryfe et al. 1999; Brabletz,
Jung et al. 2001; Segditsas and Tomlinson 2006; de Lau, Barker et al. 2007). The
phospho-p68 binds to and promotes nuclear translocation of β-catenin. This stimulates
transcription of cyclin D1 and c-myc genes leading to cellular proliferation. This
interaction of p68 and β-catenin also stimulates EMT (Epithelial- Mesenchymal
transition), an event that is essential not only during embryogenesis but also for
invasion and metastasis (Yang, Lin et al. 2006; Yang, Lin et al. 2007; Thiery, Acloque et
al. 2009). Reduction of p68 in colon cancer cells also inhibits their proliferation and
diminishes their tumor-forming ability in nude mice (Yang, Lin et al. 2006; Shin, Rossow
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et al. 2007; Yang, Lin et al. 2007). All these results collectively indicate that p68
overexpression and post-translational modifications may lead to colon carcinogenesis
through β-catenin.
The emerging role of p68 in tumorigenesis other than in colorectal carcinoma can
be further substantiated by the report of p68 being overexpressed in 30-58% of breast
tumors (Wortham, Ahamed et al. 2009; Mooney, Grande et al. 2010). Approximately
70% of human breast tumors are ER-α-positive and current breast cancer therapy
targets ER-α inhibition (Normanno, Di Maio et al. 2005; Yager and Davidson 2006).
Since p68 functions as a coactivator of ER-α transcription, it is possible that increased
overexpression and probable modifications of p68 enhances the transcriptional
activation of ER-α and consequently the oncogenic activities of ER-α in breast
tumorigenesis. Similarly, p68 expression is elevated in prostate cancer cells in
comparison with the normal prostate tissues and it enhances coactivation of androgen
receptor-regulated gene expression. These results show the p68 function in the
progression of prostate cancer to hormone-refractory disease (Clark, Coulson et al.
2008).
In contradiction, p68 has also been found to function as a tumor suppressor
under certain situations (Bates, Nicol et al. 2005). P68 stimulates transcription from p53responsive promoters by interacting with p53. P53 is a tumor suppressor protein
encoded by the TP53 gene. It is latent transcription factor activated by genotoxic
stresses like DNA damage to mediate transcriptional regulation of cell cycle and
apoptosis related genes. P68 RNA helicase acts as a coactivator of p53-responsive
genes. Interestingly, p68 knockdown inhibits p53-dependent transcription and apoptosis
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triggered by the drug, etoposide, suggesting the importance of p68 in such processes.
This role is further substantiated by chromatin immunoprecipitation assay that
demonstrates the association of p68 with the p21 promoter, further extending the role of
p68 in transcription initiation. P21 is an inhibitor of cell-cycle progression. This shows
that the transcriptional ability of p68 plays an important role in cancer. P68 may not be
completely essential in this process, but possibly employed only under specific
circumstances. The ability of p68 to enhance the tumorigenesis process or act as a
tumor-suppressor may be dependent on the form of p68 i.e. modifications, cellular
context, or upstream signaling events.

1.4 MODIFICATIONS OF P68
Mammalian cells constantly receive various signals from their environment to
respond to cell growth, proliferation or differentiation. The cellular responses to these
signals are mediated mainly by post-translational protein modifications and gene
regulation. Post-translational modification is the process by which a protein is
chemically modified, with ubiquitylation and phosphorylation being the most common
ones. These modifications can modulate enzymatic activities, protein conformations,
protein-protein interactions, protein-DNA interactions, and cellular localization of various
proteins (Olsen, Blagoev et al. 2006).

1.4.1 Ubiquitylation and Sumoylation of P68
Ubiquitylation is an enzymatic, post-translational modification process where
ubiquitin, a small regulatory protein is attached to proteins to direct them to the
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proteasome for degradation. Ubiquitylation processes employ activating (E1),
conjugating (E2), and ligase (E3) enzymes (Hershko, Heller et al. 1983). E1 enzyme
activates and transfers ubiquitin to the E2 enzyme. The E3 ligase forms bond between
the glycine residue of ubiquitin and lysine of substrate (Alberts et al. 2002). The
presence of protein tagged with ubiquitin recruits the 26S proteasome that unfolds and
hydrolyzes the polypeptide chain of the protein to small peptides using the energy
derived from ATP. The ubiquitin molecule(s) is prevented from degradation by deubiquitinating enzymes (Hershko, Ciechanover et al. 1980; Baumeister, Walz et al.
1998; Pickart 2004).
Sumoylation is another form of post-translational modification where SUMOs
(small ubiquitin-related modifiers), which are small ubiquitin-like proteins, are
conjugated to proteins in different cellular activities like transcription activation and
repression,

apoptosis,

cell-cycle

and

mitosis,

chromatin

remodeling

and

nucleocytoplasmic shuttling (Rodriguez, Dargemont et al. 2001; Gill 2004; Hay 2005).
However, unlike ubiquitylation, SUMO modification does not cause protein degradation,
but modulates subcellular localization of target proteins, protein-protein interactions or
protein-DNA interactions (Matunis, Coutavas et al. 1996; Mahajan, Delphin et al. 1997;
Melchior 2000).
P68 undergoes post-translational modifications. It is overexpressed and polyubiquitylated in colorectal adenocarcinoma in comparison to normal colon tissues. This
indicates a defect in proteasomal-degradation in colorectal tumors and ubiquitylation of
p68 occurs in the initial stages of tumor development. However, the exact sites where
p68 is ubiquitylated remain to be identified (Causevic, Hislop et al. 2001). P68 is found
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to be preferentially sumoylated by SUMO-2 at Lys53 amino-acid, while SUMO E3-ligase
PIAS1 as one of its functions enhances its SUMO modification. This SUMO modification
of p68 inhibits its ability to transcriptionally coactivate p53 by increasing its
transcriptional repression function and enhancing its interaction with HDAC1 (FullerPace, Jacobs et al. 2007; Jacobs, Nicol et al. 2007).

1.4.2 Phosphorylation of P68
Phosphorylation, a form of post-translational modification, is used in signal
transduction for regulating protein activity. It is involved in almost every cellular
processes, such as cell growth, division, differentiation, migration, metabolism,
membrane transport, organelle trafficking, muscle contraction, immunity, learning and
memory (Manning, Plowman et al. 2002; Manning, Whyte et al. 2002). Protein kinases
are enzymes that phosphorylate proteins by transferring γ-phosphate from ATP, the
phosphoryl donor, to the specific residues in proteins, usually serine, threonine and
tyrosine (Hunter 2000). Protein kinases represent one of the largest families of genes in
eukaryotes. They are encoded by over 500 genes and make up ~ 2% of the genome
(Zhu, Klemic et al. 2000; Manning, Whyte et al. 2002; Caenepeel, Charydczak et al.
2004). Roughly 30% of cellular proteins are modified by phosphorylation on atleast one
residue, emphasizing the importance of phosphorylation (Pinna and Ruzzene 1996;
Cohen 2000). Thus, in cells, phosphorylation (adding phosphoryl group) and
dephosphorylation (removing phosphoryl group) by protein kinases and phosphatases,
respectively, at specific sites are among the most general regulatory steps in the
eukaryotic cells. Kinases and phosphatases modify the functions of proteins by
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increasing or decreasing their biological activities, by stabilizing or tagging them for
destruction, by enhancing or inhibiting subcellular compartment movements or
modulating protein-protein interactions (Cohen 2002). In fact, abnormal phosphorylation
is now identified as a cause or consequence of many pathologies such as cancer
(Hanahan and Weinberg 2000), auto-immune diseases (Gatzka and Walsh 2007),
metabolic disorders (Taniguchi, Emanuelli et al. 2006) and pathogenic infections
(Sirard, Vignal et al. 2007).
Studies carried out by Yang et al showed for the first time that p68 gets
phosphorylated at several residues (Yang and Liu 2004). Interestingly, p68 is found to
be phosphorylated at tyrosine in six cancer cell-lines and not in the respective normal
cell lines (Yang, Lin et al. 2005). This observation correlates with p68 phosphorylation
status in tumor tissue samples where p68 is tyrosine phosphorylated in tumor tissues
and not in the respective normal tissues. Thus, tyrosine phosphorylation in p68 is
associated with abnormal cell growth leading to tumor development (Yang, Lin et al.
2005). Strikingly, p68 tyrosine phosphorylation is higher in metastatic cells in
comparison to primary cells further suggesting roles of p68 tyrosine phosphorylation
with respect to tumor development and progression (Carter, Lin et al. 2010).
Phosphorylation of p68 at tyrosine is found to be induced by PDGF and IL-2 and
diminished by treatment with apoptosis agents such as TNF-α, TRAIL, and STI-571.
However, tyrosine phosphorylation of p68 is not influenced by other anti-cancer drugs
such as piceatannol, etoposide, and taxol. In addition, ATPase and RNA helicase
activities are affected by tyrosine phosphorylation of p68, thereby influencing its role in
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splicing. This suggests the potential for use of p68 phosphorylation as a diagnostic
marker and therapeutic target for cancer diagnosis and therapy (Yang, Lin et al. 2005).
Another study carried out by Yang et al. demonstrated p68 phosphorylation in
HeLa cells. TNF-α and TRAIL cause p68 to be phosphorylated at threonine and
subsequently dephosphorylated upon longer exposure to TNF-α. Interestingly, TNF-α
treatment causes tyrosine dephosphorylation of p68 after 15 mins of treatment. This
result suggests that threonine or tyrosine phosphorylations of p68 react differently in
response

to

TNF-α

and

that

phosphorylation

at

threonine

and/or

tyrosine

dephosphorylation of p68 may trigger apoptosis in the presence of TNF-α treatment
(Yang, Lin et al. 2005).

1.4.2.1 Phosphorylation of P68 by PKC
Protein Kinase C (PKC) is a multifunctional protein kinase that phosphorylates
target proteins (Newton 1995). Phosphorylation of cellular proteins by PKC changes
their activation status leading to further changes in cellular functions (Alberts et al.
2002). PKC plays essential roles in processes such as proliferation (Murray,
Baumgardner et al. 1993), differentiation (Cutler, Maizels et al. 1993), development
(Otte, Kramer et al. 1991), memory (Alkon 1989) and cancer (Ashendel 1985). PKC
enzymes are present in the cytoplasm in their inactive state and upon activation
translocate to cell membranes or different cellular organelles (Martelli, Faenza et al.
2003). There are atleast 10 different isoforms of PKC depending on protein structure
and cofactor requirements. The conventional isoforms of PKC, α, βI, βII, γ, need Ca2+,
diacylglycerol and phosphatidylglycerol for activation; the novel isoforms, δ, ε, η, θ, μ,

24
are activated by diacylglycerol and phosphatidylglycerol, but do not require Ca2+; and
the last group, the atypical (ζ, ι) isoforms do not require Ca2+, but are stimulated by
phosphatidylserine. Different isoforms can sometimes phosphorylate the same target
substrate (Newton 1997). The general structure of a PKC molecule consists of a single
polypeptide with a catalytic and a regulatory domain found at the COOH- and NH2terminus, respectively (Way, Chou et al. 2000). Aberrant PKC activity is linked with
diseases of cellular dysregulation, such as diabetes and cancer. Overexpression of
different PKC isoforms have been observed in squamous cell carcinoma (PKCε)
(Wheeler, Martin et al. 2004), serous epithelial ovarian cancer (PKCι) (Eder, Sui et al.
2005), breast tumor (PKCα) (Lahn, Kohler et al. 2004), non-small cell lung carcinoma
(PKCι) (Regala, Weems et al. 2005) and multiple myeloma (PKC δ, ι, μ ζ) (Ni, Ergin et
al. 2003). Downregulation of PKCδ is observed in colon cancer (Cerda, Bissonnette et
al. 2001) while PKCα and PKCδ promote cell death in androgen-dependent prostate
cancer cells (Gavrielides, Frijhoff et al. 2004).
The earliest reports of p68 phosphorylation were shown by the study performed
by Buelt et al. In vitro and immunological studies showed that p68 can be
phosphorylated by PKC in the IQ domain in the absence of RNA and it can bind
calmodulin in a Ca2+-dependent manner. The phosphorylation and binding to calmodulin
block RNA-dependent ATPase activity of p68, indicating that PKC negatively regulates
ATPase activity of p68. Thus, PKC phosphorylation regulates the RNA binding or
helicase activity of p68 (Buelt, Glidden et al. 1994). Another study demonstrated that
PKC phosphorylation of p68 inhibits its RNA-binding ability, while dephosphorylation
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restores the function further substantiating the role of PKC phosphorylation in regulating
the function of p68 (Yang, Yang et al. 2004).

1.4.2.2 Phosphorylation of P68 by Tlk1
Mammalian Tousled-like kinase 1 (Tlk1) is a relatively recently discovered
nuclear serine/threonine kinase that was identified in 1999. There are two known human
Tlks that are ubiquitously expressed. They are Tlk1 and Tlk2 that share 84% amino-acid
sequence identity and act as dimers/oligomers. Tlk1 is found to be maximally active in
S-phase showing the potential role of Tlk1 in cell-cycle progression (Sillje, Takahashi et
al. 1999). It is also implicated in processing replicated DNA and chromatin formation
and this role of Tlk1 in regulating chromatin assembly was first noted by the discovery of
human chromatin-assembly factors, Asf1a (Anti-silencing function 1) and Asf1b, as Tlk
substrates (Sillje, Takahashi et al. 1999; Sillje and Nigg 2001). Tlk1 is activated in
response to genotoxic stress, such as UV, ionizing radiation or treatment with
hydroxyurea (Groth, Lukas et al. 2003; Krause, Jonnalagadda et al. 2003). DNAdamage generates double strand breaks (DSBs) that require Ataxia Telangiectasia
Mutated kinase (ATM) and Checkpoint protein kinase 1 (Chk1) functions. ATM
phosphorylates Chk1, which in turn phosphorylates Tlk1 on serine 695 (S695) in vitro
and in vivo leading to the rapid and transient deactivation of Tlk1 (Krause,
Jonnalagadda et al. 2003). Deactivation of Tlk1 causes a delay of Tlk-dependent
processes in S-phase, such as activation and phosphorylation of hAsf1, essential in
DNA-repair or blockage of activation of certain transcription factors resulting in
subsequent cell death (Groth, Lukas et al. 2003). Other downstream targets of Tlks
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besides Asf1a and Asf1b include histone H3 and DEAD-box protein p68 (Sillje and Nigg
2001; Kodym, Henockl et al. 2005; De Benedetti 2009).
Like PKC, p68 gets phosphorylated by Tousled-like kinase 1 (Tlk1). In addition,
Tlk1 phosphorylation of p68 affects its RNA-binding activity, further confirming the
regulatory effect of phosphorylation on p68-enzymatic activity (Kodym, Henockl et al.
2005). Tlk1 has been implicated in the UV- and ionizing-radiation-induced pathways
(Groth, Lukas et al. 2003; Krause, Jonnalagadda et al. 2003). So, p68 phosphorylation
by Tlk1 may potentially link p68 in the UV- or IR-induced pathways. Tlk1 is also known
to regulate chromatin assembly (Sillje, Takahashi et al. 1999; Sillje and Nigg 2001)
while p68 is known to function in transcriptional co-activation. These observations
suggest that Tlk1 and p68 may participate in the chromatin remodeling process by
regulating the expression of chromatin remodeling genes. However, the downstream
targets and substrates are not known yet.

1.4.2.3 Phosphorylation of P68 by c-abl kinase
C-abl belongs to the non-receptor tyrosine kinase family (Abelson and Rabstein
1970) (Goff, D'Eustachio et al. 1982; Shaul 2000). It is ubiquitously expressed, but is
localized at different sites including cellular membranes, cytoskeleton, and in the
cytoplasm (cytoplasmic c-Abl), and nucleus (nuclear c-Abl). It has nuclear localization in
the fibroblasts, while cytoplasmic localization is seen primarily in haematopoietic cells
and neurons (Van Etten 1999). This subcellular localization and shuttling ability of c-Abl
is due to the nuclear localization signal (NLS) and a nuclear export signal (NES)
(Taagepera, McDonald et al. 1998). The NLSs and DNA-binding sequences in c-Abl are
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crucial for its nuclear functions (Pendergast 2002). Alternative splicing leads to the
formation of abl- 1a and 1b isoforms. Abl-1b isoform with predominant localization in the
nucleus is myristoylated. Isoform 1a lacks myristoylation site and is mostly cytoplasmic
(Kharbanda, Pandey et al. 1997).
The functional domains of c-Abl include a myristoylation site in the N-terminus of
1b isoform, tyrosine-kinase region, Src homology 2 (SH2) domain and SH3-domain with
high affinity for proline-containing regions containing the PxxP motif (Cicchetti, Mayer et
al. 1992; Ren, Mayer et al. 1993; Songyang, Shoelson et al. 1993; Pawson 1994;
Songyang, Shoelson et al. 1994; Cohen, Ren et al. 1995). C-Abl also has a long Cterminal tail that consists of three PxxP motifs, three NLS and a NES, actin and DNAbinding domains. These structural domains are responsible for the ability of c-Abl to
regulate different cellular processes by either direct protein-protein interactions or
diverse subcellular localization (Tybulewicz, Crawford et al. 1991; Kipreos and Wang
1992; Van Etten, Jackson et al. 1994; Miao and Wang 1996). C-Abl has functions in cell
growth (Sawyers, McLaughlin et al. 1994), morphogenesis and actin dynamics
(Woodring, Hunter et al. 2003), cell homeostasis (Schwartzberg, Stall et al. 1991;
Tybulewicz, Crawford et al. 1991), and migration (Woodring, Litwack et al. 2002;
Woodring, Hunter et al. 2003). C-abl also regulates cell-cycle and cell-growth arrest
(Yuan, Huang et al. 1996) and induces apoptosis (Yuan, Huang et al. 1997). Growthfactors, including PDGF (Plattner, Kadlec et al. 1999), EGF (Plattner, Kadlec et al.
1999), TGFβ (Wang, Wilkes et al. 2005) etc activate cytoplasmic c-Abl. C-Abl with
cytoplasmic localization is involved in normal cell transformation and cancer progression
specifically in chronic myeloid leukemia (Krause and Van Etten 2005). Cytoplasmic c-
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Abl kinase demonstrates kinase activities in non-small cell lung cancers (Rikova, Guo et
al. 2007) and breast carcinoma (Srinivasan and Plattner 2006). Studies carried out by
Yang et al. showed an unanticipated function of cytoplasmic c-Abl in epithelialmesenchymal transition (EMT), and p68 being a substrate of this signaling process
(Yang, Lin et al. 2006). EMT is defined as a process in which epithelial cells loose cell
polarity, loose cell-cell contact and acquire a fibroblastoid, invasive morphology
essential for cell motility. They found that PDGF stimulation of HT-29 colon cancer cells
activates c-Abl which was phosphorylated by Src. Activated c-Abl phosphorylates p68 at
Y593 in the cell nucleus. Phospho-p68 interacts with β-catenin in the nucleus after
translocation and displaces β-catenin from the axin destruction complex. It does this by
blocking GSK-3β-induced β-catenin phosphorylation. Phosphorylated p68 then
promotes nuclear translocation of β-catenin causing stimulation of the EMT process
(Yang, Lin et al. 2006). Phosphorylated p68 also promotes cell proliferation by activating
the transcription of proliferative genes, such as c-myc and cyclin D1 (Yang, Lin et al.
2007). Another study showed that phosphorylated p68 at Y593 suppresses E-cadherin
expression by activating Snail 1 transcription. It does so by displacing HDAC1 from the
MBD3:Mi-2/NuRD nuclear-remodeling and deacetylation-complex assembled at the
Snail 1 promoter (Carter, Lin et al. 2010).

1.4.2.4 A-kinase-anchoring protein (AKAP95)
A-kinase-anchoring protein (AKAP95) is a nuclear protein with zinc-finger
domain. It has a docking site for PKA kinase, nuclear matrix targeting site, two zincfinger motifs and a PKA-binding domain (Coghlan, Langeberg et al. 1994; Akileswaran,
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Taraska kinase et al. 2001). By virtue of its binding to cAMP/PKA, AKAP95 regulates
chromatin condensation during mitosis (Collas, Le Guellec et al. 1999; Steen,
Cubizolles et al. 2000). P68 binds to AKAP95 (Akileswaran, Taraska et al. 2001).
During interphase, interaction of p68 with AKAP leads to localization of p68 to the
nuclear matrix, and further suggests the possibility for PKA to target p68. Since AKAP95
has the scaffolding function and a docking site for PKA, known for its established role in
regulating CBP/CREB transcriptional initiation complexes, (Arias, Alberts et al. 1994;
Kwok, Lundblad et al. 1994) and p68 associates with CBP regulating CBP-mediated
transcription (Endoh, Maruyama et al. 1999), it is quite possible for the involvement of
this complex in the changes in chromatin structure and gene expression regulation
(Akileswaran, Taraska et al. 2001).

1.5 COLORECTAL CANCER (CRC)
Colorectal cancer (CRC) has a very high mortality rate and more than a million
cases are reported every year. The incidence of colorectal cancer is equally distributed
between both the sexes. The highest rate of occurrence is seen in developed nations
such as North America, Australia, Western Europe, most probably due to dietary factors
(Parkin, Bray et al. 2005; Saunders and Iveson 2006). The risk factors for developing
colorectal cancer are genetic, increasing age, colonic polyps and lifestyle factors such
as diet (fiber deficiency, obesity, high consumption of alcohol), sedentary lifestyle,
diabetes mellitus, and smoking (Cunningham, Atkin et al. 2010). The diagnosis of CRC
is based on colonoscopy or sigmoidoscopy with tumor biopsy. After detection of the
newly diagnosed cancer, physical examination and complete colonoscopy are
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performed to detect tumor (Mauchley, Lynge et al. 2005). Approximately 70 to 80% of
CRC patients develop localized disease and surgery is the optimum curative treatment
(Bennouna and Douillard 2002). Adjuvant chemotherapy is used for high-risk patients
after surgery to avoid recurrence. Nearly half of the CRC patients still develop
disseminated, advanced disease and receive systemic chemotherapy or surgery. The
survival rates have increased in the past few years due to large scale screening and
early diagnosis (Saunders and Iveson 2006). Nearly 20% of CRC patients develop
metastatic disease (mCRC) with the liver, lung, peritoneum, and retroperitoneum being
the most common sites of CRC metastasis. The systemic chemotherapy approved by
FDA (Food & Drug Administration) includes 5-fluorouracil (5-FU), leucovorin,
bevacizumab, oxaliplatin, cetuximab, irinotecan, capecitabine, and panitumumab. The
systemic therapy for CRC aims at mitigating the symptoms, increasing the life
expectancy and regression of the tumor in liver-only metastases for surgical resection.
Combination systemic therapy has increased the median survival of CRC patients in the
last decade to roughly 2 years (Goodwin and Asmis 2009). Thus, combination of
targeted treatments with conventional cytotoxic drugs and population screening has
improved outcomes and has caused incremental survival advantage in the colorectal
cancer treatment.

1.5.1 Chemotherapy for Metastatic Colorectal Cancer
1.5.1.1 FOLFIRI or FOLFOX Regimen
The standard chemotherapeutic agent for metastatic CRC has been 5fluorouracil (5-FU) for over half a century (Krueger, Alexander et al. 2006) (Saunders
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and Iveson 2006). The drug 5-FU is a cytotoxic thymidylate-synthase (essential for DNA
synthesis) inhibitor and is typically administered with leucovorin. Leucovorin, a
thymidylate-synthase modulator, also called folinic acid increases the antineoplastic
effects of 5-FU (Goodwin and Asmis 2009). When 5-FU is administered alone, it is not
very effective, with the response rate being just 20% in advanced disease and survival
rate just 12 months. Leucovorin and 5-FU administered together have a slightly better
response rates but the overall survival is 11 to 13 months. The latest combination
therapy consisting of 5-FU-leucovorin, irinotecan or oxaliplatin has doubled the overall
survival of 14 to 21 months in advanced disease (Grothey and Schmoll 2001; Grothey,
Sargent et al. 2004). Irinotecan belongs to the campothecin family, and is an inhibitor of
topoisomerase I during replication. Optimal chemotherapy for metastatic CRC includes
administration of 5-FU (F=fluorouracil) and leucovorin (FOL=folinic acid) combined with
either oxaliplatin (OX) or irinotecan (IRI), forming FOLFIRI or FOLFOX regimens,
respectively (Goodwin and Asmis 2009). Studies carried out by Tournigand et al.
reported that FOLFIRI has 56% response rate and progression-free survival (PFS) of
8.5 months, while FOLFOX has 54% response rate and 8 months PFS concluding that
both the regimens have similar efficacy (Tournigand, Andre et al. 2004).

1.5.1.2 Targeted Therapies
Targeted cancer therapies utilize drugs that specifically interfere with particular
molecules involved in tumor growth and progression. Treatment for metastatic CRC in
the last several years has included the administration of inhibitors of vascular
endothelial growth factor (VEGF) and of epidermal growth factor receptor (EGFR)
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(Patiyil and Alberts 2006). Bevacizumab is a VEGF antibody that binds to VEGF-ligand
thereby blocking and inhibiting angiogenesis. It aids in more effective delivery of
chemotherapy to the tumor site by normalizing abnormal tumor vasculature and
inhibiting neovacularization. It is generally given in combination with 5-FU-based
chemotherapy regimen since being sanctioned by US Food and Drug Administration
(FDA) in 2004 (Hurwitz, Fehrenbacher et al. 2004). According to a study carried out by
Hurwitz et al., Bevacizumab given with FOLFIRI regimen increases the RR of patients
from 35% to 45% (Hurwitz, Fehrenbacher et al. 2004). Bevacizumab administered with
FOLFOX regimen does not cause any change in RR (Goodwin and Asmis 2009).
Panitumumab, a fully humanized (not chimeric) monoclonal antibody for EGFR was
approved by FDA in 2006. It is normally given to patients following 5-FU, oxaliplatin and
irinotecan regimens. Panitumumab has a RR of 10% and does not cause much serious
infusion reactions as seen with cetaximab (3%) (Van Cutsem, Peeters et al. 2007).
However, the efficacy of panitumumab when given with systemic chemotherapy or its
effect in comparison to cetaximab is still not known.

1.5.1.3 Oxaliplatin
Oxaliplatin is a platinum-based agent containing a 1,2-diaminocyclohexane
ligand. It is used in colorectal cancer chemotherapy (Jung and Lippard 2007).
Oxaliplatin administered as a single agent has low activity in many tumors and is
generally given in combination therapy with 5-FU and leucovorin. Exact mechanism of
oxaliplatin in this complex is not known, however, it is suggested that it can
downregulate dihydropyrimidine dehydrogenase, slowing the catabolism of 5-FU
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(Fischel, Formento et al. 2002). Cellular uptake of oxaliplatin occurs through passive
diffusion and carrier-mediated transport systems (Ghezzi, Aceto et al. 2004; Safaei and
Howell 2005). Oxaliplatin exerts its cytotoxic effect by causing DNA-damage brought
about by platinum DNA-adducts formed by binding of oxaliplatin to guanine residues of
DNA (Raymond, Faivre et al. 2002; Chaney, Campbell et al. 2005; Hah, Sumbad et al.
2007). The DNA lesions lead to inhibition of DNA replication resulting in cell-cycle arrest
and apoptosis (Di Francesco, Ruggiero et al. 2002). It also causes inhibition of RNA
synthesis and triggers immunologic reactions causing immunogenic death of colon
cancer cells (Todd and Lippard 2009; Tesniere, Schlemmer et al. 2010). In terms of
toxicity caused by oxaliplatin, it is less neurotoxic than other platinum compounds, but
still causes adverse reactions specifically in the haematopoietic system, the peripheral
nerves, and the gastrointestinal system (Donzelli, Carfi et al. 2004; Alcindor and
Beauger 2011).
Oxaliplatin causes cell death through DNA-platinum adducts, which trigger
massive apoptosis (Faivre, Chan et al. 2003). γ-H2AX, a marker of double-strand
breaks and factor in DNA-repair process, is found to be induced by oxaliplatin via p53dependent and -independent pathways (Chiu, Lee et al. 2009). The molecular
mechanism of oxaliplatin action involves G/M arrest and apoptosis. G2/M arrest leads to
reduction in both cyclin B1 expression and phosphorylated-CDC2 (Arango, Wilson et al.
2004; Chiu, Lee et al. 2009). Treatment of HCT116 colorectal cancer cells with
oxaliplatin activates intrinsic-mediated apoptosis. Subsequently, there is caspase-3
activation followed by cellular apoptosis (Arango, Wilson et al. 2004). The cytotoxic
effects of oxaliplatin are p53 status-dependent. One study demonstrated that p53 wild-
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type cells, including HCT116 cells, are sensitive to oxaliplatin while p53-mutated cells
are resistant to its action. Oxaliplatin effects are influenced by p21, a cyclin-dependent
kinase inhibitor regulated by p53, gene status. Oxaliplatin strongly induces p21
expression and G0-G1 arrest in p53 wild-type cells (Hata, Yamamoto et al. 2005).
Oxaliplatin is also known to deactivate ERK, which induces PUMA (p53 up-regulated
modulator of apoptosis), involved in apoptosis through the intrinsic pathway (Wang, Li et
al. 2006). Oxaliplatin is also found to inhibit survivin expression, a protein that protects
cell from apoptosis. Furthermore, the mechanism of reducing survivin expression is
through

p38

MAPK

pathway.

Oxaliplatin

treatment

causes

activation

and

phosphorylation of p53, which in turn activates and phosphorylates p38 MAPK.
Phosphorylated p38 reduces survivin protein level to enhance oxaliplatin-induced
cancer cell death (Liu, Hu et al. 2010; Sohn, Lee et al. 2010).

1.5.2 Phosphorylation of P68 by P38MAPK
The transmission of wide-array of extracellular stimuli to their intracellular targets
is mediated through intracellular mitogen-activated protein kinase (MAPK) pathways.
MAPKs relay, amplify, and integrate these stimuli to produce required physiological
responses, such as inflammation, cellular proliferation, and apoptosis (Rouse, Cohen et
al. 1994). The MAPK-cascade consists of 3 canonical, parallel, serine/threonine-kinase
cascades: (1) extracellular signal-regulated kinases (ERKs), (2) c-jun N-terminal or
stress-activated protein kinases (JNK/SAPK), and (3) p38-group of protein kinases.
ERK promotes cellular proliferation and inhibit cell death. JNK and p38-MAPK promote
cellular inflammation or programmed cell-death (Galcheva-Gargova, Derijard et al.
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1994; Xia, Dickens et al. 1995). These MAPKs are expressed in all eukaryotic
organisms in an inactive state (non-phosphorylated form). The MAPK pathway consists
of three kinase cascades made up of Mitogen-activated protein kinase, Mitogenactivated protein kinase kinase and Mitogen-activated protein kinase kinase kinase.
Each MAPK is tightly regulated in the cells (Cobb and Goldsmith 1995).
P38 MAPK was first isolated after LPS stimulation (Han, Lee et al. 1993; Han,
Lee et al. 1994). P38 MAPK is activated by dual phosphorylation of two TGY motifs by
upstream MAPKK-3 and MAPKK-5 in response to cellular stresses including
proinflammatory cytokines, such as TNF-α, IL-1, heat shock, UV-irradiation, high
osmotic stress, LPS, protein synthesis inhibitors such as anisomycin, arsenite, H2O2,
anti-cancer drugs, such as cisplatin, oxaliplatin, and certain mitogens such as GM-CSF,
FGF etc (Raingeaud, Gupta et al. 1995; Jiang, Chen et al. 1996; Cuenda, Cohen et al.
1997; Jiang, Gram et al. 1997). Activated phosphorylated p38 is subsequently
inactivated by dephosphorylation by protein phosphatase 2A, MAPK phosphatase etc
(Barancik, Htun et al. 1999; Lee, Kim et al. 2003; Levy-Nissenbaum, Sagi-Assif et al.
2003). There are four different isoforms of p38: α, β, γ and δ isoforms (Han, Lee et al.
1994; Lee, Laydon et al. 1994; Jiang, Chen et al. 1996; Lechner, Zahalka et al. 1996; Li,
Jiang et al. 1996; Cuenda, Cohen et al. 1997; Jiang, Gram et al. 1997; Kumar,
McDonnell et al. 1997; Enslen, Raingeaud et al. 1998). P38 α- and β-isoforms are found
in all cell-types (Jiang, Chen et al. 1996) while γ and δ isoforms have a limited
expression depending on the tissue type. The γ-isoform is mostly found in the skeletal
muscle cells (Lechner, Zahalka et al. 1996; Li, Jiang et al. 1996; Jiang, Gram et al.
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1997) whereas the δ-isoform is found in the small intestine, lungs, kidneys, testis, and
pancreas (Jiang, Gram et al. 1997; Kumar, McDonnell et al. 1997).
P38α is belongs to the p38 MAPK family. Activated p-p38α MAPK
phosphorylates and activates a number of downstream targets, notably protein kinases
such as MNK1 (Fukunaga and Hunter 1997; Waskiewicz, Flynn et al. 1997), p38
regulated/activated kinase (PRAK) (New, Jiang et al. 1998), or Mitogen-and stress–
activated protein kinase-1 (MSK1) (Deak, Clifton et al. 1998), transcription factors, such
as SRF accessory protein (Sap1) (Janknecht and Hunter 1997), growth arrest and
DNA-damage inducible gene 153 (CHOP) (Wang and Ron 1996), activating
transcription factor (ATF-1/2/6) (Tan, Rouse et al. 1996), p53 (Huang, Ma et al. 1999),
myocyte enhance factor 2C (MEF2C) (Han, Jiang et al. 1997), and high-mobility groupbox protein 1 (HBP1) (Yee, Paulson et al. 2004). Other p38 substrates include cPLA2
(Kramer, Roberts et al. 1996), tau (Reynolds, Nebreda et al. 1997), keratin 8 (Feng,
Zhou et al. 1999), and stathmin (Parker, Hunt et al. 1998).
P38

plays

important

roles

in

differentiation,

apoptosis,

inflammation,

development, and cell cycle. P38 is found to be activated by a number of anti-cancer
agents to trigger apoptosis. Treatment of Rat-1 cells with cisplatin induces p38
phosphorylation which leads to heat-shock protein 27 phosphorylation and subsequent
apoptosis (Deschesnes, Huot et al. 2001). Retinoid CD437 induces extensive p38mediated apoptosis in CA-OV-3 ovarian carcinoma cells (Holmes, Soprano et al. 2003).
P38 is also known to participate in G1 and G2/M cell cycle phases (Takenaka,
Moriguchi et al. 1998; Wang, McGowan et al. 2000). Activation of p38 is required for
Cdc-42 induced G1 arrest in the NIH3T3 cells (Wang, McGowan et al. 2000).
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Furthermore, G2 cell cycle arrest induced by UV light is p38-dependent (Wang, Huang
et al. 1998). P38 is implicated in cellular differentiation such as differentiation into
adipocytes, cardiomyocytes, chondroblasts, erthyroblasts, myoblasts and neurons
(Nebreda and Porras 2000). Specifically, p38 is essential for the differentiation of PC12
cells into neuronal cells,

mouse 3T3-L1 cells into adipocytes, and SKT6 cells into

haemoglobinised cells (Engelman, Lisanti et al. 1998; Nagata, Takahashi et al. 1998; Li,
Jiang et al. 2000). P38 involvement in senescence is also reported (Bulavin, Demidov et
al. 2002; Haq, Brenton et al. 2002; Wang, Chen et al. 2002). P38 has also been
associated with tumorigenesis in certain cells. One study demonstrated that decreased
activation of p38 in tumors results in increased proliferation and tumorigenic conversion
of the cells (Brancho, Tanaka et al. 2003). P38 is also implicated in placental
angiogenesis and erythropoiesis suggesting the differential role of p38 in development
(Nagata and Todokoro 1999; Mudgett, Ding et al. 2000). P38 is also implicated in
inflammation and is associated with diseases such as Rheumatoid arthritis, Alzheimer’s
disease, and inflammatory bowel disease (Perregaux, Dean et al. 1995; Johnson and
Bailey 2003; Hollenbach, Neumann et al. 2004).
In vitro studies carried out by Yang et al showed that p68 is a cellular target of
p38 (Yang, Lin et al. 2005). They observed threonine phosphorylation of p68 following
TNF-α treatment which was inhibited with the exposure to increasing concentrations of
SB203580. SB203580 is a pyridinyl imidazole inhibitor that inhibits the phosphorylation
and the activation of p38 (Cuenda, Rouse et al. 1995). In vitro kinase assay also
demonstrated that p68 is phosphorylated by p38. All these results confirm the p68
threonine phosphorylation. This is in consistence with the fact that p38 usually
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phosphorylates and activates transcription factors and protein kinases and p68 is a well
known transcriptional co-activator. However, whether p38 phosphorylates p68 in vivo
and the biological consequence of this phosphorylation is still unknown and warrants
further investigation.

1.6 CYTOSKELETON
Cytoskeleton is an interconnected, dynamic, and adaptive filamentous network of
polymeric proteins that regulate cell structure, shape, and function (Fletcher and Mullins
2010). It consists of F-actin, microtubules, and intermediate filaments which are in turn
made up of chemically distinct subunits, actin, tubulin, and intermediate protein (Janmey
1998). Cytoskeleton integrates the activity of these proteins to carry out three main
functions of sensing extracellular stimuli to respond to transmembrane receptors and
intracellular signals, organizing the contents of the cell spatially and modulating the
mechanical properties of the cell required for locomotion and cytokinesis (Condeelis
1993; Cornet, Ubl et al. 1993; Stossel 1994; Fishkind and Wang 1995). The cytoskeletal
network generates forces that provide scaffolding on which molecular motors move
organelles or generate internal stress. There are many regulatory proteins that control
the cytoskeletal network formed by the polymers.

1.6.1 Actin
Actin is the most highly expressed protein in the eukaryotic cells and is
composed of actin monomers. It is composed of three main actin isoforms: α-isoforms
of skeletal, cardiac, and smooth muscles and β- and γ-isoforms of nonmuscle and
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muscle cells. It is highly conserved and can transit between monomeric and filamentous
states and associate with actin-binding proteins (Herman 1993; Dominguez and Holmes
2011). Bundles of actin filaments give support to filopodia essential during chemotaxis,
cell motility, and cell-cell communication and provide polarity to the regulation of
transcription (Dominguez and Holmes 2011).

1.6.2 Intermediate Filaments
Intermediate filaments belong to a class of cytoskeletal proteins that have an
average diameter of 10 nm. They get their name from their diameter as their average
diameter is between those of actin (7 nm) and microtubules (25 nm) (Ishikawa, Bischoff
et al. 1968). They are mostly cytoplasmic with one exception of lamins that are nuclear.
Intermediate filaments are present only in multinuclear eukaryotes whereas actins and
microtubules are expressed in eukaryotic and prokaryotic organisms (Erber, Riemer et
al. 1998). There are atleast 65 functional genes encoding intermediate filament proteins
(Hesse, Magin et al. 2001). They are classified into 6 types: from type I to type VI.
Intermediate proteins contain α-helix rod domain and have a coiled-coil structure (Fuchs
and Cleveland 1998; Herrmann, Hesse et al. 2003). A protein called plectin links
intermediate filaments to each other as well as to actin and microtubules (Wiche 1998).
Keratins help the cells to resist shear stress while lamins provide mechanical strength to
the nucleus and trigger nuclear membrane breakdown at the beginning of mitosis.
However, intermediate filaments cannot provide directional movement of molecular
motors as they are not polarized (Tsai, Wang et al. 2006; Flitney, Kuczmarski et al.
2009).
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1.6.3 Microtubules
Microtubules are filamentous, tubulin-containing proteins representing important
part of the cytoskeleton. Microtubules are made up of α- and β- tubulins that can grow
as long as 25 μm and are highly dynamic. They are involved in maintaining cell shape
and structure, in the vesicular and mitochondrial transport, in the formation of spindle
during mitosis and cell division and in cell signaling (Jordan and Wilson 2004).
Dynamics of microtubule polymerization are tightly regulated and many regulatory
proteins such as microtubule-associated proteins (kinesin, dynein, katanin) bind to
microtubules for regulating microtubule dynamics. The functional diversity of
microtubules is also regulated by the expression and functions of different tubulin
isoforms, and several modifications of tubulin at the post-translational level including
polyglutamylation, polyglycylation, phosphorylation, and acetylation

(Desai and

Mitchison 1997; Luduena 1998; Verdier-Pinard, Wang et al. 2003).
Microtubule nucleus is generated by α- and β- tubulin heterodimers which is
extended by polymerization of tubulin dimers end to end to form a cylinder. This cylinder
has 13 protofilaments of tubulin heterodimers. Protofilaments form the building block of
the microtubule structure which can be extended by the addition of more protofilaments.
Microtubules have a distinct polarity with α-subunit [designated (-) minus end] of one
tubulin dimer linked to the β-subunit [designated (+) plus end] of the next dimer. (Jordan
and Wilson 2004) (Desai and Mitchison 1997).
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1.7 TPPP/P25
TPPP/p25 (Tubulin polymerization promoting protein/p25), also known as p25α,
is a small, basic, heat resistant, 219 amino-acid containing protein. It was initially
purified from bovine brain in tau protein kinase II (TPKII) fraction (Takahashi, Tomizawa
et al. 1991). TPPP/p25 is evolutionary conserved among mammalian species with the
human homolog of TPPP/p25 sharing 90% homology with bovine TPPP/p25. TPPP/p25
is located on chromosome 5 (Seki, Hattori et al. 1999). It is found only in animals but not
in prokaryotes, plants and fungi (Orosz and Ovadi 2008). It is a newly discovered tubulin
targeting protein and functionally, it closely resembles the characteristics of microtubuleassociated proteins (MAPs) by binding to tubulin (Hlavanda, Kovacs et al. 2002).
TPPP/p25 is also called as p25α because it binds to α-synuclein, a protein that
accumulates as insoluble aggregate in cytoplasmic inclusions in Parkinson’s disease
and other α-synucleinopathies (Gai, Power et al. 1999; Lindersson, Lundvig et al. 2005).
It is also described as p24 due to its function as a glycogen synthase kinase-3 inhibitor
(Martin, Vazquez et al. 2002).

1.7.1 Structure and Expression
TPPP/p25 has a α-helical content of 4% as against the predicted values of 3043% (Hlavanda, Kovacs et al. 2002). It is natively folded under physiological conditions
but has a flexible structure that unfolds co-operatively under equilibrium conditions
(Otzen, Lundvig et al. 2005). However, there is a disagreement about the structure of
TPPP/p25 with another group reporting that TPPP/p25 is an unfolded protein. It has a
well defined 3D structure only when it is associated with specific binding proteins such
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as chaperones (Hlavanda, Kovacs et al. 2002; Tirian, Hlavanda et al. 2003; Orosz,
Kovacs et al. 2004). It shows an abundance of “disorder promoting amino-acids” such
as Q,S,P,E,K,A,R,G but does not contain “order promoting amino-acids” such as
W,C,F,I,Y,L,N,V. TPPP/P25 has an N-terminal region which is disordered, consisting of
50 amino-acids followed by a highly flexible ordered core of 40 residues consisting of βstructure. TPPP/p25 is not very hydrophobic and has a high net charge with a pI of 9.5
(Orosz, Kovacs et al. 2004).
There are two shorter homologs of TPPP/p25 with which it shares roughly 6075% homology. They are TPPP/p18 consisting of 170 amino-acids with the gene name
p25β and TPPP/p20 consisting of 176 amino-acids and having the gene name CGI-38.
TPPP/p18 and TPPP/p20 lack the unstructured N-terminal region (from 3-43) of
TPPP/p25 and demonstrate extensive homology in the middle and C-terminal regions
including the conserved Rossmann motif GXGXXG (Shiratsuchi, Sato et al. 1995; Seki,
Hattori et al. 1999; Zhang, Wu et al. 2002; Vincze, Tokesi et al. 2006). TPPP/p18 is
more ordered and shares 57% identity with TPPP/p25 with high expression in the liver
and pancreas and is moderately expressed in the heart, kidney and skeletal muscle.
Interestingly, its transcript is detected only in the fetal brain. It is also detected only in
breast carcinoma, pancreas adenocarcinoma and occasionally, colon adenocarcinoma
(Zhang, Wu et al. 2002). TPPP/p18 is distributed homogenously in the cytoplasm. It is
more ordered and does not crosslink microtubules like TPPP/p25 implying that
TPPP/p18 does not influence microtubule network. TPPP/p20, on the other hand,
behaves like a disorganized protein and has a very high microtubule bundling ability
(Vincze, Tokesi et al. 2006).
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TPPP/p25 was first detected in the bovine brain specifically in the
oligodendrocytes of the nervous tissue (Takahashi, Tomizawa et al. 1991; Takahashi,
Tomizawa et al. 1993; Kovacs, Laszlo et al. 2004). Rat brain homogenates showed that
TPPP/p25 expression begins to be detectable on E20 (embryonic day 20) in myelinating
oligodendrocytes and gradually increases in the brain from 1-2 years of age to
adulthood (Skjoerringe, Lundvig et al. 2006). However, Seki et al. demonstrated that
TPPP/p25 mRNA is found in various tissues (Seki, Hattori et al. 1999). Acevedo et al
showed that TPPP/p25 is not exclusively expressed in the brain inspite of its high
expression in the brain. They detected TPPP/p25 expression in the liver, lung and heart
tissue extracts. Immunoblot analysis revealed high expression in the brain, testis, heart,
skeletal muscle, and eyes (Table 1.1) (Acevedo, Li et al. 2007). In the mouse brain,
specifically, TPPP/p25 is found in the oligodendrocytes and in the axons of myelinated
neurons of the white matter of the cerebellum and nuclei of the granule cells of the
cerebellum. TPPP/p25 is also found in the neuroglia and the neuropil and pyramidal
neurons of the cerebral cortex. However, it is not expressed in the hippocampus
(Acevedo, Li et al. 2007). TPPP/p25 gene is not present in the non-ciliated organisms
but is conserved in the ciliated organisms. In these ciliated organisms, TPPP/p25 could
be involved in the motile or sensory functions of the cilia/basal bodies. Basal bodies are
the microtubule rich cellular elements that resemble centrioles (microtubule organizing
centers, MTOC). Very high concentration of TPPP/p25 is seen in the MTOC and
cytokinetic cleavage furrow suggesting the TPPP/p25 involvement in the cell cycle
process (Orosz and Ovadi 2008).
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At the subcellular level, nuclear and cytoplasmic localization of TPPP is observed
in the cells such as HUVEC, HeLa and NIH3T3 and it co-localizes specifically with the
stabilized microtubules in the cytoplasm. However, in the migratory cells, it is detected
only in the cytoplasm co-localized with the microtubules and around the nucleus
(Acevedo, Li et al. 2007). Over-expression of TPPP/p25 causes dramatic changes in
the cellular morphology and leads to the formation of two major types of structures: the
aggresome and the perinuclear cage observed in pathological brain tissues. The
nucleus becomes bi- or multilobed in highly expressing cells with a bright aggregate of
the protein and a dense network of disordered bundles of microtubules and intermediate
filaments interdispersed with small cisternae of RER. These round juxtanuclear bodies
are called aggresomes which are pathological inclusion like structures observed near
the microtubule-organizing center (MTOC). Such superstructures (aggresome/inclusion
body) may either lead to cell death or provide cytoprotecting mechanism evading cell
death (Lehotzky, Tirian et al. 2004).

1.8 FUNCTIONS OF TPPP/P25
1.8.1 Cellular Functions of TPPP/p25
Tubulin/microtubule system is the main target of TPPP/p25. Brain extract
harboring increased TPPP/p25 protein levels demonstrated increased tubulin
polymerization activity in comparison to the muscle extract which did not exhibit any
activity while neuroblastoma cells showed ~10 fold lesser activity in comparison to the
brain extract (Hlavanda, Kovacs et al. 2002; Tirian, Hlavanda et al. 2003). The Cterminal has a segment that is also present in the protein tau which is the tubulin
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binding region of tau and consequently, may also be the region where TPPP/p25 binds
to tubulin (Himmler, Drechsel et al. 1989; Lee, Neve et al. 1989; Hlavanda, Klement et
al. 2007). TPPP/p25 binds to both tubulin and microtubules in vitro and in the cells and
perturbs the physiological tubulin assemblies and microtubular ultrastructures. In vitro
binding of TPPP/p25 to tubulin, most probably, tubulin dimers influences microtubule
assembly by promoting the formation of tubulin assemblies while binding to
microtubules alters microtubule ultrastructures by inducing strong bundling of
microtubules. TPPP/p25, at substoichiometric concentration, interacts with tubulin to
cause its polymerization into intact-like microtubules, polymorphic aggregates, and
bundling of paclitaxel stabilized microtubules (Hlavanda, Kovacs et al. 2002; Tirian,
Hlavanda et al. 2003).
At low expression levels in the eukaryotic cells, TPPP/p25 co-localizes with the
microtubule network maintaining its physiological integrity. This co-localization is
dynamic and alters during mitosis without affecting the cell cycle process. TPPP/p25
also causes bundling of microtubules in the eukaryotic cells similar to that observed in in
vitro studies and the bundled microtubules counteract and resist the destabilizing
function of vinblastine, a specific microtubule destabilizing agent. The stabilization of
microtubule filaments/bundles mediated by TPPP/p25 denotes the basic physiological
function of TPPP/p25 to strike a balance between stabilization of microtubules and their
polymerization dynamics which, in fact, could play an important role during
oligodendrocyte differentiation. This microtubule specific function of TPPP/p25 along
with its interaction suggests that it is a microtubule associated protein (MAP) like tau
protein (Lehotzky, Tirian et al. 2004). In contrast, high expression levels of TPPP/p25
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are observed in the pathological conditions. Overexpression of TPPP/p25 rearranges
microtubule network into aggresome like structure consisting of TPPP/p25 accumulation
around the centrosome, protruding into the nucleus and perinuclear cage consisting of
TPPP/p25 forming a filamentous cage of microtubules surrounding the nucleus. These
aberrant structures interfere with the intracellular transport processes, inhibiting cell
division and ultimately, leading to cell death (Lehotzky, Tirian et al. 2004). In fact,
introduction of bovine TPPP/p25 into Drosophila embryos blocks formation of mitotic
spindles and breakdown of nuclear envelop during mitosis without affecting centrosome
duplication and separation, nucleation of microtubules, and nuclear growth (Hlavanda,
Kovacs et al. 2002). However, GTP can modulate and inhibit the interaction of tubulin
and TPPP/p25, thereby, inhibiting TPPP/p25-induced tubulin polymerization. GTP
interacts with tubulin and serves as a main regulator of microtubules in brain. In
addition, TPPP/p25 has GTP binding motifs and Mg2+ dependent GTPase-activity by
virtue of which it specifically hydrolyzes GTP suggesting its potential role in different
physiological processes (Hlavanda, Kovacs et al. 2002; Tirian, Hlavanda et al. 2003;
Zotter, Bodor et al. 2011).
Studies by Acevedo et al showed that TPPP/p25 functions in the stabilization and
maintainence of the integrity of the microtubular network. They found that reduction of
TPPP/p25 by siRNA decreases acetylated tubulin and also reduces microtubule
concentration affecting the ultrastructure of the microtubule network. They also found
that cells stably expressing TPPP/p25 are larger in size as a consequence of greater
amount of acetylated microtubules. Thus, down-regulation of TPPP/p25 decreases
microtubule levels while overexpression increases stable microtubules and cell size
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(Acevedo, Li et al. 2007). The mechanism by which TPPP/p25 enhances tubulin
acetylation involves inhibition of HDAC6 which is an enzyme responsible for tubulin
deacetylation. TPPP/p25 interacts with HDAC6 and inhibits its deacetylase activity and
in turn promotes acetylation of the microtubule network. However, stabilization of
microtubules by TPPP/p25 cannot be completely attributed to tubulin acetylation alone
but also to its bundling activity (Tokesi, Lehotzky et al. 2010). TPPP/p25 decreases the
growth of microtubule plus ends thereby influencing microtubule derived cell motility.
However, the precise mechanism by which it affects the cell motility is not known
(Tokesi, Lehotzky et al. 2010).
Phosphorylation of TPPP/p25 prevents microtubule assembly (Hlavanda, Kovacs
et al. 2002; Tirian, Hlavanda et al. 2003; Acevedo, Li et al. 2007). Phosphorylation of
TPPP/p25 specifically in its N-terminal region dramatically affects its tubulin
polymerization ability leading to the formation of only aberrant microtubules (Hlavanda,
Kovacs et al. 2002; Tirian, Hlavanda et al. 2003). LIMK1 phosphorylates TPPP/p25 to
affect its ability to promote polymerization of tubulin resulting in microtubule-dissembly
(Acevedo, Li et al. 2007). ERK2 and Cdk5-mediated phosphorylation also blocks tubulin
assembly mediated by TPPP/p25. Phosphorylation causes some structural changes in
the tubulin binding interface of TPPP/p25 due to which it is unable to induce appropriate
conformation required for the tubulin assembly into microtubules (Hlavanda, Klement et
al. 2007).
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1.8.2 Role of TPPP/p25 in Differentiation
TPPP/p25 was first found to be expressed in the oligodendrocytes of most
regions of the adult brain as a tubulin binding protein (Takahashi, Tomizawa et al. 1991;
Takahashi, Tomizawa et al. 1993; Vincze, Tokesi et al. 2006). Oligodendrocytes are a
type of brain cells required for axon and myelin sheath development that insulate the
axons in the central nervous system (Baumann and Pham-Dinh 2001). They extend
their filopodial processes to ensheath axons with myelin which consists mostly of lipids
and some proteins. Myelin consists of myelin basic protein (MBP) as the main protein
component during differentiation of oligodendrocytes (Hardy and Reynolds 1991; Schiff
and Rosenbluth 1995; Akiyama, Ichinose et al. 2002). Oligodendrocyte progenitor cells
give rise to pre-myelinating oligodendrocytes which in turn differentiate into myelinforming oligodendrocytes with long, arborized, microtubule containing projections. Premyelinating oligodendrocytes do not express myelin proteins but express proteins like βIV-tubulin essential for the transport of myelin components (Barres and Raff 1994;
Trapp, Nishiyama et al. 1997; Terada, Kidd et al. 2005). TPPP/p25 is expressed by
myelin-forming oligodendrocytes and thus, can be a marker of myelinating
oligodendroglia. Oligodendrocyte progenitor cells show low expression of TPPP/p25
where it is confined to the centrosome and MTOC. It is upregulated during
differentiation of oligodendrocyte progenitor cells to oligodendrocytes being found
around the nucleus, in the cytoplasm and along the microtubules. It co-localizes with
MBP that is specifically expressed during oligodendrocyte differentiation (Goldbaum,
Jensen et al. 2008). TPPP/p25 knockdown by siRNA decreases oligodendrocyte
differentiation (Lehotzky, Lau et al. 2010). In summary, TPPP/p25 expression during
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differentiation and its interaction with tubulin before myelin development may be
essential in the formation of tubulin-related processes and microtubule network required
for

transport

of

lipids

and

proteins

for

myelin

formation

in

differentiating

oligodendrocytes.

1.8.3 Involvement of TPPP/p25 in Different Diseases
TPPP/p25 is implicated in several neuro-degenerative diseases and could serve
as a novel marker of alpha-synucleinopathies (Kovacs, Laszlo et al. 2004). Neurodegenerative diseases are characterized by accumulation of proteinaceous aggregates
of α-synuclein or hyperphosphorylated tau (Goedert, Spillantini et al. 1998; Goedert
2001).

Accumulation

of

neuron-specific

protein,

α-synuclein

is

typical

of

neurodegenerative diseases such as alpha-synucleinopathies like Parkinson’s Disease
(PD), Multiple System Atrophy (MSA), Diffuse Lewy Body Disease (DLBD) etc
(Spillantini, Schmidt et al. 1997; Wakabayashi, Yoshimoto et al. 1998; Gai, Power et al.
1999). Tauopathies include progressive supranuclear palsy (PSP), Pick’s Disease
(PiD), corticobasal degeneration (CBD), Alzheimer’s Disease (AD) etc (Arai, Ikeda et al.
2001;

Dickson

2009).

TPPP/p25

is

abnormally

found

in

the

degenerating

oligodendrocytes and neurons in alpha-synucleinopathies and is identified as αsynuclein filament-binding protein. It binds to α-synuclein and participates in the tubulininduced alpha-synuclein aggregation and fibril formation. This contributes to the
degenerative process which is accompanied by cytoskeletal disruption including the
microtubular system (Lindersson, Lundvig et al. 2005). In MSA, there is an altered
expression of α-synuclein and α-synuclein is localized with TPPP/P25. TPPP/p25 and
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α-synuclein are also detectable in the neuronal Lewy body inclusions of PD and Lewy
body dementia (Lindersson, Lundvig et al. 2005). Unlike α-synuclein, TPPP/p25 is not
linked with the phosphorylated tau and does not stimulate its aggregation in tauopathies
including AD. However, high expression of TPPP/p25 is seen in the granules of
granulovacuolar degeneration and is found deposited near the tau filaments in AD brain
(Kovacs, Laszlo et al. 2004).
Immunohistochemical

analysis

of

oligodendroglial

neoplasms

such

as

oligodendroglioma, oligoastrocytoma, and central neurocytoma showed that these
tumor cells lack TPPP/p25 expression. Absence of TPPP/p25 in these cells suggests
that the brain tumor cells may either loose TPPP/p25 expression during histogenesis of
oligodendroglial neoplasms or they may arise from TPPP/p25 immuno-negative
progenitor cells (Preusser, Lehotzky et al. 2007). This shows that TPPP/p25 is not
required for providing the tubulin-related processes or stabilization of microtubules in
oligodendroglial neoplasms.

1.9 AIMS AND SIGNIFICANCES OF THE DISSERTATION
The purpose of this dissertation is to characterize the functional role of threonine
phosphorylation of p68 and study the transcriptional regulation function of p68 in
regulating the cytoskeletal gene, TPPP.
P68 RNA helicase is involved in several cellular processes from pre-mRNA
splicing, transcription etc. to cell proliferation and differentiation (Liu 2002) (Endoh,
Maruyama et al. 1999) (Stevenson, Hamilton et al. 1998). P68 is also found to be
overexpressed in colon cancer (Causevic, Hislop et al. 2001). Previous studies
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demonstrated phosphorylation of p68 at several residues (Yang and Liu 2004). P68 is
tyrosine-phosphorylated in several cancer cells (Yang, Lin et al. 2005). PDGFstimulation of HT-29 cells lead to tyrosine phosphorylation of p68 at Y593 by c-abl
(Yang and Liu 2006). Also, studies by Yang et al. showed that TNF-α treatment of HeLa
cells phosphorylates p68 at threonine and dephosphorylates p68 at tyrosine residues
indicating that TNF-α treatment reciprocally regulates the threonine and tyrosine
phosphorylations of p68 (Yang, Lin et al. 2005). All these studies imply that p68 is a
pleiotrophic protein that has different biological roles in multiple cellular pathways and
that phosphorylation of p68 regulates the enzymatic activity and cellular functions of p68
in different pathways in response to different external stimuli. In this dissertation study,
we found that p68 gets phosphorylated at threonine residue(s) (T564 and/or 446) under
the treatment of anti-cancer drug oxaliplatin in colon cancer cells. The protein is
phosphorylated by p38 MAP-kinase upon the drug treatment. Further characterization of
the role of threonine phosphorylation of p68 showed that it mediates, at least partially,
the effects of the drug on apoptosis induction. Thus, the phosphorylation of p68, effect
of phosphorylation on its cellular function, and the signaling pathway causing the
phosphorylation are studied. This study shows an important mechanism of action of the
anti-cancer drug which could be used for improving cancer treatment.
The second part of the dissertation involves studying the role of p68 in the
transcriptional regulation of TPPP. Numerous studies have shown that p68 functions as
a transcriptional co-activator for a number of genes (Endoh, Maruyama et al. 1999).
Previous reports demonstrated that p68 may regulate the expression of several genes
that regulate the stability and dynamics of different cytoskeletal elements. In this
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dissertation, the involvement of p68 in regulating TPPP expression is characterized.
P68 is found to interact with the promoter region of TPPP and regulate its mRNA and
protein expression. Control of TPPP expression by p68 is found to be an important
event for neuronal differentiation. Expression of TPPP is important for cellular
differentiation while its loss contributes to the development and progression of cancer.
Our studies reveal an important mechanism that is critical for cellular differentiation.
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Figure 1.1 DEAD-box RNA helicases in multiple cellular processes.
DEAD-box RNA helicases are involved in ribosome biogenesis (Fal1, Rok1, Spb4 and
Dbp10), pre-mRNA splicing (Prp28, Prp5 and Sub2), mRNA export (Dbp5 and Sub2),
translation initiation (eIF4A, Ded1 and Vasa), organellar gene expression (Mss116,
Mrh4 and Cyt-19), and RNA decay (RhlB, Dbp2 and Dhh1). Some of these RNA
helicases is involved in two or more biological processes serving as a consequent link
or control element for those processes. [Figure taken from Rocak et al. (2004). Nature
reviews molcellbio. 5:232-241]. (Rocak and Linder 2004).
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Figure 1.2 Drawing of the structure of full-length p68.
The figure shows typical DEAD-box structure and it is refined to 2.6Aₒ resolution. The
DEAD domain has a central 8-stranded β-sheet between 5 α-helices on each face and
ADP molecule in the nucleotide binding pocket. [Figure taken from SGC http://www.thesgc.org/structures/details?pdbid=3FE2/]
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Figure 1.3a Structure of the human p68 gene (EMBL accession no. AF015812)
with the distribution of exons and introns along with conserved DEAD-box motifs.
Filled boxes with roman numbers on the top denote exons while introns and flanking
regions are represented by thin lines (bar=500nt). The amino-acid sequences of
conserved motifs are given in single letter code. [Figure taken from Rossler et al.
(2000). Nucleic acids Research. 28(4): 932-939]. (Rossler, Hloch et al. 2000).
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Figure 1.3b Schematic depiction of domains of p68 RNA helicase
P68 is a 614 amino-acids containing protein. The bottom panel represents the domain
structure of p68 consisting of N-terminal, C-terminal and helicase core region. Different
sequence motifs are labeled while amino-acids are represented by numbers. The panel
on the top denotes the core domain of p68 (134-430 amino-acid). [Figure taken from
Yang et al. (2004). Biochemical and Biophysical Research Communications. 314: 622630]. (Yang and Liu 2004).
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Figure 1.4 GTF assembly at a typical eukaryotic promoter
The assembly of the basal transcription machinery is depicted here. A general
eukaryotic promoter with a TATA box (TATA), an initiator motif (INR), which overlaps
the transcription initiation site (arrow), and two GAGA elements (GAGA, not coloured) is
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depicted. TBP (pink) is assembled when one or more GAGA factors interact with one or
more GAGA elements. Several TAFs (pale pink) then join the basal complex followed
by TFIIA (TFs not coloured). Stepwise addition of TFIIB, RNA pol IIa (red)±TFIIF dimer,
TFIIE, TFIIH and the mediator (dark pink) complex takes place after isomerisation of the
TFIIA±TFIID complex. This pre-formed RNA pol II holoenzyme increases the frequency
of transcription initiation. Next step involves DNA melting and CTD phosphorylation in
order for elongation to take place. Recycling of the various parts of the spent GTFs
(broken arrows) helps to increase the rate of re-initiation. [Figure taken from Ogbourne
et al. (1998). Biochem Journal. 331: 1-14]. (Ogbourne and Antalis 1998).
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Figure 1.5 Depiction of functional interactions that affect basal (Upper) and
activator-dependent transcription (Lower).
The “pol II holoenzyme” components are denoted by square brackets while the basal
coactivators (TBP, TFIIB, TFIIF, TFIIE, and TFIIH and pol II) are shown in yellow
symbols. [Figure taken Nikolov et al. (1997). PNAS. 94:15-22]. (Nikolov and Burley
1997).
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Figure 1.6 Proteins interacting with p68/Dbp2 and the different biological
functions carried out by them.
The different roles of the DExD/H box protein are shown here. P68 found to co-purify
with spliceosomes has an important function in the splicing process. P68
transcriptionally coactivates a number of genes including ERα, Smad3, SRA, SRC1,
RNA Pol II/CBP/p300 and functions as a transcriptional repressor for HDAC1 mediated
transcription. P68 is also found to be involved in rRNA processing, mRNA decay and
RNAi but the precise role is not yet known. [Figure taken Fuller-Pace et al. (2006).
Nucleic Acids Research. 34(15): 4206-4215]. (Fuller-Pace 2006).
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Table 1.1 Expression of TPPP/p25 in mouse tissues
The table summarizes the different regions or cell types with TPPP/p25 expression. It is
expressed both in the nucleus and the cytoplasm. “+” represents low levels of
expression while “++” and “+++” denotes moderate and high levels respectively. Tissues
without TPPP/p25 expression are as −. [The table is taken from Acevedo et al. (2007).
Experimental Cell Research. 313(20): 4091-4106]. (Acevedo et al. 2007).

Tissue
Brain
Heart
Kidney
Lung
Liver
Stomach
Intestine
Spleen
Testis
Ovaries

IB IHC Cell-type or region
+++ +++ Neuropil, neuroglia, cortical neurons
++ +++ Cardiac muscle cells
− −
Glomeruli, distal and proximal convoluted tubules
++ ++ Bronchiole epithelium, alveolar cells
++ −
−
+ ++ Parietal cells in funding glands
Crypts of Lieberkühn, lamina propria containing smooth muscle
++ ++
bundles, muscularis mucosae
++ ++ B lymphocytes (lymphoid follicles)
− +++ elongated spermatids, spermatocytes, early spermatids
Follicles—oocytes, granulosa cells, follicular epithelium, corpus
− +++
luteum—granulosa lutein cells

Skeletal
Muscle

−

+++ Dark and light striations in muscle fibres

Eye

−

+++

Retina—photoreceptors (cones and rods), outer and inner
plexiform layer and ganglion cell fibre layer
Lens—anterior epithelium and lens fibres

103
CHAPTER 2
PHOSPHORYLATION OF P68 RNA HELICASE BY P38 MAP-KINASE
CONTRIBUTES TO COLON CANCER CELLS APOPTOSIS INDUCED BY
OXALIPLATIN

This chapter is published in BMC Cell Biol. 2012 Oct 31; 13(1):27.

2.1 ABSTRACT
It was shown initially that phosphorylation of p68 at threonine was associated
with cancer cell apoptosis under the treatments of TNF-α and TRAIL (Yang, Lin et al.
2005). The role of p68 phosphorylation in apoptosis induction following the treatment of
colon cancer cells in culture with oxaliplatin was investigated in this study. Our data
indicated that oxaliplatin treatment activates p38 MAP-kinase, which subsequently
phosphorylates p68 at T564 and/or T446. P68 phosphorylation, at least partially,
mediates the effects of the drug on apoptosis induction, as mutations at these two sites
greatly reduce the cancer cell death. This study shows an important mechanism of
action of the anti-cancer drug which could be used for improving cancer treatment.

2.2 INTRODUCTION
Oxaliplatin belongs to a new generation of platinum compounds currently used in
the front line for human colorectal cancer and other cancers treatment (Raymond,
Faivre et al. 1998). The therapeutic functions of oxaliplatin are from the DNA damage
caused by the compound, which leads to arrest of the cell cycle and apoptosis (Faivre,
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Le Chevalier et al. 2002; Rakitina, Vasilevskaya et al. 2007). The compound can
damage DNA by crosslinking DNA thereby blocking DNA replication and transcription
(Faivre, Le Chevalier et al. 2002; Fischel, Formento et al. 2002; Ang, Myint et al. 2010).
It activates multiple signaling pathways in mediating apoptosis induction (Wang, Li et al.
2006; Chiu, Lee et al. 2009). Oxaliplatin treatment causes activation of p38 and/or JNK
kinases, which subsequently targets a number of downstream effector molecules
leading to cancer cell apoptosis. Although the mechanism underlying the tumor
apoptosis induced by the drug has been intensively studied, the detailed mechanism,
especially the cellular molecules that contribute to the effects of the drug, is not fully
understood. P38 is a stress-activated MAP-kinase that is activated by cellular stresses
such as oxidative stress and toxic chemicals (Gould, Cuenda et al. 1995; Lu, Rau et al.
2011). Activated p38 relays stress signals in the induction of cell apoptosis (Xia,
Dickens et al. 1995; Zarubin and Han 2005). A number of anti-cancer agents act via
activation of p38, such as platinum compounds (Wang and Lippard 2005), etoposide
(Wood, Nail et al. 2006), and taxol (Shtil, Mandlekar et al. 1999). Phosphorylation of p38
MAP-kinase at Thr180 and Tyr182 residues in its conserved TGY motif leads to its
activation (New and Han 1998; Gong, Ming et al. 2010). The p38 MAP-kinase targets a
number of very important downstream proteins to exert its effects on apoptosis
induction. It is reported that phosphorylation of p53 on Ser46 by p38 is essential for
apoptosis induction by several anti-cancer drugs or by certain viruses (Perfettini,
Castedo et al. 2005; Perfettini, Castedo et al. 2005). Oxaliplatin treatment of colon
cancer cells leads to activation of p38 MAP-kinase, which subsequently phosphorylates
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gamma-H2AX and securin. These phosphorylation events lead to cancer cell apoptosis
caused by oxaliplatin (Chiu, Chao et al. 2008; Liu, Liu et al. 2010).
P68 RNA helicase is a RNA helicase with a DEAD-box motif (Lane and Hoeffler
1980; Crawford, Leppard et al. 1982). It is implicated in cellular proliferation,
differentiation (Stevenson, Hamilton et al. 1998) and cancer progression (Causevic,
Hislop et al. 2001). P68 RNA helicase gets phosphorylated at several residues (Yang,
Lin et al. 2005). Tyrosine phosphorylation of p68 is demonstrated in several cancer
cells. C-abl phosphorylates p68 in HT-29 cells following PDGF-BB stimulation. P68
phosphorylation at Y593 promotes EMT by allowing nuclear translocation of β-catenin
(Yang, Lin et al. 2006). P68 phosphorylation in T98G glioblastoma cells causes
resistance to apoptosis induced by TRAIL. Interestingly, when the cancer cells become
apoptotic resistant, the double tyrosine phosphorylations of p68 increase while the
phosphorylation of p68 at threonine decreases implying that phosphorylation of p68 at
threonine may be important in the induction of apoptosis induced by the anti-cancer
drug (Yang, Lin et al. 2005). We report here that, upon the anti-cancer drug oxaliplatin
treatment, p68 RNA helicase becomes threonine-phosphorylated in colon cancer
HCT116 cells. Oxaliplatin treatment activates p38 MAP-kinase in the cells, which
subsequently phosphorylates p68 at T564 and/or T446. The phosphorylation of p68 at
T564 and/or T446 is found to be important for the apoptosis induction by the drug. This
study demonstrates an important factor responsible for the effects of oxaliplatin in
apoptosis induction and may suggest a potential therapeutic strategy for cancer
treatment.
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2.3 RESULTS
2.3.1 Oxaliplatin treatment of colon cancer cells induced p68-threonine
phosphorylation
A previous study showed that p68 tyrosyl-phosphorylation is associated with
tumor development (Yang, Lin et al. 2005). In studying the effects of several anti-cancer
drugs and p68 phosphorylation status, p68 threonine phosphorylation was reported in
the colon cancer cells following the treatment with those anti-cancer drugs (Yang, Lin et
al. 2005). So, the next question is whether p68 phosphorylation at threonine plays a role
in mediating the anti-cancer drug effects. We used oxaliplatin which is used in the
treatment of colon cancer patients and HCT116 as the study system. HCT116 is a colon
cancer cell-line with a positive expression for transforming growth factor-beta. It has a
mutation in the β-catenin gene (gain of function mutation). This mutation causes
constitutive activation of a number of β-catenin-regulated downstream genes as a result
of prevention of degradation of β-catenin. It also contains a homozygous mutation in
mismatch repair gene hMLH1 (mutL homolog1), a gene whose mutation increases
susceptibility to sporadic colorectal cancer. HCT116 cells has wild-type p53 gene and
undergo apoptosis in a p53-responsive manner after exposure to different anti-cancer
agents (Vikhanskaya, Colella et al. 1999). Treatment of HCT116 cells with different
dosages of oxaliplatin for 24 hours induced cell-death. The cells showed roughly 30 to
32% cell death at 20 μM concentration while 50% of the cells died at 40 μM drug
concentration (Figure 2.1A). We then examined the threonine phosphorylation of p68 by
using anti-phospho-threonine antibody and using the procedure reported in previous
studies (Yang, Lin et al. 2005; Yang, Lin et al. 2007). Oxaliplatin treatment
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demonstrated increased p68 phosphorylation at threonine (Figure 2.1B). This
phosphorylation increase was observed with both the detached cells and the cells that
were still attached to the culture plate following 24 hours of drug treatment (Figure
2.1C). We subsequently tested the timing of the p68 threonine phosphorylation following
oxaliplatin treatment. It was evident that the p68 threonine phosphorylation reached a
peak around 4 – 6 hours of 20 μM treatment and the phosphorylation decreased
thereafter (Figure 2.1D).

2.3.2 P68 is phosphorylated by p38 MAP-kinase at T564 and T446 upon the drug
treatment
We next sought to investigate the protein kinase that phosphorylates p68 in
response to oxaliplatin. It is very well known that oxaliplatin treatment of colon cancer
cells activates p38 MAP-kinase which is critical for apoptosis induction in cancer cells
(Xia, Dickens et al. 1995; Holmes, Soprano et al. 2003). To investigate the relation of
p68-threonine phosphorylation and p38 MAP-kinase activation, we simultaneously
probed threonine phosphorylation of p68 and phosphorylation of p38 MAP-kinase at the
TGY

motif

using

an

antibody

against

phospho-threonine

(14B3)

after

immunoprecipitating p68 (using p68 antibody) and phosphorylated/activated p38 (p-p38
antibody) respectively in the HCT116 cells. It was clear that p38 MAP-kinase was
activated upon the oxaliplatin treatment (Figure 2.2A). Interestingly, the timing of p38
MAP-kinase activation/phosphorylation correlated with the p68-phosphorylation at
threonine with the oxaliplatin treatment, atleast upto 4 hours (Figure 2.2A); indicating
the possibility that p68 is a substrate of p38 MAP-kinase following oxaliplatin treatment.
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This possibility was tested by examining the interaction of p68 and p38 MAP-kinase by
co-immunoprecipitation. HCT116 cells expressing endogenous p68 and p38 were
treated with 20 μM oxaliplatin for 4 hours. P68 was immunoprecipitated from the
oxaliplatin-treated cell lysate using anti-p68 antibody. It was evident that p38 MAPkinase coimmunoprecipitated with p68 (Figure 2.2B). We then further verified the
phosphorylation of p68 by performing in vitro kinase assay with recombinant p68 and
p38 MAP-kinase. It was clear that the recombinant p38 MAP-kinase phosphorylated
recombinant p68. As a control, BSA was not phosphorylated by the recombinant MAPkinase (Figure 2.2C). To further confirm that p38 phosphorylated p68 at threonine, a
constitutively activated p38 MAP-kinase-mutant D176AF327L was generated by
QuickChange site-directed mutagenesis (Diskin, Askari et al. 2004). D176A-F327L is a
constitutively activated p38 MAP-kinase mutant with double mutations at D176 and
F327 sites that induce conformational changes mimicking the naturally imposed
changes by dual phosphorylation in the loop region between kinase domains of p38 by
upstream p38 MAP-kinase activators. The double mutations render p38 MAP-kinase
constitutively active with high intrinsic activity independent of upstream activation and
regulation. This mutant retains the ability to phosphorylate and activate downstream p38
substrates (Diskin, Askari et al. 2004). Thereafterm, D176A-F327L was expressed in
HCT116 cells. P68 threonine phosphorylation in the cells was examined by the
immunoprecipitation with the anti-p68 antibody and immunoblot procedures with antiphospho-threonine and anti-p68 antibodies. Apparently, phosphorylation of p68 at
threonine was increased upon the p38 MAP-kinase-mutant expression (Figure 2.2D).
We, thus, concluded from our studies that p38 MAP-kinase phosphorylates p68.
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We next determined the p68 phosphorylation sites recognized by p38 MAPkinase. Phosphorylation-site search using a web-based program, NetPhos 2.0 was
performed. The consensus phosphorylation-site search indicated several potential S/T
phosphorylation sites on p68 by p38 MAP-kinase (Figure 2.3A). Based on the
phosphorylation-site predictions, several mutants were generated where the threonine
(T) residue at the predicted phosphorylation-sites was mutated to alanine (A) by Quickchange site-directed mutagenesis. This mutation abolished the ability of the mutants to
be phosphorylated as alanine did not have any phosphoacceptor site for phoshorylation
by p38 MAP-kinase (Figure 2.3A). Data from in vitro phosphorylation reactions with the
generated mutants using the recombinant p38 suggested that there was a decrease in
p68-phosphorylation with the mutant T564A, while there was almost no change with
other mutants (Figure 2.3B, Upper panel), suggesting that T564 phosphorylation may
result from activated p38 MAP-kinase. To verify whether the T564 is the
phosphorylation site, the T564A mutant or other mutants were transfected in the
HCT116 cells and the phosphorylation of the p68 mutant at threonine was examined
after treating the cells with oxaliplatin. Surprisingly, there was no change in p68
threonine phosphorylation with wild-type and any mutant (Figure 2.3C Upper panel).
One possible explanation is that p68 may have additional sites that are phosphorylated
by p38 MAP-kinase as p38 is known to often phosphorylate its targets at multiple sites
(Yang, Xiong et al. 2002; De Chiara, Marcocci et al. 2006). To confirm this, we created
two p68-double mutants, T564/446A and T446/224A.

T564/446A has mutations at

T564 and T446 sites where threonine (T) residue is mutated to alanine (A). Apart from
T564 phosphorylation site, p38 may be phosphorylating p68 at additional minor sites to
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achieve maximal phosphorylation. T446 and T224 have the p38 consensus sequence
and show higher possilbity of being phosphorylated by bioinformative analysis. Hence,
double

mutants,

T564/446A

and

T446/224A

were

generated

and

in

vitro

phosphorylation was performed with these two mutants. It was clear that p38 MAPkinase induced phosphorylation of T564/446A was reduced, while the phosphorylation
of T446/224A had very minor reduction (Figure 2.3B Lower panel). The in vitro
phosphorylation results suggested that it is likely that the T564 and T446 of p68 are the
sites phosphorylated by p38. To verify that T564 and T446 are the phosphorylation
sites, HA-tagged p68-wild-type (wt), T564/446A, and T446/T224A mutants were
expressed in HCT116 cells followed by oxaliplatin treatment. Phosphorylation of the HAtagged p68-wt and the mutants were examined. Clearly, phosphorylation of
T446/T224A experienced a minor decrease, while phosphorylation of T564/446A was
almost abolished (Figure 3.3C Lower panel). The results strongly suggest that p38
phosphorylated p68 at T564 and T446 by the anti-cancer drug.

2.3.3 Phosphorylation of p68 at threonine mediates the effects of oxaliplatin in the
induction of apoptosis
We next investigated whether p38 MAP-kinase-induced p68 threoninephosphorylation is involved in the oxaliplatin-mediated pathway. The HA-tagged wt p68
or T564/446A was expressed in HCT116 cells after knocking down endogenous p68
(Figure 2.4A). The cells were then subsequently treated by oxaliplatin for 24 hrs at a
concentration of 10 μM. Cellular apoptosis was measured using caspase-3 colorimetric
assay as caspase-3 is an important factor for detection of apoptosis. Caspase-3
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cleavage and subsequent activation is a primary hallmark of apoptosis mediated by
both intrinsic and extrinsic apoptotic pathway. There were no significant changes in cell
apoptosis without oxaliplatin treatment. However, oxaliplatin-induced apoptosis was
reduced with the T564/446A-expressing cells. This effect was not observed with the wt
p68-expressing cells (Figure 2.4B). Similar results were observed with MTT assays
(Figure 2.4C). Thus, we conclude that phosphorylation of p68 at T564/446, at least
partially, mediates the effects of oxaliplatin on apoptosis induction.

2.4 DISCUSSION
We found in this study that p68 gets phosphorylated at T564 and/or T446 in
HCT116 colon cancer cells following oxaliplatin treatment. P38 MAP-kinase
phosphorylates p68 following the drug treatment. The phosphorylation(s) of p68
appears to be essential for caspase-3 cleavage, an event which culminates in
apoptosis. These results echo a report from Yang and colleagues that the loss of p68
threonine phosphorylation correlates with cancer cell TRAIL- resistance (Yang, Lin et al.
2007). Thus, phosphorylation of p68 at T564 and T446 may represent a common
molecular mechanism that acts in multiple pathways of apoptosis induction.
Activated p38 MAP-kinase is a common factor in multiple apoptosis induction
with a number of anti-cancer drugs with different molecular mechanisms (Wang, Li et al.
2005; Wang, Li et al. 2006; Wood, Nail et al. 2006), oxidative stresses (Lu, Rau et al.
2011), cells damaged by UV light (Tanos, Marinissen et al. 2005). Moreover, the
downstream substrates of p38 MAP-kinase that execute the apoptosis effects is not
very clear. In fact, only a few substrates of p38 MAP-kinase involved in cell apoptosis
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induction, including p53 (Perfettini, Castedo et al. 2005) and HSP27 (Deschesnes, Huot
et al. 2001; Gonzalez-Mejia, Voss et al. 2010) are known. The mechanism by which
phosphorylation of these substrates mediates the effects of apoptosis induction is not
fully known.
How the p68 phosphorylation at T564 and T446 mediates cell apoptosis is an
open question. One plausible explanation is that the phosphorylated p68 may change
p68-interacting partners in the cells, which allows p68 to target a specific apoptosismediating protein or complex. The consequence for the p68-targeting is activation of
apoptotic function of the targeted protein or complex. Some DEAD-box RNA helicases
associate with apoptosis induction protein or complex. For example DDX42 modulates
the apoptotic function of ASPP2 by direct interaction with it (Uhlmann-Schiffler,
Kiermayer et al. 2009). Interaction between GABA-receptor associated protein
(GABARAP) and DDX47 is required for induction of neuronal cell apoptosis (Lee, Rho
et al. 2005). However, the mechanism by which this DEAD-box RNA helicase regulates
the apoptotic process is not known. Thus, it will be very interesting to find whether p68
phosphorylation at T564 and/or T446 mediates the association of the protein with a
particular apoptosis inducing complex to activate the complex.

2.5 MATERIALS AND METHODS
2.5.1 Cell Culture and Antibodies
HCT116 cells (Catalog # CRL-247) were obtained from ATCC (Manassas, VA,
USA). They were cultured according to the vendor’s instruction. Antibodies against p68
were raised against C-terminal domain (a.a.437-614) of human p68 (Invitrogen, Grand
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Island, NY, Carlsbad, CA, USA, and Auburn University Hybridoma Facility). The
antibodies used were: anti-phospho-threonine (14B3) antibody (Calbiochem, Billerica,
MA), p38 and phospho-p38 antibodies (Cell Signaling Technology, Beverly, MA), antiHA antibody (Abcam, Cambridge, MA and Georgia State University, Animal Center
Facility, Atlanta, GA), anti-GAPDH antibody (Millipore, Billerica, MA) and Flag antibody
(Sigma, St. Louis, MO).

2.5.2 Drug Treatment, DNA constructs, Transfections, and siRNA Interference
Oxaliplatin was bought from Sigma (Sigma, St. Louis, MO). It was diluted with
medium to prepare working concentrations. The cDNA of p68 ORF was subcloned into
pHM6 vector at HindIII site to get HA-tagged p68 expression vector. The various p68
single and double threonine mutants (threonine replaced by alanine) were made using
Quick-Change mutagenesis kit (Stratagene, Cedar reek, TX) and the mutations were
confirmed by DNA sequencing. P38α cDNA (Origene, Rockville, MD) was subcloned
into p3XFLAG-myc-CMV™-24 Expression Vector (Sigma, St. Louis, MO). A number of
mutations to obtain the constitutively activated p38 MAP-kinase was done according to
the studies performed by Diskin and colleagues (Diskin, Askari et al. 2004). All DNA
transfections were done using fugene HD and lipofectamine 2000 (Invitrogen, Grand
Island, NY) while siRNA knockdown was done with lipofectamine RNAimax (Invitrogen,
Grand Island, NY). SiRNA against p68 was purchased from Dharmacon (Thermo Fisher
Scientific Dharmacon, Lafayette, CO), and the sequence was as follows: siRNA
oligonucleotides against p68 (sense: 5’-GCAAGUAGCUGCUGAAUAUUU-3’; antisense:
5’-AUAUUCAGCAGCUACUUGCUU-3’). Cells were transfected

after p68-siRNA
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knockdown and further treated with the drug for 24 hrs. The cells were then harvested
for nuclear extract preparation as p68 is a predominantly nuclear protein using a kit from
Active motif (Active motif, Carlsbad, CA).

2.5.3 Protein Expression and Purification
The procedure used to express and purify p68 was similar to the procedure
reported previously. P68 ORF was cloned as well as various mutants into expression
vector pET-30a+ using the restriction sites Bam HI/Hind III and subsequently used to
transfer on E.coli BL21-CodonPlus bacteria (Stratagene, Cedar Reek, TX) to express
protein. The bacteria were subcultured in fresh sterile Luria Bertani (LB) broth until
optical density at A600 reached around 0.6. Bacteria were subsequently induced with
IPTG at 16°C overnight for protein expression. The cells were pelleted and stored. The
cells were then lyzed by freeze-thaw cycle at -80°C and further lysed in lysis buffer (50
mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM DTT, 10 mM PMSF, 10% glycerol). They
were then subjected to lysozyme (0.5 mg/ml) digestion to ensure complete lysis of the
cells. DTT and PMSF were also added at 1 mM final concentration. DTT reduces the
disulphide bonds of proteins thereby preventing them from linking the cysteine residues
of proteins while PMSF inactivates proteases that digest proteins after cell lysis. The
cells were further subjected to ultrasonication and pelleted. After centrifugation, the
expressed protein was precipitated which was dissolved in denaturing buffer containing
8 M urea, 250 mM NaCl, 50 mM Tris-HCl pH 8.0, and 0.2% Triton-100. The lysate was
passed through Ni-NTA column for purification of recombinant protein by affinity
separation and was washed with the denaturing wash buffer (8 M urea, 50 mM Tris-HCl
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pH 8.0, 250 mM NaCl, 0.2% Triton-100 and 20 mM imidazole pH 8.0). Elution buffer
(250 mM imidazole, 8 M urea, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.2% Triton-100,
0.5 mM DTT and 10% glycerol) was used to elute the protein. The eluted protein
solution was refolded using stepwise dialysis procedure (8M→ 6M→ 4M→ 2M→ 0M) to
remove urea using refolding buffer (200 mM arginine, 50 mM Tris-HCl pH 8.0, 250 mM
NaCl, 0.2% Triton-100, 0.5 mM DTT and 10% glycerol) and preserved in further 15 to
20% glycerol.

2.5.4 In Vitro Kinase Assay
In the kinase assay, the 25 μl reaction consisted of 1 μg of purified proteins, 200250 ng of p38α/SAPK2a enzyme (Upstate cell signaling, Beverly, MA), 10 μCi/μl of [γ32P]ATP, 5X buffer (125 mM Tris-HCl, pH 7.5 and 0.1 mM EGTA), and
Magnesium/ATP cocktail (75 mM MgCl2 and 500 μM ATP in 20 mM MOPS, pH 7.2, 25
mM β-glycerol phosphate, 1 mM sodium orthovanadate, 5 mM EGTA, and 1 mM DTT).
The 5X-loading buffer (Fermentas, Glen Burnie, MA) was added after incubation of the
reaction mixtures at 30°C for 30 mins. Two 10% SDS-PAGE gels were run to analyse
the samples. One of the gels was subjected to autoradiography while other one was
treated with Coomassie blue solution followed by destaining.

2.5.5 Cell Viability and Apoptosis Assay
Cell viability of HCT116 cells was analyzed by MTT (Sigma, St. Louis, MO)
assay. 4000 cells were seeded 24 hrs before either knockdown or transfection of cells
with vectors containing p68 and the mutants. Subsequently, 24 hrs after transfection,

116
the cells were induced for apoptosis by oxaliplatin treatment. The next day,
reconstituted MTT-reagent was added in an amount equal to 10% of the volume of the
cell culture medium and incubated at 37°C. MTT Solubilization solution used to dissolve
the formazan crystals formed during incubation was subsequently added. Cell viability
was determined spectrophotometrically by measuring absorbance at A570. Cells plated
on 6-well plates were treated with 10 μM oxaliplatin after p68 knockdown and
transfection and caspase-3/CPP32 colorimetric assay kit (Biovision Research Products,
Milpitas, CA) was used for measuring caspase-3 cleavage. Briefly, after apoptosis
induction, the cells were lyzed in Cell Lysis Buffer for 10 mins, centrifuged and
subjected to cleavage assay. The reaction consisted of cell lysate diluted in Cell Lysis
Buffer, 2X Reaction buffer, and 4 mM DEVD-pNA substrate. The samples were read at
A405 using a microtiter plate reader. FITC-Annexin V Apoptosis Detection Kit
(BDBiosciences, San Jose, CA) was also used to measure apoptosis induced by
oxaliplatin.
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Figure 2.1. Threonine phosphorylation of p68 in HCT116 cells following
oxaliplatin (Oxa) treatment.
(A) Apoptosis of HCT116 cells induced by different concentrations of oxaliplatin was
measured and presented as percent of apoptotic cells after 24 hours treatment. Error
bars represented standard deviations of four independent experiments.
(B), (C), and (D) Threonine phosphorylations of p68 measured by immunoblotting using
anti-phospho-threonine antibody (14B3) (1:1000 dilution) in HCT116 cells that were
treated with different oxaliplatin concentration (B) and (C), or 20 μM of oxaliplatin for
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different

times

(D)

were

analyzed
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immunoblotting

the

p68

that

was

immunoprecipitated (IP: p68) using antibody against anti-phospho-threonine (IB: 14B3).
The immunoblot of p68 (IB: p68) in the immunoprecipitates represented the amount of
p68 that was precipitated. In (C), the analyses were carried out with the cells that were
already detached and the cells that were still adherent following the treatment for 24
hours.
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Figure 2.2 P68 Phosphorylation by p38 MAP-kinase
(A) Threonine phosphorylation of p68 in HCT116 cells following treatment of the cells
with 20 μM of oxaliplatin for different times were analyzed by immunoblotting the p68
that was immunoprecipitated (IP: p68) using antibody against phospho-threonine (IB:
14B3) from the cell lysates. Phosphorylation of p38 MAP-kinase during the same
treatment was analyzed by immunoblot of cell lysates using antibody against the
phosphorylated p38. The immunoblot of p68 (IB: p68) in the immunoprecipitates
represented the amount of p68 that was precipitated. The immunoblot of p38 in the cell
lysate (IB: p38) indicated the cellular levels of p38 as a control.
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(B) Coimmunoprecipitation of p38 and p68 in the cell extracts of HCT116 cells
with/without oxaliplatin treatment (Oxa, +/-) was analyzed by p68 immunoblot with p68
antibody after immunoprecipitation (IP: p68) and by using antibody against p38 (IB:
p38). The immunoblot of p68 (IB: p68) from the immunoprecipitates represented the
amount of p68 that was precipitated. The IP: IgG was the immunoprecipitation using
rabbit IgG, serving as a negative control IP.
(C) Phosphorylation of recombinant His-p68, or BSA as a control, by recombinant p38
was demonstrated by autoradiography. The amount of protein used in the
phosphorylation reactions was shown by Coomassie Blue Staining (CBS).
(D) Phosphorylation of p68 by overexpression of Flag-tagged p38 MAPK, wild-type and
constitutively active mutant D176A-F327L, in HCT116 cells was analyzed by
immunoblotting the p68 that was immunoprecipitated (IP: p68) using antibody against
phospho-threonine (IB: 14B3). The immunoblot of p68 (IB: p68) in immunoprecipitates
represented the amount of p68 that was precipitated. The immunoblot of Flag-tag (IB:
FLAG) indicated the overexpressed p38 levels. The immunoblot of GAPDH (IB:
GAPDH) served as a loading control.
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Figure 2.3 Phosphorylation site(s) of p68 by p38 MAPK
(A) Prediction of potential p38 MAP-kinase-induced phosphorylation site(s) in the p68reading frame and compared to consensus p38 MAPK phosphorylation sites of several
authentic p38 MAP-Kinase substrates by a web-based phosphorylation-site prediction
program NetPhos 2.0, (B) Phosphorylation of recombinant His-p68 and mutants with
single site mutation (Upper) and double site mutations (Lower) by recombinant p38 was
demonstrated by autoradiography. The amount of protein used in the phosphorylation
reactions was shown by Coomassie Blue Staining (CBS). (C) Phosphorylation of
overexpressed HA-p68s, wild type (WT) and mutants (Single site mutation, Upper, and
Double site mutations, Lower), in HCT116 cells with/without oxaliplatin treatment (Oxa,

127
+/-) was analyzed by immunoblotting the p68 that was immunoprecipitated (IP: p68)
using antibody against phospho-threonine (IB: 14B3). The immunoblot of p68 (IB: p68)
from immunoprecipitates represented the amount of p68 that was precipitated.
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Figure 2.4 Effects of p68 phosphorylation on cell apoptosis
(A) HCT116 cells were treated by non-targeting siRNA (NT) or siRNA targeting p68
(p68) to knockdown p68 for 24 hours. Wild type and the different mutants of p68 were
overexpressed in the p68 knockdown cells. P68 (IB: p68) immunoblot represented the
cellular levels of p68 (both endogenous and overexpressed). The immunoblot of
GAPDH (IB: GAPDH) served as a loading control.
Cell apoptosis (B) and viability (C) of the cells in (A) that were treated or untreated with
oxaliplatin were measured by a caspase-3 apoptosis kit (B) or MTT assay (C). The cell
apoptosis and viability were presented as relative apoptosis and relative viability by
defining the apoptosis and viability of the vector expressing cells without oxaliplatin
treatment as 1. Error bars represented standard deviations of four independent
experiments.
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CHAPTER 3
P68 RNA HELICASE REGULATES THE EXPRESSION OF TUBULIN
POLYMERIZATION PROMOTING PROTEIN INVOLVED IN NEURITE
OUTGROWTH AND GLIOMA SUPPRESSION

3.1 ABSTRACT
P68 RNA helicase is a RNA helicase with DEAD-box motif. It functions in the
regulation of gene transcription. Previous studies revealed that p68 regulates the
expression of several genes whose products are required in controlling the stability and
dynamics of different cytoskeleton.

Experiments were designed to characterize the

function of p68 in transcriptional regulation of tubulin polymerization-promoting protein
(TPPP/p25). P68 is shown to mediate transcriptional regulation of TPPP/p25 gene by
associating with TPPP/p25 gene promoter. Expression of TPPP/p25 and its regulation
by p68 is found to be an important event for cell differentiation and neurite outgrowth.
Loss of TPPP/p25 expression contributes to the development and progression of
gliomas. The studies performed reveal an important molecular factor that regulates
TPPP/p25 to mediate the regulation of differentiation induced by the growth-factor.

3.2 INTRODUCTION
TPPP/p25 was thought to be expressed only in nervous tissues, including in
neural cells and myelinating oligodendrocytes (Takahashi, Tomizawa et al. 1993)
(Takahashi, Tomizawa et al. 1991) (Kovacs, Laszlo et al. 2004). Careful analyses
revealed that TPPP/p25 is expressed in many tissue types, including liver, heart, and
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lung tissues (Acevedo, Li et al. 2007). However, the elevated levels of the protein are
only observed in a few specific tissue types. The detailed cellular function of TPPP/p25
is not yet well defined. It is believed that the protein is likely involved in stabilizing the
microtubular structure/network to maintain specific cell shape or morphology (Lehotzky,
Tirian et al. 2004) (Hlavanda, Kovacs et al. 2002). Abnormal expression of TPPP/p25
has been associated with a number of pathological conditions (Kovacs, Laszlo et al.
2004). Abnormally high levels of TPPP expression that lead to protein deposition is an
important characteristic of several neurodegenerative diseases, such as multiple system
atrophy (MSA) and Parkinson’s disease (Kovacs, Laszlo et al. 2004) (Kovacs, Gelpi et
al. 2007) (Lindersson, Lundvig et al. 2005). Very high levels of TPPP/p25 have been
observed to closely correlate with multiple sclerosis (MS) progression (Vincze, Olah et
al. 2011). TPPP/p25 expression is almost completely lost in oligodendrogliomas,
indicating a critical role of the protein in the disease development and progression
(Preusser, Lehotzky et al. 2007).
P68 RNA helicase is a RNA helicase with DEAD-box motif (Lane and Hoeffler
1980; Crawford, Leppard et al. 1982). It is implicated in cellular proliferation and
differentiation (Stevenson, Hamilton et al. 1998), and its abnormal expression is linked
to cancer progression (Causevic, Hislop et al. 2001). It is implicated by several
independent studies that p68 is involved in regulating the transcription of several genes,
including estrogen receptor alpha (ERα) (Endoh, Maruyama et al. 1999), and p53regulated genes (Bates, Nicol et al. 2005). It interacts with RNA Pol II and p300/CBP
(Rossow and Janknecht 2003). However, molecular mechanism of p68 to execute
transcriptional regulation is not well understood. P68 interacts with histone deacetylase
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1 (HDAC1) to functionally regulate gene expression (Wilson, Bates et al. 2004). Studies
suggested the functional involvement of p68 in chromatin remodeling through
modulation of various protein interactions in the large, assembled chromatin
remodeling-complex, Mi-2/NuRD. This suggests a novel mechanism by which p68 RNA
helicase regulates gene expression (Carter, Lin et al. 2010). In this study, p68 is found
to be functionally involved in regulating TPPP/p25 expression. P68 regulates the
expression of TPPP/p25, and thus, consequently, controls the differentiation of neuronal
cells. TPPP/p25 has been shown to be dramatically downregulated in human brain
tumors (Preusser, Lehotzky et al. 2007). Our results show that expression of TPPP/p25
in glioma cells significantly reduces the cell growth, indicating a therapeutic potential of
this protein.

3.3 RESULTS
3.3.1 P68 RNA helicase regulates transcription of TPPP/p25 gene.
P68 RNA helicase transcriptionally regulates several genes (Endoh, Maruyama
et al. 1999) (Bates, Nicol et al. 2005) (Rossow and Janknecht 2003). To further
understand the function of p68 in transcription regulation, we carried out a ChIP–onChip study with SW620 colon cancer cells using antibody against p68 and human
promoter Tiling 1.0R array (Affymetrix, Santa Clara, CA) which is a single array
consisting of probes spanning a subset of human promoter regions selected from NCBI
human genome assembly. ChIP-on-Chip analysis indicated that p68 interacted with the
promoters of a number of cytoskeleton-regulating genes (Table 3.1). Tubulin
Polymerization Promoting Protein (TPPP/p25) showed a high affinity for the p68
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promoter from the ChIP-on-ChIP results. Subsequently, ChIP experiments were
performed to confirm data from the ChIP-on-Chip analyses of TPPP/p25 promoter using
antibody against p68, and suggested that p68 interacted with the TPPP/p25 promoter
(Fig 3.1A). To further confirm the data from ChIP that p68 RNA helicase indeed
regulated TPPP/p25 expression, we used RT-PCR analysis to probe the effects on
TPPP/p25 gene expression by knocking down p68 from the cells by siRNA. Data from
these analyses indicated that p68 knockdown down-regulated the expression of
TPPP/p25 (Fig 3.1B). Quantitative RT-PCR analysis demonstrated that p68 knockdown
decreases TPPP/p25 mRNA by almost 3-fold (Fig 3.1C). Next, the effect of p68
knockdown in the regulation of TPPP/p25 expression at the protein level was further
verified by immunoblot analysis. Knockdown of p68 decreases TPPP/p25 protein
expression levels in the cells (Fig 3.1D). Overexpression of p68 in the cells after p68
knockdown restored the downregulation of TPPP/p25 expression (Fig. 3.1E). These
results together suggested that p68 played a role in TPPP/p25 gene transcription.

3.3.2 P68 RNA helicase regulates the neurite outgrowth of PC12 neuronal cells.
The preceeding experiments demonstrated that p68 regulates TPPP/p25
expression. Next, we explored the physiological relevance of this regulation. To address
this issue, we used PC12 cells as our study system. PC12 cells (ATCC, Manassas, VA)
are rat adrenal gland pheochromocytoma cells which can differentiate into cells
resembling neurons with Nerve-Growth Factor (NGF) stimulation (Greene and Tischler
1976). The expression levels of TPPP/p25 in PC12 cells were first examined using
immunoblot analysis. The results showed that TPPP/p25 was expressed in these cells
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(Fig 3.2A). TPPP/p25 expression was increased upon stimulation of the PC12 cells for 3
days. This increase correlated with the neurite outgrowth of the PC12 cells under NGF
stimulation (Fig 3.2B). To further evaluate whether TPPP/p25 expression plays a role in
the differentiation, TPPP/p25 was knocked-down in the PC12 cells (Fig. 3.2C). The
TPPP/p25 knockdown cells were induced for differentiation with 50 ng/ml NGF
treatment. Data analysis showed that neurite outgrowth was reduced under NGF
stimulation, while it was apparent in the cells treated with non-specific siRNA (Fig.
3.2D). We questioned whether the regulation of TPPP/p25 expression by p68 RNA
helicase has any functional significance in controlling the differentiation of PC12 cells to
neurons. Thus, p68 was knocked-down in PC12 cells. As expected, TPPP/p25 levels in
the p68 knockdown PC12 cells were reduced (Fig 3.2E & F). The p68 knockdown PC12
cells were subsequently induced for differentiation by the NGF treatment. It was evident
that the PC12 cells displayed a significantly reduced number of neurites upon NGF
treatment with p68 knockdown (Fig 3.2G). These experiments indicated that p68 plays a
role in PC12 differentiation via regulation of TPPP/p25 transcription.

3.3.3 TPPP/p25 expression plays a role in the progression of gliomas.
High levels of TPPP/p25 are observed in oligodendrocytes and neurons. Upon
development and progression of oligodendrogliomas, TPPP/p25 expression is
decreased until undetectable (Preusser, Lehotzky et al. 2007). The TPPP/p25 levels in
10 different glioma tissue samples with same number of normal brain tissue sections
were examined. Histology analyses revealed that TPPP/p25 levels were very high in
both oligodendrocytes and neuronal cells in the normal brain tissues. However, in the
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corresponding sites from glioma tissues, TPPPp25 levels were very low or undetectable
(Fig 3.3A). Thus, histology analyses suggested that loss of TPPP/p25 expression
correlates with the development and progression of the disease. To understand whether
TPPP/p25 expression is involved in glioma development, the growth of several human
glioma cell-lines specifically, T98G (ATCC, Manassas, VA), U87MG (ATCC, Manassas,
VA), and LN229 (ATCC, Manassas, VA) were examined after overexpressing
TPPP/p25. We first probed the expression levels of TPPP/p25 in these selected cell
lines using RT-PCR and immunoblot analyses. The analyses showed that TPPP/p25
was poorly expressed, if at all in these gliomas cells (Fig. 3.3B & C). We then analyzed
its overexpression effects on the cell proliferation of these selected cells transfected
with FLAG-TPPP/p25 expression plasmid. TPPP/p25 over-expression led to high levels
of expression of TPPP/p25 protein relative to vector alone transfected cells (Fig 3.3D).
Cell proliferation and viability of the TPPP/p25 expressing cells were analyzed by BrDU
cell proliferation assay. Expression of TPPP/p25 dramatically decreased the cell
proliferation rate of these glioma cells as shown by use of histology and BrDU assay
(Fig 3.3E & F). We further analyzed whether the effects of expression of TPPP/p25 on
the growth was mediated by cell apoptosis. To this end, we probed for activation of
caspase-3 due to TPPP/p25 expression in T98G and U87MG cells. Data shown in
figure 3.3G show that caspase-3 was not activated with or without TPPP/p25
expression (Fig 3.3G). Since TPPP/p25 is a microtubule associated protein (Hlavanda,
Kovacs et al. 2002), we measured the microtubule stability upon TPPP/p25 expression
in T98G cells. Analysis of these experiments demonstrated that expression of
TPPP/p25 in these glioma cells caused an increase in microtubule stability. The levels
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of acetylated tubulin, a modified tubulin that has high tendency to polymerize and is a
measure of microtubule stability (Piperno, LeDizet et al. 1987), increased (Fig 3.3H).

3.4 DISCUSSION
In this report, regulation of expression of TPPP/p25 gene is described. P68 is
shown to mediate transcriptional regulation of TPPP/p25 gene by associating with
TPPP/p25 gene promoter. The study suggests that p68 is functionally involved in
neuronal differentiation, which echoes early observations showing that p68 plays a role
in differentiation of adipocytes and skeletal muscle cells (Caretti, Schiltz et al. 2006)
(Kitamura, Nishizuka et al. 2001).
Molecular mechanism by which p68 regulates TPPP/p25 expression is still not
known. Clearly, p68 is expressed in high levels in undifferentiated PC12 cells, while
TPPP/p25 levels increase beyond this level during differentiation. There maybe two
explanations for the observations: p68 is necessary, but not sufficient for upregulation of
TPPP/p25 expression, and other factors are also required in concert to regulate
TPPP/p25 expression and activate cell differentiation programs; p68 may be
posttranslationally modified with growth factor stimulation and may be only a modified
sub-population of p68 is active in regulating TPPP/p25 expression. It has been reported
that p68 undergoes various posttranslational modifications upon exposure to different
growth factors and cytokines stimulation of specific cells (Yang, Lin et al. 2005; Yang,
Lin et al. 2006; Yang, Lin et al. 2007). These modified p68s function in a number of
different cellular processes (Yang, Lin et al. 2005; Yang, Lin et al. 2006; Yang, Lin et al.
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2007). It would be interesting to probe whether p68 is posttranslationally modified during
induction of differentiation.
Abnormal overexpression and accumulation of TPPP/p25, and its association
with other neuronal-aggregating proteins, are major causes for a number of neuronal
degenerative diseases (Kovacs, Laszlo et al. 2004; Lindersson, Lundvig et al. 2005;
Kovacs, Gelpi et al. 2007). TPPP/p25 is believed to co-aggregate with tau and other
cytoskeletal associated proteins and this leads to deposition of the peptides cleaved
from these proteins especially under several stress conditions (Kovacs, Gelpi et al.
2007). On the other hand, reduction of TPPP/p25 expression in oligodendrogliomas is
clearly associated with the development of the disease by an unknown mechanism
(Preusser, Lehotzky et al. 2007). Thus, regulation of the expression of TPPP/p25 needs
to be finely balanced. Currently, molecular mechanisms that control TPPP/p25
expression are largely unknown. This report represents the first study of exploring the
regulatory mechanism for TPPP/p25 gene expression.
TPPP/p25 is down-regulated in human brain tumors. Overexpression of
TPPP/p25 in transfected glioma cell-lines reduced cancer cell proliferation. How
expression of TPPP/p25 arrests glioma cell growth is another unanswered question.
Our results demonstrate that expression of TPPP/p25 does not activate the caspase-3
mediated cell apoptosis signaling. Furthermore, our results showed that the stability of
microtubules is increased with the expression of TPPP/p25, suggesting a possibility of
interrupting

cell-cycle

progression

at

mitosis,

where

both

polymerization/deploymerization of microtubules is supposed to be active. This notion is
consistent with one observation that TPPP/p25 expression affects the mitotic spindle
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assembly. Alternatively, expression of TPPP/p25 may have a role in maintaining the
differentiated state of neuronal cells, while loss of TPPP/p25 expression may be
important for their de-differentiation.

3.5 MATERIALS AND METHODS
3.5.1 Reagents and Antibodies
NGF was bought from Sigma (Sigma, St. Louis, MO). P68 antibodies were raised
against C-terminal domain of p68. Polyclonal antibody was generated from Auburn
University Hybridoma Facility while the monoclonal antibody was obtained from
Invitrogen (Invitrogen, Grand Island, NY). The different commercial antibodies used
were: TPPP/p25 antibody from Santa Cruz, Santa Cruz, CA and Abcam, Cambridge,
MA, GAPDH antibody (Millipore, Billerica, MA), caspase-3 and cleaved caspase-3
antibodies (Cell Signaling Technology, Beverly, MA), acetylated tubulin antibody (Cell
Signaling Technology, Beverly, MA) and lamin A/C antibody (Cell Signaling Technology,
Beverly, MA).

3.5.2 Cell Culture, DNA constructs, Transfections, and siRNA Interference
PC12 (Catalog # CRL-1721), HeLa (Catalog # CCL-2), T98G (Catalog # CRL1690) and U87MG (Catalog # HTB-14) cells were obtained from ATCC (ATCC,
Manassas, VA). The cDNA of p68 ORF was subcloned into pHM6 (Roche, Indianapolis,
IN) vector at HindIII site to get HA-tagged p68 expression vector. TPPP/p25 cDNA
(Origene, Rockville, MD) was subcloned into p3XFLAG-myc-CMV™-24 Expression
Vector (Sigma, St. Louis, MO). Fugene HD (Roche, Indianapolis, IN) and lipofectamine
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2000 (Invitrogen, Grand Island, NY) were used to carry out transfections. SiRNA
knockdown was done using lipofectamine RNAimax (Invitrogen, Grand Island, NY). P68
siRNA was purchased from Dharmacon (Thermo Fisher Scientific Dharmacon,
Lafayette, CO). SiRNA oligonucleotides with random sequence (non-targeting) was
used as negative control. The siRNA sequence was as follows: siRNA oligonucleotides
against

p68

(sense:

5’-GCAAGUAGCUGCUGAAUAUUU-3’;

antisense:

5’-

AUAUUCAGCAGCUACUUGCUU-3’).

3.5.3 Cellular Extract Preparation, Immunoblot Analysis and Immunofluorescence
staining
All cell lysates were prepared using 1X RIPA buffer and Bradford assay (BioRad, Hercules, CA) was used to determine protein concentration. Immunoblot analyses
were performed by a previously developed procedure (Liu, Z. R., Sargueil, B. et al.
1998). The immunocomplexes were visualized by chemiluminescence with Supersignal
West Dura Extended Substrate (Pierce, Thermo Fisher Scientific Dharmacon, Lafayette,
CO) and goat anti-mouse IgGs or anti-rabbit IgGs coupled to horseradish peroxidase
were used as secondary antibodies (Thermo Fisher Scientific Dharmacon, Lafayette,
CO). The immunofluorescence and confocal imaging procedures were very similar to
previous studies (Yang, Lin et al. 2006). Immunohistochemical staining of normal and
glioma tissue sections was done by Dr. Daniel Brat’s laboratory using tissue sections
obtained from Emory’s tissue bank.
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3.5.4 RT-PCR
Total RNA extraction kit (Qiagen, Valencia, CA) was used to carry out RNA
isolation and Improm II reverse transcription system (Promega, Madison, WI) was used
for RT-PCR. The cDNA used in the reaction consisted of cDNA, forward and reverse
primers and 1X master mix from Promega (Promega, Madison, WI). The PCR cycle
was as: 94°C for 15 sec, 55°C for 30 sec, and 72°C for 30 sec with an additional
extension time of 10 mins. RT-PCR results were analysed by running the samples on 2
to 3% agarose gels with ethidium bromide. Primers used were: TPPP/p25 (sense 5’CAGGTGAAGAGCCTGGAGTC-3’; antisense 5’- GTTTCCTTGTCTGTGGGTGAA-3’);
GAPDH

(sense

5’-

GAGTCAACGGATTTGGTCGT-3’;

anti-sense

5’-

TTGATTTTGGAGGGATCTCG-3’). GAPDH was used as PCR loading control.

3.5.5 Chromatin Immunoprecipitation (ChIP)
ChIP Kit from IMGENEX (IMGENEX, San Diego, CA) was used for chromatin
immunoprecipitation assays. The TPPP/p25 promoter was immunoprecipitated using
p68 (poly-p68) antibody. TPPP/p25 promoter immunoprecipitation was detected by
PCR using primers: TPPP/p25 (sense 5’-CAGGTGAAGAGCCTGGAGTC-3’; antisense
5’-GTTTCCTTGTCTGTGGGTGAA-3’);

GAPDH

(sense

5’-

TACTAGCGGTTTTACGGGCG -3’) antisense 5’-TCGAACAGGAGGAGCAGAGAGCGA
-3’). RNA Pol II (IMGENEX, San Diego, CA) and rabbit IgG (Santa Cruz, Santa Cruz,
CA) antibodies were used for positive and negative controls respectively.
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3.5.6 Cell Proliferation Assays
Cell proliferation analysis was performed using BrdU cell proliferation kit from
EMD Millipore (Millipore, Billerica, MA). Briefly, BrdU label was added for 18 hrs and the
cells were subsequently incubated with anti-BrdU primary antibody (Millipore, Billerica,
MA) and goat anti-mouse secondary IgG (Millipore, Billerica, MA, peroxidase
conjugate). The nuclei incorporation of BrdU was measured using a spectrophotometer
microplate reader (Victor 3TM; PerkinElmer Life Sciences) at a wavelength of 450nm.
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Table 3.1 ChIP-on-ChIP analysis of cytokeletal genes regulated by p68.
ChIP-on-ChIP study was performed using SW620 cells with pAbp68 and human
promoter Tiling 1.0R array (Affymetrix). These genes showed up on all the three
different ChIP-on-ChIP experiments for high affinity binding to the p68 promoter.

ID

Gene Name

Cytoskeleton

NM_007030

Tubulin polymerization promoting protein

Microtubuleassociated

NM_021046

Keratin associated protein 5-8

Intermediate-filament
binding protein

NM_177987.2

Tubulin-β 8

Microtubuleassociated

NM_001146225.1

Keratin 72

Intermediate-filament
associated

NM_001009931

Hornerin

Intermediate-filament
associated

NM_000445

Plectin 1, intermediate filament binding
protein

Intermediate-filament
binding protein

NM_007183

Plakophilin 3

Intermediate-filament
associated
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Figure 3.1A Chromatin immunoprecipitation (ChIP) of the TPPP/p25 promoter.
HeLa cells grown at 37ºC were harvested for ChIP analyses with either p68-specific
antibody (pAbp68) or IgG antibody as a control. PCR products from sheared chromatin
served as inputs. Control reactions were set up using ChIP by RNA POL II and IgG
antibodies.
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Figure 3.1B & C Qualitative and quantitative RT-PCR demonstrating p68
regulation of TPPP /p25 mRNA expression.
Expression of TPPP/p25 was analyzed by qualitative RT-PCR (B) and real time RTPCR (C). Total RNA was isolated from the HeLa cells and used for RT-PCR. GAPDH
RT-PCR was used as a PCR loading control. RT-PCR samples containing no template,
no reverse transcriptase or positive control template were additional controls employed.
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Figure 3.1D TPPP/p25 protein expression affected by p68 expression
Expression of TPPP/p25 and p68 in HeLa cells were determined by immunoblot
analysis of TPPP/p25 and p68 antibodies respectively. The lysate was prepared from
cells with non-target (NT) or siRNA targeting p68 (p68). Immunoblot analysis of GAPDH
using GAPDH antibody was used as a loading control for loading of total cellular
proteins.
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Figure 3.1E P68 upregulates TPPP/p25 expression
Expression of TPPP/p25 and p68 in HeLa cells were determined by immunoblot
analysis of TPPP/p25 and p68 antibodies respectively. The lysate was prepared from
cells with non-target (NT) or siRNA targeting p68 (p68). HA vector and HA-p68 were
exogenously expressed in the cells with p68 knockdown. Immunoblot analysis of
GAPDH using GAPDH antibody was used as a loading control for loading of total
cellular proteins.
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Figure 3.2A Expression of TPPP/p25 in PC12 cells
Immunoblot analysis of cellular extracts made from PC12 and HCT-116 cells was used
to detect cellular level of TPPP/p25 by using TPPP/p25 antibody. HCT-116 cell lysate
served as a positive control. Immunoblot analysis of GAPDH using GAPDH antibody
was used as a loading control for loading of total cellular proteins.
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Figure 3.2B NGF treatment upregulates TPPP/p25 expression
Phase contrast microscopy of PC-12 cells (Upper panel) cultured on poly-lysine with
NGF for 3 days (right column). The left column indicates PC12 cells grown in medium
without NGF for 3 days. NGF concentration used was 50 ng/ml. Note the appearance of
neurite outgrowth in NGF containing PC12 cell cultures. Expression of TPPP/p25
protein level in PC12 cells was examined by immunoblot analysis of cell lysate with
TPPP/p25 antibody. The cells were harvested for immunoblot analysis after treatment
with NGF at 50ng/ml for 3 days. Immunoblot analysis with GAPDH antibody served as a
control for equal loading.
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Figure 3.2C Knockdown of TPPP/p25 in PC12 cells
Expression of TPPP/p25 after knockdown was detected by RT-PCR. GAPDH RT-PCR
served as a PCR control for loading.

152

D
NT

NT

With
NGF

No NGF

K-TPPP/p25

K-TPPP/p25

Figure 3.2D TPPP/p25 regulates the differentiation of PC12 neuronal cells.
Immunofluorescent staining of PC12 cells after knockdown of TPPP/p25. TPPP/p25
was knocked down in PC12 cells with TPPP/p25 siRNA and non-target siRNA was a
control. PC12 cells were then stimulated with NGF. NGF was used at 50ng/ml
concentration for 3 days. The left columns indicate PC12 cells cultured in medium
without NGF for 3 days while the right columns denote PC12 cells with NGF treatment.
The upper two panels represent non-targeting siRNA treated cells while the lower two
panels represent TPPP/p25 knockdown cells. Tubulin antibody was used for detection
of differentiation. Note the appearance of neurite outgrowth in NGF containing PC12 cell
cultures.
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Figure 3.2E P68 upregulates TPPP/p25 expression under NGF treatment of PC12
neuronal cells at the RNA level.
Expression of TPPP/p25 was examined by RT-PCR. P68 was knocked down in the
PC12 cells and the cells were treated with and without NGF. NGF concentration used
was 50 ng/ml. GAPDH RT-PCR served as a PCR control for loading.
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Figure 3.2F P68 upregulates TPPP/p25 protein expression under NGF treatment of
PC12 neuronal cells.
Expression of TPPP/p25 protein in PC12 cells was determined by immunoblot analysis
with TPPP/p25 antibody. The cells were harvested for immunoblot analysis after
knockdown with p68 siRNA (p68) and non-target (NT) siRNA served as a control. The
cells were grown in with and without NGF medium for 2 days. NGF concentration used
was 50 ng/ml. Immunoblot analysis with GAPDH antibody was used as a loading
control.
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Figure 3.2G P68 RNA helicase regulates the differentiation of PC12 neuronal cells.
Immunostaining of PC12 cells after knockdown of p68. PC12 cells with p68 siRNA and
non-target siRNA were treated for 2 days with NGF. NGF was used at 50 ng/ml
concentration. PC12 cells were stained with tubulin antibody for demonstration of
microtubule rearrangement and differentiation and TPPP/p25 antibody to detect
expression levels and distribution of TPPP/p25. Note the appearance of neurite
outgrowth in NGF containing non-targeting PC12 cell cultures.
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Normal Brain Sections

Glioblastoma Brain Sections

Figure 3.3A Immunohistochemical staining of TPPP/p25 in sections from normal
brain and glioblastoma tissue sections.
Left two panels represent TPPP/p25 staining of normal brain tissue sections while the
right two panels denote TPPP/p25 staining of representative cases of glioblastoma
tissue sections. In the left two panels, TPPP/p25 expression in paraffin-embedded
normal brain tissue specimens was evaluated using anti-TPPP/p25 antibody. Intense
brown staining of TPPP/p25 is observed in neuronal cell bodies with diffuse staining of
neuropil and neuronal processes. TPPP/p25 immunoreactivity is also observed in
oligodendrocytes of non-tumor brain tissue sections. Endothelial cells also stain positive
for TPPP/p25. Right two panels represent glioblastoma tissue sections lacking
TPPP/p25 expression in most tumor sections. Strong staining of vascular endothelial
cells of native vascular structures and newly developing proliferating endothelial cells is
also observed. Blue color indicates haematoxylin nuclear staining of the nuclei of all
cells.
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Figure 3.3B Expression of TPPP/25 in three different glioma cell-lines at the
mRNA level.
RT-PCR analysis of RNA extracted from glioma cells, specifically, T98G, U87MG and
LN229 was performed using TPPP/p25 primers to detect endogenous TPPP/p25 RNA
levels. HEK and HCT116 were used as positive controls of TPPP/p25 expression.
GAPDH RT-PCR served as a PCR control for loading.
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Figure 3.3C Expression of TPPP/25 in different glioma cell-lines at the protein
level.
Immunoblot analysis of cell lysate prepared from different glioma cells was performed to
detect endogenous protein levels using TPPP/p25 antibody. Correspondingly, p68
expression levels in these cells were also probed using p68 antibody. Mouse brain
extract (MBE) was used as a positive control along with HEK and HCT-116 cell lysates.
Immunoblot with GAPDH antibody served as a loading control while TPPP/p25 protein
was seen as a doublet in these cells.
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Figure 3.3D Analysis of TPPP/p25 expression in T98G and U87MG cells after
transient overexpression of TPPP/p25.
Immunoblot analysis of T98G and U87MG cell lysate after transfecting with FLAG or
FLAG-TPPP/p25 (TPPP/p25) expression plasmid was done. Immunoblot analysis was
performed with TPPP/p25 antibody and demonstrated abundant expression of
TPPP/p25 protein. Immunoblot with GAPDH antibody served as a loading control.
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Figure 3.3E TPPP expression effects on cellular proliferation and morphological
features.
Methylene blue staining of T98G and U87MG cells 48 hrs after transfection with FLAG
(Vector) or FLAG-TPPP/p25 (TPPP/p25) was performed to detect morphological
features. Two left panels represent T98G cell staining while two right panels denote
U87MG cell staining. Top two panels are U87MG and T98G cells with TPPP/p25
overexpression while bottom two panels represent U87MG and T98G cells without
TPPP/p25 overexpression. Note dendritic processes in TPPP/p25 transfected cells.
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Figure 3.3F TPPP/p25 expression decreases cell proliferation
The role of TPPP/p25 overexpression on T98G and U87MG cells was established by
BrdU proliferation assay. Cells were overexpressed with FLAG (Vector) or FLAGTPPP/p25 (TPPP/p25) expression plasmids. Growth rate was measured at 48 and 72
hrs after transfection using mean absorbance reading at OD 405 nm. Error bars show
standard deviations from three different experiments.
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Figure 3.3G Detection of caspase-3 activation in apoptosis induction in T98G and
U87MG cells upon expression of TPPP/p25.
Immunoblot analysis was performed to show caspase-3 activation by detection of
cleaved caspase-3 peptides using cleaved caspase-3 antibody. Cells were harvested
48 hrs after tranfection with FLAG or FLAG-TPPP/p25 (TPPP/p25) expression
plasmids. Immunoblot analysis with caspase-3 antibody was done to detect total
caspase-3 levels in the cells. Immunoblot with lamin a/c antibody was the loading
control.
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Figure 3.3H Expression of TPPP/p25 increases stable microtubule levels.
Immunoblot analysis of lysates from T98G cells was performed after transfecting with
FLAG (Vincze, Olah et al.) or FLAG-TPPP/p25 (TPPP/p25) was performed. Immunoblot
analysis with acetylated tubulin was done to measure the levels of stable microtubule.
Immunoblot with tubulin antibody was used as a loading control while immunoblot with
TPPP/p25 antibody was used to measure TPPP/p25 expression levels.
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CHAPTER 4
CONCLUSIONS AND DISCUSSIONS

4.1 INTRODUCTION
P68 RNA helicase is implicated in different biological processes. It has been
shown that p68 is an important splicing factor in pre-mRNA splicing (Liu 2002).
Numerous studies have shown that p68 serves as a transcriptional co-activator for a
number of different genes such as ERα, p53, Snail etc (Endoh, Maruyama et al. 1999)
(Bates, Nicol et al. 2005; Carter, Lin et al. 2010). Previous reports have indicated the
role of p68 in organ development and transformation (Stevenson, Hamilton et al. 1998).
Tyrosine phosphorylation of p68 was studied by Yang et al. and they discovered an
unanticipated function of c-abl in the EMT process. Tyrosine phosphorylated p68
interacts with β-catenin and consequently, is involved in cell proliferation (Yang, Lin et
al. 2006). Phosphorylated p68 also activates transcription of proliferative genes such as
c-myc and cyclin D1 (Yang, Lin et al. 2007). The aim of this dissertation is to elucidate
the role(s) of p68 in other processes, including characterizing the function of threonine
phosphorylation of p68. This dissertation also aims to understand the transcriptional
regulation of a cytoskeletal gene, TPPP by p68 and also study the role of p68 in cellular
differentiation.
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4.2

OXALIPLATIN

TREATMENT

OF

CRC

INDUCES

P68

THREONINE

PHOSPHORYLATION.
Colorectal cancer was relatively resistant to chemotherapy initially (Blijham
1991). However, the clinical outcomes have improved in the past few years as a result
of using a combination of two to three chemotherapeutic agents (Buyse, ZeleniuchJacquotte et al. 1988). Platinum-based DNA damaging agents like oxaliplatin are
among the commonly used drugs in colorectal cancer teatment. The apoptosis induced
in tumor cells by oxaliplatin has been demonstrated as one of its mechanism of actions
in chemotherapy (Zunino, Perego et al. 1997). However, characterization of molecular
pathways that mediate the cellular response to oxaliplatin and complete understanding
of its mode of action are essential for further improving the therapeutic efficacy of the
drug.
In our study, we found that p68 is one of the cellular targets of oxaliplatin that
mediates the downstream effects of oxaliplatin in apoptosis. P68 is implicated in p53mediated apoptosis induced by DNA damaging agent etoposide (Bates, Nicol et al.
2005). Thus, p68 may be a common element in the DNA damaging pathways. Our
results show that oxaliplatin treatment dramatically increases p68 threonine
phosphorylation. The threonine phosphorylation reaches a peak and then p68 gets
dephosphorylated suggesting that oxaliplatin treatment activates a phosphatase that
dephosphorylates p68. Phosphorylation and dephosphorylation of proteins represent a
common mechanism for regulating enzymatic activity and cellular functions of proteins
including numerous transcription factors (Holmberg, Tran et al. 2002). P68 is known to
be subjected to modification by phosphorylation and has been demonstrated to be
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phosphorylated at multiple residues (Yang and Liu 2004). Phosphorylation at multiple
sites suggests that p68 regulation is complex. Tyrosine phosphorylation of p68 is
observed in several different cancer cells. PDGF-stimulation of HT-29 cells leads to
tyrosine phosphorylation of p68 at Y593 by c-abl (Yang, Lin et al. 2005; Yang, Lin et al.
2006) TNF-α treatment phosphorylates p68 at threonine and dephosphorylates p68 at
tyrosine residues indicating that TNF-α treatment reciprocally regulates the threonine
and tyrosine phosphorylations of p68 (Yang, Lin et al. 2005). Like TNF-α treatment,
oxaliplatin also causes threonine phosphorylation of p68 and may also dephosphorylate
p68 at tyrosine to affect cell survival. Threonine phosphorylation and tyrosine
dephosphorylation may represent a cellular apoptotic response to oxaliplatin treatment.
This may imply that p68 is a multifunctional protein that has different biological roles in
multiple cellular pathways and specifically, phosphorylation of p68 regulates the
enzymatic activity and cellular functions of p68 in different pathways in response to
different external stimuli.

4.3 P68 IS PHOSPHORYLATED BY P38 MAP-KINASE AT T564 AND/OR T446
UPON OXALIPLATIN TREATMENT.
P38 MAP-kinase is known to be activated following treatments with DNA
damaging compounds, UV light, ionizing radiation, etoposide. It is involved in mediating
cancer cell apoptosis triggered by these agents (Tanos, Marinissen et al. 2005; Wang
and Lippard 2005; Wood, Nail et al. 2006; Lu, Rau et al. 2011). Although different
activators and substrates of p38 in different DNA damaging pathways are somewhat
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known, the exact signaling pathway is still unclear and the different molecular factors
involved vary and depend on different DNA-damaging agents.
In our studies, we found that oxaliplatin treatment of colon cancer induces p38
activation

and

phosphorylation

in

a

time

dependent

manner.

P38

activation/phosphorylation follows a similar time course with p68 phosphorylation at
threonine

suggesting

a

parallel response.

In vitro

phosphorylation

and

co-

immunoprecipitation assays demonstrate that p38 interacts with and phosphorylates
p68. This data is in consistence with the earlier reports of p68 being a new substrate for
p38. P68 is phosphorylated by p38 in response to TNF-α stimulation and this represents
a new cellular mechanism by which p38 executes TNF-α signal downstream (Yang, Lin
et al. 2005). To further confirm that p38 phosphorylates p68 in vivo, p38 constitutively
activated mutant is used. Expression of the p38 constitutively activated mutant
increases p68 phosphorylation at threonine. Phosphorylation assays demonstrate T564
and/or T446A as the phosphorylation sites of p38 and it is well established that p38
MAP-kinase often phosphorylates multiple sites in its targets (Yang, Xiong et al. 2002;
De Chiara, Marcocci et al. 2006).

4.4 PHOSPHORYLATION OF P68 AT THREONINE MEDIATES THE EFFECTS OF
OXALIPLATIN IN THE INDUCTION OF APOPTOSIS
Our studies show that p68 phosphorylation at T564/446 by p38, at least partially,
mediates the effects of oxaliplatin on apoptosis induction. Phosphorylation causes
conformational change in critical domains which may enhance the binding to
downstream target proteins functioning in distinct signaling pathways. How the
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phosphorylation of p68 at T564 and T446 mediates cell apoptosis is an open question.
One plausible explanation is that the phosphorylated p68 may change p68 interacting
partners in the cells, which causes p68 to target a particular apoptosis mediating protein
or complex. The consequence for the p68 targeting is activation of apoptotic function of
the targeted protein or complex. A number of DEAD-box RNA helicases associate with
apoptosis induction protein or complex. For example, DDX42 modulates the apoptotic
function of ASPP2 by direct interaction with it (Uhlmann-Schiffler, Kiermayer et al.
2009). Interaction between GABA receptor associated protein (GABARAP) and DDX47
is required for induction of neuronal cell apoptosis (Lee, Rho et al. 2005). However, the
mechanism by which this DEAD-box RNA helicase regulates the apoptotic process is
not known. Thus, it will be very interesting to find whether p68 phosphorylation at T564
and/or T446 mediates the association of the protein with a particular apoptosis inducing
complex to activate the complex. Another explanation of p68 phophorylation mediating
the effects of oxaliplatin on apoptosis induction may be that p38 MAP-kinase
phosphorylates specific transcription factors or other proteins to regulate cell apoptosis,
proliferation or inflammatory processes. Also, the involvement of p68 in transcriptional
regulation is well studied. Thus, it seems plausible that p38-mediated p68
phosphorylation may promote or activate the transcription activation function of p68 and
may represent a new mechanism in regulating gene expression during apoptosis
induction in response to oxaliplatin. It is also of interest to note that p68 interacts with
p53 tumor suppressor in response to etoposide treatment to stimulate transcription of
p53-dependent genes, including p21 and Bax and regulates p53-mediated apoptosis
(Bates, Nicol et al. 2005). It is highly probable that phospho-p68 may be involved in this
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process, as phosphorylation may be activating the transcription co-activator function of
p68 to bind specific promoter DNA sequences. Thus, phospho-p68 may be needed by
different stressors to regulate cellular apoptosis in different pathways. It is known that
phosphorylation of p53 at key regulatory residue like serine 15 stimulates p53transcriptional activity (Siliciano, Canman et al. 1997; Banin, Moyal et al. 1998). DDX3
RNA helicase exhibits tumor suppressor function including growth inhibition by
transcriptional modulation of p21 gene expression. It activates p21 promoter in an
ATPase-dependent but helicase-independent mechanism through its multiple Sp1 sites
(Chao, Chen et al. 2006). Thus, this study may represent a new and/or alternate
pathway for oxaliplatin mediated apoptosis where in response to oxaliplatin, p38mediated p68 phosphorylation could activate gene expression by interacting with other
transcriptional factors to promote apoptosis.

4.5 P68 RNA HELICASE REGULATES TRANSCRIPTION OF THE TPPP/25 GENE.
In this study, we report that p68 plays a role in TPPP/p25 gene transcription.
TPPP/p25 is a microtubule-associated protein belonging to the cytoskeletal gene family.
Oncomine meta-analysis study of p68 showed that p68 is co-expressed with several
other cytoskeletal genes and p68 probably regulates these genes via transcription or
splicing (Wilson and Giguere 2007). This study was confirmed by Chip-on-chip analysis
in our lab using p68 antibody. The study indicated that p68 interacts with the promoters
of a number of cytoskeleton-regulating genes. Further studies were done to narrow
down p68 regulation to a particular cytoskeletal gene, TPPP/p25. Chip experiment
demonstrated that p68 is associated with the TPPP/p25 promoter. TPPP/p25 RNA and
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protein levels in p68 knockdown cells showed that when p68 is knocked down,
TPPP/p25 levels decrease whereas when p68 is not knocked down, TPPP/p25
expression is maintained at normal levels. All these results indicate that p68 positively
regulates TPPP/p25 expression.
Interestingly, TPPP/p25 is not the only gene that is regulated by p68. P68 is
known to transcriptionally coactivate a number of genes such as ERα, p53, Snail etc
(Endoh, Maruyama et al. 1999) (Bates, Nicol et al. 2005; Carter, Lin et al. 2010).
Moreover, how p68 functions in transcription co-activation is not very well defined. It is
quite possible that p68 regulates the formation of a competent transcription complex. It
may either act as an adaptor protein for recruiting or facilitating the assembly of
transcription factors or stabilizing their interactions with chromatin via chromatin
remodeling by acting as an ATPase motor. P68 has been shown to participate in active
recruitment of TBP, RNA Pol II and chromatin remodeling SWI/SNF complex to the
muscle transcriptome and facilitates chromatin remodeling (Caretti, Schiltz et al. 2006).
It also directly interacts with the transcriptional co-activators p300 and CBP to facilitate
gene transcription by RNA Pol II. ATPase and unwinding activity of p68 are essential in
this case (Rossow and Janknecht 2003). Alternatively, p68 could influence transcription
by interacting with transcriptional repressor HDAC1. P68 can also function as a
transcriptional corepressor depending on the transcriptional complex and promoter on
which it is recruited. It is known to repress transcription by associating with HDAC1
(Wilson, Bates et al. 2004). Phospho-p68 interacts with HDAC1 and MBD3:Mi-2/NuRD
in the nuclear remodeling and deacetylation complex promoting release of HDAC1 from
the complex thereby activating Snail1 gene transcription. Thus, this Snail1
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transcriptional regulation, in turn, suppresses E-cadherin expression (Carter, Lin et al.
2010). Interestingly, phosphorylated form of p68 has also been involved in
transcriptional regulation. Phosphorylation of p68 at Y593 is found to activate cyclin D1
and c-myc transcription thereby promoting cell proliferation induced by PDGF. Phosphop68 is recruited to cyclin D1 and c-myc promoters by its interaction with βcatenin.TCF/LEF complex (Yang, Lin et al. 2007). Thus, transcriptional regulation by
phospho-p68 adds another dimension to the function of p68 in the transcriptional
regulation process.

4.6 P68 RNA HELICASE REGULATES PC12 NEURITE OUTGROWTH VIA
REGULATION OF TPPP/p25 EXPRESSION.
Functional study of TPPP/p25 regulation showed that p68 coactivates TPPP/p25
transcription and is necessary for neuronal cells to differentiate. Reduction of p68 levels
in PC12 cells leads to dramatic reduction of TPPP/p25 levels and failure of neurite
formation of PC12 cells indicating that p68, in part, is crucial for the differentiation
process. In another study, p68 has been found to be involved in PC12 differentiation by
functioning as an adaptor protein in mediating the association of v-src with PtdIns-3
kinase. This interaction is critical in cytoskeletal rearrangement responsible for the
outgrowth of neurites in PC12 cells (Haefner and Frame 1997). Likewise, knockdown of
TPPP/p25 in PC12 cells partially blocked the neurite formation process. Overall, our
results indicate that p68 and TPPP/p25 are necessary for PC12 neurite formation and
that p68 plays a role in PC12 differentiation via regulation of TPPP/p25 expression.
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P68 has been showed to be involved not only in PC12 cell differentiation but also
in adipocyte differentiation. Knockdown of p68 in mouse 3T3-L1 cells blocked
differentiation of these cells into adipocytes (Kitamura, Nishizuka et al. 2001). DDX17
(p72) found in the cells in a heterodimeric form with DDX5 (p68) has been implicated in
cellular differentiation process where DDX17 transcripts are in very high levels in rat
brain during embryogenesis but found in the adult stage. This suggests that DDX17
plays a role in neuronal differentiation during CNS development (IP, Chung et al. 2000)
Similarly, transcripts of chick and mouse homologs of p68 has been found to be in high
abundance in different embryonic tissues while p68 is implicated in the differentiation of
the monocytic leukemia cells U937 to macrophages (Stevenson, Hamilton et al. 1998;
Jost, Schwarz et al. 1999; Gingras and Margolin 2000; Seufert, Kos et al. 2000).
Furthermore, p68 is also found to be essential for skeletal myogenesis and plays a
critical role in co-regulating MyoD transcription and skeletal muscle differentiation
(Caretti, Schiltz et al. 2006). DDX3 is essential for spermatogenesis and DDX4 is
required for oogenesis (Lasko and Ashburner 1988; Lasko and Ashburner 1990;
Tomancak, Guichet et al. 1998; Foresta, Ferlin et al. 2000). DDX41 is involved in visual
and CNS system development while DDX25 is critical for spermatogenesis (Schmucker,
Vorbruggen et al. 2000; Tsai-Morris, Sheng et al. 2004). Tight regulation of gene
expression is important during differentiation and since these RNA helicases participate
in various stages of RNA metabolism like transcription etc, it indicates the importance of
RNA helicases as regulators of differentiation. Nonetheless, the precise role of p68 in
differentiation is still unknown. This poses several questions where future research
could be targeted: What is the role of p68 in differentiation? Could p68 engage in
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transcriptional programs that control differentiation? What are the downstream targets of
p68 in its function as differentiation regulator?

4.7 TPPP/p25 EXPRESSION IS IMPORTANT IN GLIOMA PROGRESSION
Glioblastomas are the most common and the most aggressive malignant tumors
in humans, involving glial cells with a median survival of 10 to 12 months (Westermark
and Nister 1995; Schechter 1999). It is reported that TPPP/p25 is highly expressed in
oligodendrocytes suggesting their role in the normal functioning of the central nervous
system (Takahashi, Tomizawa et al. 1991; Takahashi, Tomizawa et al. 1993; Vincze,
Tokesi et al. 2006). However, study on the functional role of TPPP/p25 expression in
glioblastomas is not established. In our study, we found through immunohistological
analysis of tissue samples from glioblastoma patients that TPPP/p25 levels are very low
or absent. This is also confirmed by undetectable levels in several glioblastoma cell
lines. This indicates that loss of TPPP/p25 expression correlates with the development
and progression of glioblastoma as reduced expression of this protein may be involved
in the providing growth advantage to tumor cells. We also report in this study that
TPPP/p25 inhibits tumorigenicity of glioma cells in vitro. Overexpression of TPPP/p25 in
glioma cells results in significant decrease in cell proliferation suggesting that TPPP/p25
is a negative regulator of growth in glioblastomas and deregulation of expression of
TPPP/p25 may be linked with their transformed phenotype. TPPP/p25 overexpression
did not activate caspase-3 implying that TPPP/p25 suppresses glioma cell growth by its
inhibitory effect on the cell proliferation rate.
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The reason for downregulation of TPPP/p25 in brain tumors at the RNA and
protein levels is not known. It may be possible that TPPP/25 gene may be silenced by
promoter hypermethylation in glioblastomas indicating that the role of TPPP/p25 is in
either maintaining the differentiated phenotype or triggering anti-proliferative effect.
Also, since TPPP/p25 is a microtubule-associated protein that stabilizes microtubules in
T98G glioblastoma cells, induction of this microtubule stabilizing protein in glioblastoma
may have implications for not only tumor progression but also to sensitize tumors to MT
agents. MT agents like vinca alkaloids and taxols are used for the treatment for several
cancers, however, drug resistance is the major setback for treatment (Dumontet and
Sikic 1999). Cancer cells activate mechanisms to counteract these drugs by
overexpressing MT-destabilizing proteins or covalently modifying tubulins to render
themselves resistant to the effects of MT stabilizing drugs such as taxol resulting in drug
resistance (Alli, Bash-Babula et al. 2002; Martello, Verdier-Pinard et al. 2003). Thus, reexpression of TPPP/p25 by gene therapy may overcome such resistance and may have
beneficial effects on glioblastoma aggressive tumors.
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CHAPTER 5
MATERIALS AND METHODS

5.1 MAMMALIAN CELL CULTURE TECHNIQUES
5.1.1 Mammalian Cell Culture
The cell lines used were HCT116 (Catalog # CCL-247), HeLa CCL2 (Catalog #
CCL-2), PC12 (Catalog # CRL-1721) and T98G (Catalog # CRL-1690) obtained from
ATCC (American Type Culture Collection, Manassas, VA) and were grown in McCoy’s
5A medium, MEM, DMEM and MEM respectively. Media contained Fetal Bovine Serum
(FBS) (Hyclone, Logan, UT) as a supplement. The cells were routinely passaged until
they were subconfluent (70 to 80%), which was approximately every two to three days,
and were incubated at 37°C incubator. Trypsin (Cellgro, Manassas, VA) was used to
detach the cells from the T175 cm2 flasks. After detachment, the cells were centrifuged
for 5 mins at 1200 rpm to eliminate trypsin, and then cultured in the respective fresh
medium as described above.

5.1.2 Mammalian Cell Storage and Thawing
The cells were stored for long-term by freezing and storing them in liquid
nitrogen. Before placing the cells in the liquid nitrogen, they were detached from the
flasks by trypsination, centrifuged at 1200 rpm and resuspended in their normal medium
containing 20% FBS and 10% DMSO (Sigma, St. Louis, MO). The cells were added to
special cryotubes for storing cells at -80°C, slowly frozen in an isopropanol bath
overnight and left in liquid nitrogen.
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The frozen cells were thawed by placing in a water bath, centrifuged and
resuspended in required culture medium containing 10% FBS.

5.1.3 Transfection
5.1.3.1 Plasmid Transfection
Fugene HD or X-tremeGENE 9 DNA transfection reagents (Roche, Indianapolis,
IN) were used for most of the transfection experiments. The cells were trypsinized 24
hours before transfection and 3-5 x 105 cells were seeded in medium containing 10%
FBS without antibiotics in 6-well plate so that the cell density would be approximately 60
to 70% confluent the next day. Transfection reagent, diluent and the DNA that was to be
transfected were allowed to equilibrate to room temperature (22°C) and mixed well
before proceeding. The DNA (2 µg) was diluted in 100 µl Optimem-reduced serum
medium (Invitrogen, Grand Island, NY) placed in polystyrene tube and gently mixed.
The transfection reagent (3 µl) was then added to the mixture in a 3:2 ratio. The
complex was allowed to form by incubating the mix for 15 mins and added into the
wells. After incubation of the cells at 37°C incubator for 24-48 hrs, they were either
treated or harvested.

5.1.3.2 siRNA Transfection
RNA oligonucleotides used to knockdown p68 gene expression were siGENOME
duplex siRNA from Dharmacon (Thermo Fisher Scientific Dharmacon, Lafayette, CO).
The sequences of the duplex siRNA against p68 were as follows: siRNA
oligonucleotides against p68 (sense: 5’-GCAAGUAGCUGCUGAAUAUUU-3’; antisense:
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5’- AUAUUCAGCAGCUACUUGCUU-3’). The siRNA knockdown was done using
Lipofectamine RNAimax (Invitrogen, Grand Island, NY) reagent. A day before siRNA
knockdown, 2-4 x105 cells were seeded. The siRNA duplex was dissolved in 1X siRNA
buffer (Thermo Fisher Scientific Dharmacon, Lafayette, CO) at a concentration of 40
pmol/µl and RNase-free water by rotating in a rocking platform for 30 mins. About 3µl
(120 pmol) of siRNA was added to 250 µl of Optimem-reduced serum medium
(Invitrogen, Grand Island, NY) in a polystyrene tube and mixed gently. Lipofectamine
RNAimax (5μl) was added to 250 µl of Optimem medium in another tube and also
mixed well. An irrelevant siRNA or non-targeting siRNA (Thermo Fisher Scientific
Dharmacon, Lafayette, CO) served as a negative control. The siRNA-lipofectamine
complex was then allowed to form by adding the siRNA mixture slowly to the
lipofectamine mixture and incubating for 25 mins at room temperature. After incubation,
the complex (500 µl) was added dropwise to the cells that have been washed two times
with Optimem medium, incubated for 4 hrs and feedbacked with complete medium.
After 24 hrs, fresh medium with 10% FBS (Hyclone, Logan, UT) was added. After 48
hrs, they were then harvested or the p68 wild-type or mutants were transfected the
same day using fugene HD transfection reagent and harvested after an additional 48
hrs. The transiently expressed p68 wild-type and the mutants were blocked from
knockdown by mutating four nucleotides in the siRNA targeting sequence such that the
amino-acid sequence was not altered.

184
5.2 BACTERIAL CULTURE TECHNIQUES
5.2.1 Culture of Bacterial Cells and their Storage
Plasmid DNA that was used for transfection, cloning, and other techniques was
amplified using bacterial E.coli strains JM109 (Promega, Madison, WI), DH5α
(Promega, Madison, WI) and XL-1 blue (Stratagene, Cedar reek, TX), while BL21codon Plus (Stratagene, Cedar reek, TX) was used for the expression of recombinant
protein. The bacteria were inoculated in sterile Luria-Bertani (LB) medium in a 37ºC
shaker set to 220 rpm. The composition of LB medium was as: 1% tryptone, 1% NaCl,
0.5% yeast extract, and 50 µg/ml of Ampillicin or kanamycin for antibiotic-resistant strain
selection. The antibiotics were added to autoclaved medium approximately around 40 to
50°C. The LB agar plates contained 1.5% agar in addition to the above mentioned
composition of LB medium. The bacteria were either inoculated into sterile LB medium
using a sterile inoculation loop or spread onto the agar plates using a sterile plastic
spreader, and incubated in an incubator at 37°C for 16-18 hrs.

5.2.2 Competent Cell Preparation
Competent cells are bacterial cells whose cell walls are rendered porous to allow
the plasmid DNA to enter the cells. E.coli strains JM109 and DH5α were made
competent using the following steps. An isolated bacterial colony was seeded into
sterile 10 ml LB broth, and grown overnight in a 37°C shaker. Next day, culture (1 ml)
was inoculated into sterile LB medium (50 ml) and grown till OD600 of 0.375. The culture
was then aliquoted into 50 ml of sterile, pre-chilled, polypropylene tubes (or 50 ml
centrifuge tubes). After placing the cells for 10 mins on ice, the pelleted cells were
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resuspended in CaCl2 solution (10 ml) and centrifuged again. After resuspension in
CaCl2 solution (10 ml), the cells were left on ice for 30 mins. After this final incubation
step, the pelleted competent cells were resuspended in ice-cold CaCl2 solution (1 ml)
and dispensed into prechilled, sterile micro-centrifuge tubes (100 µl each). Prechilled
pipette tips were used for dispensing. The tubes were then immediately transferred and
transferred at -80°C until further use.

5.2.3 Transformation
E.coli competent cells (JM109 or DH5α) were used for transformation of plasmid
DNA. Competent cells (100 µl) were placed in a sterile micro-centrifuge tube and 10500 ng of plasmid DNA was then added to the tube. The DNA/competent cells were
placed for 30 mins in an ice bucket and then heat-shocked at 42°C waterbath for 90
seconds. After heat-shock, the mix was immediately placed on ice for 2 to 3 mins.
Thereafter, 200 µl of prewarmed sterile LB medium without any antibiotics was added to
and further incubated in a shaker maintained at 37°C with a speed of 220 rpm for 1
hour. The cells were then spread onto sterile LB agar plates with either ampicillin or
kanamycin and incubated overnight at 37°C.

5.3 DNA RELATED TECHNIQUES
5.3.1 Isolation of Plasmid DNA
5.3.1.1 Isolation of Plasmid DNA in a Mini-Scale (Mini-prep)
Plasmid DNA isolation and purification were performed using Qiaprep Spin Mini
Kit (Qiagen, Valencia, CA). An isolated bacterial colony, inoculated into 2 ml of sterile
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LB medium, was incubated for 16 to 18 hrs in a 37°C shaker set to 220 rpm. The
pelleted cells were resuspended in the resuspension buffer P1. Around 250 µl of lysis
buffer P2 was added to the tube which was inverted 4-6 times. This step lysed the
bacteria. After the lysis, neutralization buffer N3 (300 µl) was immediately added to
neutralize the alkaline conditions generated by the lysis buffer and the contents of the
tube were again mixed by inverting 4-6 times. The mixture was then subjected to
centrifugation and the supernatant containing the DNA solution was applied to the spin
column. It was again centrifuged to enable the DNA to bind to the silica column. The
column was rinsed with buffer PB (500 µl) to eliminate the endonuclease present in
endA+ bacteria such as JM109 and subsequently washed again with buffer PE (750 µl)
containing ethanol and centrifuged. Elution was done with elution buffer TE (10 M TrisHCl, pH 8.5) or water and confirmed by either agarose gel electrophoresis or DNA
sequencing.

5.3.1.2 Isolation of Plasmid DNA in a large-scale (Midi-prep)
Large scale DNA purification was done using Wizard Plus DNA Purification
System (Promega, Madison, WI). Plasmid DNA containing bacteria were seeded into
sterile LB medium with required antibiotic and grown in 37°C shaker for 18 hrs. After
centrifugation, the pellet was dissolved in resuspension buffer (3 ml). Lysis buffer (3 ml)
was added and then the solution was inverted 4 to 6 times to mix. The lysate was then
neutralized by adding 3ml of neutralization buffer and centrifuged at 13000 rpm for 20
mins. Pellet was mixed with DNA purification resin. This mixture was then added to a
midiprep column and vacuum was used to remove the solution. The DNA-resin mix in
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the column was rinsed two times with column wash buffer with ethanol (15 ml) and the
supernatant was removed each time with the application of vacuum. After the wash
solution was removed from the column, the vacuum was allowed to further run for
additional 30 seconds for the complete removal of wash solution. However, the resin in
the column was always prevented from being dried for too long as the DNA yield would
decrease. The column was then centrifuged to eliminate any trace wash buffer. The
DNA was then eluted with pre-warmed (60 to 70°C) 300 µl of nuclease free water. After
adding water to the column, it was incubated for 1 min and then centrifuged to elute the
DNA. DNA solution was then further centrifuged for 5 mins to remove any white resin
that might be left in the solution. The supernatant containing the DNA was then
concentrated and stored at -20°C.

5.3.2 Concentration of DNA
DNA was purified by ethanol precipitation to remove any salt or protein contamination.
In this method, 3M sodium acetate (1/10th volume) and 100% ethanol (2 volumes) were
added to the DNA sample. After thorough mixing, the sample was kept at -20°C for 18
hrs. The tube was centrifuged for 15 mins to pellet DNA which was rinsed with 80%
ethanol and centrifuged. The pellet was then dried and dissolved in sterile D/W. The
DNA concentration was then measured using a spectrophotometer (UV-1700
Spectrophotometer, Shimadzu Corporation) at OD260.
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5.3.3 Measurement of DNA Quality and Concentration
DNA concentration was measured photometrically using a spectrophotometer. The
absorbance was measured at OD260 and applied to the following formula which gives
the DNA concentration: DNA concentration (µg/ml) = OD260 X Dilution factor X (50 µg
DNA/ml)/ (1 OD260 unit). DNA quality was determined by measuring the ratio of
absorbance at OD260 and at OD280. A ratio between 1.65 and 1.85 was acceptable.

5.3.4 Agarose Gel Electrophoresis
Agarose gel electrophoresis is the technique for purification and visualization of
nucleic acids on agarose gel using a double stranded DNA binding dye such as
Ethidium Bromide. Larger molecular weight DNAs ranging from 0.5 to 2 kbp like
plasmids and genomic DNA were separated on 1% agarose gels (w/v) while smaller
molecular DNAs (less than 0.5 kbp) were separated on 2-3% gel. 2% agarose gel was
prepared by adding 2 gm of agarose (EMD, San Diego, CA) in 100 ml of 1X TAE buffer
(Tris-Base, Glacial acetic acid, EDTA, pH 8.0). The mix was heated in a microwave till
the agarose was completely melted and ethidium bromide was added. Ethidium
bromide is a DNA binding dye that intercalates between DNA and allows for
visualization of DNA using UV light. This agarose solution was then poured onto gel
casting apparatus with a comb containing well inserts to make suitable wells and
allowed to set for 30 mins. After solidification of the gel, 1X TAE buffer was used as the
running buffer and poured into the gel running unit after removing the comb. Next, the
DNA sample was mixed with 6X DNA loading buffer (Fermentas, Glen Burnie, MA) to a
final concentration of 1X and loaded into the wells. DNA marker was also loaded to
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determine the DNA size. The gel was run at a voltage at 120 V and 200 mA for 1 hour
and visualized using a UV transilluminator.

5.3.5 Gel Extraction of DNA
After agarose gel electrophoresis, DNA purified by QIAquick Gel Extraction Kit
(Qiagen, Valencia, CA) can be used for restriction enzyme digestion, ligation and
purification of PCR products. The DNA is excised from the gel after electrophoresis
using a scalpel and weighed after placing in a microcentrifuge tube. Buffer QG provided
with the kit was then added to the DNA sample which solubilizes the agarose gel
fragment enabling the DNA to bind to the silica membrane and determine the optimum
pH for DNA binding. Three times the volume of Buffer QG was added per gram of the
weight of the gel (100 mg of agarose slice = 300 µl of Buffer QG). The DNA was placed
in a 50°C waterbath to enable the gel to dissolve. After 10 mins, if the color of the
solution was orange or purple, it meant that the pH of the solution was not appropriate
for the proper binding of the DNA to the column. In this case, 3M sodium acetate, pH
5.0 (10 μl) was added so that the pH of the solution would turn to <7.5. Next, one gel
volume of isopropanol was added to increase the yield of DNA. The solution was then
loaded onto a QIAquick column and centrifuged. The column was then rinsed with
buffer QG again and centrifuged. Finally, ethanol containing buffer PE was added to the
column to remove the residual salts, agarose and dyes. The column was let to sit for 1
min and centrifuged until completely dried. DNA eluted using water or buffer EB (10 mM
Tris-HCl, pH 8.5) was used for subsequent applications.
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5.3.6 Polymerase Chain Reaction
Polymerase chain reaction (PCR) is used in applications such as mutagenesis
(to mutate specific sequence), RT-PCR (amplify cDNA from mRNA), cloning (cloning
specific sequences of genes in plasmid vector) etc. A typical PCR reaction consisted of
the following: 1 unit of DNA polymerase- Hotstart pfuTurbo (Stratagene, Cedar reek,
TX), 10X cloned pfu buffer at a final concentration of 1X, 100 ng of template DNA, 1 mM
dNTP and 100 ng of forward and reverse primers specific for the DNA to be amplified
and nuclease free water to make up the volume to 50 µl. The primers were designed
using the Primer3 software. The PCR mix containing the template was first denatured at
95°C for 2 mins to unwind the double helix. Next, 28-33 cycles of the following steps
were performed: 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 30 seconds.
Elongation at 72°C for 10 mins was done to make sure that all the PCR products were
double stranded and then ectrophoresed.

5.3.7 Restriction Enzyme Digestion
Restriction enzyme digestion is an important tool in recombinant DNA technology
and molecular biology. The process employs a restriction enzyme which recognizes
specific DNA sequences and cleaves them at those sites. These DNA sequences can
then be ligated into another plasmid which also has been cleaved at the same site. The
standard components for restriction enzyme digestion were as: water, appropriate
buffer, DNA upto 1 μg and restriction enzyme upto 1μl. The mixture was incubated at a
temperature that was optimal for the enzyme which was mostly around 37°C. The
digestion products were extracted after electrophoresis. A double restriction enzyme
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digestion was also performed using the above procedure with the exception of using
two enzymes instead of one. Also, the buffer and other conditions were compatible for
both the enzymes. If two enzymes were not compatible for single reaction, then
sequential restriction digestion was performed.

5.3.8 DNA ligation
Ligation is the process of joining the linearized cut segments of DNA that has
been either digested by restriction enzyme or phosphorylated at 5’ phosphate end of the
insert DNA and dephosphorylated at the 3’ hydroxyl end of the vector. Ligation is
performed by an enzyme called DNA ligase that joins the 5’ phosphate and 3’ hydroxyl
groups of DNA segments that have either overhangs generated by restriction enzyme
digestion or cohesive ends generated by PCR products. T4 DNA ligase (Fermentas,
Glen Burnie, MA) was used for the ligation. A typical ligation reaction consisted of the
following: 5X ligation buffer used at a final concentration of 1X, insert DNA, vector DNA
and T4 DNA ligase. After vortexing and centrifuging, the reactions were left for 4 hours
at room temperature and for 18 hrs at 4°C and finally transformed into competent
bacterial cells for amplification or stored at -20°C.

5.3.9 Insert DNA Phosphorylation and Vector DNA Dephosphorylation
For some applications that required single restriction enzyme digestion instead of
using two restriction enzymes, the following procedure was followed to prevent the
single restriction site digested vector DNA from self recircularization and ligation.
Alkaline phosphatases catalyze the removal of phosphate group from 5’ end of DNA
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thereby preventing the DNA from self recircularization. Shrimp alkaline phosphatase
(Fermentas, Glen Burnie, MA) was used for this purpose. 1 unit of the phosphatase, 1
µg of cut vector DNA were mixed in 1X SAP buffer and incubated for 30 mins at 37°C.
Phosphorylation of the insert DNA was the next step for ligating the
dephosphorylated vector. Phosphorylation was generally performed using T4
Polynucleotide Kinase (T4 PNK) (Fermentas, Glen Burnie, MA) which catalyses γphosphate transfer from ATP to the 5’ terminal of polynucleotides or 3’ phosphate
bearing mononucleotides. A typical reaction consists of: 10X reaction buffer, water,
PCR product and T4 PNK. The DNA then was subsequently used for the ligation
reaction.

5.3.10 DNA Sequencing
Sequencing of the plasmid DNA after ligation or mutagenesis was done at the
Georgia State University Core Facility. Sequencing primers such as T7 or SP6 were
provided by the facility while some application specific primers were designed using
Primer3 software. The primers were suspended in nuclease free water and used.

5.3.11 Cloning of TPPP/P25/p68/p68 mutants/p38 mutants
The cDNA of p68 ORF was subcloned into mammalian expression vector pHM6
(Roche, Indianapolis, IN) at HindIII site to get HA-tagged p68 expression vector. The
expressed protein has HA tag at the N-terminus. Quick-Change site-directed
mutagenesis kit (Stratagene, Cedar reek, TX) was used to prepare various p68 single
and double threonine mutants (threonine replaced by alanine) and the mutations were
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confirmed by DNA sequencing. P38α cDNA (Origene, Rockville, MD) was subcloned
into p3XFLAG-myc-CMV™-24 Expression Vector (Sigma, St. Louis, MO). Mutations to
get the constitutively active form of p38 were done using the reference (Diskin, Askari et
al. 2004). TPPP/p25 cDNA was subcloned into p3XFLAG-myc-CMV™-24 Expression
Vector (Sigma, St. Louis, MO). P38 and TPPP/p25 expressed proteins have FLAG tag
at the N-terminus.

5.4 RNA RELATED TECHNIQUES
5.4.1 RNA Isolation
RNeasy Plus kit (Qiagen, Valencia, CA) was employed for RNA extraction. To
isolate RNA, the cells were grown on 6-well plates until they reached 80-90%
confluence and then rinsed twice with cold 1X PBS. The cell lysis was done with 350 µl
buffer RLT supplemented with β-mercaptoethanol (Sigma, St. Louis, MO). The cells
were lifted from the plates with cell lifters (Corning Costar, Corning, NY), added to
Qiashredder column (Qiagen, Valencia, CA) for homogenization and centrifuged.
Homogenized lysate was then loaded onto gDNA eliminator column for removal of the
genomic DNA and centrifuged for 1 min. Ice-cold 70% ethanol was then mixed with
equal volume of supernatent and applied to RNeasy column and centrifuged for 30
seconds. Buffer RW1 was used to wash the column and subsequently rinsed twice with
buffer RPE (500 µl). After centrifugation, the RNA was eluted twice with 30–50 µl DEPC
treated water. The RNA concentration was measured using a spectrophotometer and
stored at -20°C.
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5.4.2 Measurement of RNA Concentration
The RNA concentration was measured photometrically using a spectrophotometer (UV1700 Spectrophotometer, Shimadzu Corporation). The absorbance was measured at
OD260 and applied to the following formula which gives the RNA concentration: RNA
concentration (µg/ml) = OD260 X Dilution factor X (50 µg RNA/ml)/ (1 OD260 unit).

5.4.3 Reverse Transcription – Polymerase Chain Reaction (RT-PCR)
RT-PCR couples reverse transcription and PCR methods to generate double
stranded cDNA from mRNA to examine gene expression. Two step RT-PCR was
performed using the kit, ImProm II Reverse Transcription System (Promega, Madison,
WI). The first step of RT-PCR is reverse transcription. RNA isolated from the
mammalian cells was converted to cDNA and PCR was performed in the second step. 1
µg of RNA was added in the RNase-free PCR tube along with 1 µl of Oligo dt and water.
A positive control containing 1.2 kb kanamycin RNA and a negative control without any
RNA were also set up according to the same procedure mentioned above. The samples
were incubated at 70°C and then placed in ice water for atleast 5 mins. The following
concoction consists of: 5X reaction buffer (4 µl), 5 mM MgCl2 (4 µl), water (4 µl), 100
mM dNTP (1 µl), RNase inhibitor (1 µl) and Reverse transcriptase (1 µl). The reactions
were then subjected to the following cycle: 25°C for 5 mins, 45°C for 1 hour and 70°C
for 15 mins in the PCR machine. Once the RNA was transcribed to cDNA, the
amplification of the cDNAs was performed using PCR. PCR reactions were set up using
roughly 2 µl (100ng) of cDNA, 50-100 ng of appropriate forward and reverse primers
and 1X master mix from Promega, Madison, WI (containing DNA polymerase, dNTPs
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and MgCl2). The PCR cycle was as: initial denaturation (94°C for 2 minutes), followed
by 30 cycles of 94°C for 15 sec, 55°C for 30 sec, and 72°C for 30 sec with an additional
extension

time

of

10

mins.

Primers

used

were:

TPPP/p25

(sense

5’-

CAGGTGAAGAGCCTGGAGTC-3’; antisense 5’- GTTTCCTTGTCTGTGGGTGAA-3’);
GAPDH

(sense

5’-

GAGTCAACGGATTTGGTCGT-3’;

TTGATTTTGGAGGGATCTCG-3’).

anti-sense

5’-

RT-PCR results were analyzed by running the

samples on 2 to 3% agarose gels with ethidium bromide.

5.4.4 Real time RT-PCR
Quantitative RT-PCR allows simultaneous visualization and quantification of the
PCR product. The reverse transcription was performed to generate the cDNA before its
amplification. For the real time PCR, the following concoction was prepared: 100 ng of
cDNA, 1X Fast SYBR Green master mix (Applied Biosystems, Foster City, CA),
primers, water to 25 μl. The mixture was loaded to a specific 96 well PCR plate (Applied
Biosystems, Foster City, CA). Applied Biosystems 7500 Fast Real Time machine was
used for PCR: 95ºC for 15 seconds, then 40 cycles of 95ºC for 3 seconds and 60ºC for
30 seconds. Plate analysis was performed using Applied Biosystems SDS v1.4
program. A dissociation curve was generated to examine the purity of the PCR product
and the results were analyzed using relative analysis. From the Ct values and the
formula 2-(dCt), dCt and ddCt values were calculated and the results were shown as fold
change.
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5.5 PROTEIN RELATED TECHNIQUES
5.5.1 Cell Lysate Preparation
5.5.1.1 Whole Cell Lysate Preparation
Mammalian cells subjected to various treatments such as transfection or drug
treatment have to be lysed in order to release different cellular proteins that need to be
investigated. The cells were initially rinsed twice with 1X PBS. The PBS was removed
and required volume of cold 1X PBS containing Protease inhibitor cocktail (Sigma, St.
Louis, MO), Phosphatase inhibitor cocktail 2 (Tyrosine phosphatase inhibitor (Sigma, St.
Louis, MO) and Phosphatase inhibitor cocktail 3 (Threonine phosphatase inhibitor
(Sigma, St. Louis, MO) were added. Cell lifter (Corning Costar, Corning, NY) was used
to harvest the cells and the cells were pelleted. Cell lysis was done using 1X RIPA
(Radioimmunoprecipitation) buffer (Millipore, Billerica, MA) (0.5M Tris-HCl, pH 7.4, 2.6%
deoxycholic acid, 1.5M NaCl, 10mM EDTA, 10% NP-40) containing 1mM PMSF
(phenylmethylsulphonyl fluoride), 1mM NaF, 1:100 dilution Protease inhibitor cocktail,
Phosphatase inhibitor cocktail 2, and Phosphatase inhibitor cocktail 3 and rotated. After
one hour, the tubes were centrifuged for 10 mins at 13,200 rpm to remove the cellular
debris. The supernatant which contained the desired protein was placed in another
centrifuge tube and stored at -80°C.

5.5.1.2 Nuclear and Cytoplasmic Extract Preparation
Some proteins are expressed in the nucleus and it is often necessary to separate
them from the cytoplasm for downstream applications. Nuclear extract kit (Active motif,
Carlsbad, CA) was used for preparation of nuclear fraction of the cells. Cells treated
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according to the application, were first rinsed with 1X PBS and subsequently harvested
in cold 1X PBS supplemented with Phosphatase inhibitor cocktail to limit protein
modifications. The pellet was dissolved in 1X Hypotonic Buffer (500 µl) and placed for
15 mins on ice to make the cell membrane fragile. Detergent (25 µl) was added into the
tubes and vortexed. The tubes were then centrifuged at 13000 rpm for 30 seconds to
pellet the nuclear fraction and collect the cytoplasmic extract in the supernatant in
another tube. The nuclear pellet was then rinsed with 1X PBS buffer to prevent
cytoplasmic extract contamination into the nuclear pellet. The nuclei were then lysed in
AMI lysis buffer with PIC and DTT and rotated on a rotating platform. After vortexing for
30 seconds, the tubes were centrifuged to pellet the nuclear debris. The supernatant
representing the nuclear extract was collected.

5.5.2 Recombinant Protein Expression and Purification
The procedure used to express and purify p68 is similar to the procedure
reported previously. P68 ORF and various mutants were cloned into pET-30a+
expression vector and transformed into E.coli BL21-CodonPlus bacteria (Stratagene,
Cedar reek, TX) were used to express protein. The bacteria were subcultured in fresh
st. LB broth till OD600 reached around 0.6. Induction of the cells was done with IPTG for
18 hr and washed with 1X PBS buffer after harvesting, pelleted and stored at - 80°C.
They were then disrupted by freeze-thaw cycle at -80°C, resuspended in lysis buffer (50
mM Tris-HCl pH 8.0, 1 mM DTT, 10 mM PMSF, 300 mM NaCl ad 10% glycerol). They
were then subjected to lysozyme (0.5 mg/ml) digestion. DTT and PMSF were also
added at 1 mM final concentration. The cells were further subjected to ultrasonication
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and pelleted. After centrifugation, the expressed protein was found in the precipitate
which was dissolved in denaturing buffer containing 8 M urea, 50 mM Tris-HCl pH 8.0,
0.2% Triton-100 and 250 mM NaCl. The lysate was passed through Ni-NTA column for
purification of recombinant protein by affinity separation. After column wash using the
denaturing wash buffer (8 M urea, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 20 mM
imidazole pH 8.0, and 0.2% Triton-100), the protein was eluted using elution buffer with
8 M urea, 250 mM Imidazole, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.5 mM DTT and
10% glycerol, and 0.2% Triton-100. Refolding of the eluted protein was done by
stepwise dialysis procedure (8 M→6 M→4 M→2 M→0 M) to remove urea using
refolding buffer (200 mM arginine, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.5 mM DTT,
10% glycerol, and 0.2% Triton-100) and preserved in further 15 to 20% glycerol.

5.5.3 Determination of Protein Concentration by Biorad Method
The proteins obtained from either whole cell lysate or nuclear/cytoplasmic extract
or pure recombinant protein preparation was accurately quantified by modified Bradford
Assay using Coomassie Brilliant Blue (Bio-Rad, Hercules, CA). 200 µl of 5X Biorad dye
solution was added in a cuvette to which appropriate amount of either standard protein
or 1 µl of sample whose concentration has to be determined was added. A volume of
800 µl was made up for each dilution with sterile distilled water so that the total volume
of each reaction was 1 ml. The absorbance was determined at an OD595 using a
spectrophometer (Shimadzu) after incubation at room temperature for 5 mins. Those
absorbance values were applied to the slope-intercept formula generated by the
standard curve using Excel to give the protein concentration.
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5.5.4 In Vitro Kinase Assay
In this assay, about 1μg of purified proteins were added to the reaction consisting
of 200-250ng of p38α/SAPK2a enzyme (Upstate cell signaling), 10 μCi/μl of [γ32P]ATP, Magnesium/ATP cocktail (75 mM MgCl2 and 25 mM β-glycerol phosphate,
500 μM ATP in 20 mM MOPS, pH 7.2, 1 mM sodium orthovanadate, 5 mM EGTA, and
1mM dithiothreitol) and 5X reaction buffer (125 mM Tris-HCl, pH 7.5, 0.1 mM EGTA) in
a volume of 25μl. After incubation for 30 mins at 30°C, 5X loading buffer (Fermentas,
Glen Burnie, MA) were added. The samples run on two SDS-PAGE gels were subjected
to either autoradiography or Coomassie blue staining.

5.5.5 SDS-PolyAcrylamide Gel Electrophoresis (SDS-PAGE)
SDS-PAGE (Sodium dodecyl sulphate polyacrylamide gel electrophoresis)
separates proteins according to their electrophoretic mobilities. SDS is an anionic
detergent whose binding to proteins gives uniform distribution of charge per unit mass
on the proteins so that during electrophoresis, they can be fractionated based on their
size. The electrophoretic apparatus used to separate proteins was bought from BioRad
and assembled. Polyacrylamide gels consisted of acrylamide, bisacrylamide, SDS, a
buffer of designated pH and stabilizer to initiate polymerization. Normally, by varying the
acrylamide concentrations in the gel, 5 to 25% acrylamide gels can be prepared with
higher percentage gels used to separate smaller proteins and lower percentage gels
used to separate proteins with higher molecular weight. Normally, 10 to 14% gels were
used to study p68 and TPPP/P25 expression. The separating gel consisting of
polyacrylamide 29:1, 40%, 1.5 mM Tris-HCl, pH 8.8, 10% ammonium persulphate, 10%
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SDS, TEMED, and water was poured into the casting system formed from two glass
plates and allowed to polymerize for atleast 40 mins. A layer of isopropanol was added
during the polymerization procedure to remove any bubbles. After polymerization of the
separating gel, the isopropanol was poured off and the region above the gel was
washed with distilled water. 4% stacking gel was prepared which consisted of the same
components as mentioned for the separating gel except 0.5 mM Tris-HCl, pH 6.8 was
used instead of 1.5 mM Tris-HCl, pH 8.8. Stacking gel was allowed to polymerize for 10
mins after which they were ready for electrophoresis.
The protein samples (roughly 50 µg) to be separated were denatured by mixing
with 2X SDS loading buffer containing either DTT or β-mercaptoethanol and placed for
10 mins at 100°C. The1X SDS-PAGE running buffer was added to the gel running unit
consisting of the prepared gels. The samples loaded were first run at 60 V and then run
for 120 V till the dye ran out of the gel. Appropriate molecular weight maker was also
simultaneously run with the gel and any unused wells were filled with 2X SDS loading
buffer. Gel was subsequently either stained with Coomassie Blue dye to visualize the
protein bands or subjected to transfer to nitrocellulose membrane if immunoblotting was
to be performed.

5.5.6 Coomassie Blue Staining
The proteins on a polyacrylamide gel can be observed by staining with
coomassie blue stain (0.1% Coomassie Brilliant Blue, 10% acetic acid, 20% methanol,
and water). After staining with coomassie blue stain on a rotator, the gel was placed in
destaining buffer (40% methanol, 10% acetic acid, water) overnight. They were washed
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with water and visualized using UVP Bioimaging and Analysis System (White light only)
attached to CCD camera.

5.5.7 Generation of anti-p68 antibody
Anti-p68 antibody was generated from the C-terminal region of human p68 (a.a
437-614). Polyclonal (from rabbit) antibody was generated at Auburn Hybridoma
Facility) while monoclonal (from mouse) antibody against p68 was obtained from
Invitrogen.

5.5.8 Immunoblotting
Immunoblotting is a technique used for detection of expression and regulation of
proteins from either pure protein preparation or whole cell lysate or extract. The proteins
separated on a gel by electrophoresis are examined for the expression of the protein
using an antibody against the protein. In a typical western blot experiment, the protein
sample in the extract was denatured by heating at 100°C and loaded onto a gel of
appropriate concentration. It was run at appropriate voltage and the proteins from the
gel were transferred. The gel was placed on a sheet of 3 MM Whatman filter paper
prewetted with the transfer buffer and a presoaked nitrocellulose membrane was then
placed on top of the gel. The air bubbles trapped in between the layers were removed
using a roller apparatus and another filter paper was placed. The cassette was then
placed in a tank submerged with transfer buffer and the transfer was allowed to take
place either at 50 mA for overnight at 4°C or 120 mA at RT for 2 hrs. It is generally
preferred to transfer the proteins overnight for larger molecular weight proteins. After the
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transfer was complete, the membrane was rinsed with water and then stained with
Ponceau S stain (VWR International, West Chester, PA) for 2 mins to visualize the
complete transfer of proteins and equal loading of the samples. The membrane was
then again rinsed with water and then with 1X TBS containing 0.1% Tween-20 until the
Ponceau S stain was completely removed. The membrane was subsequently incubated
on a rocking platform with a blocking buffer containing 5% BSA in 1X TBST for 1 hour to
mask non-specific binding sites. Next, the membrane was exposed to primary antibody
diluted in 1X TBST buffer containing 5% BSA at an appropriate dilution ranging from
1:500 to 1:2000 and incubated overnight. It was rinsed with 1X TBST for five minutes
three times each and then incubated with secondary antibody (Pierce, Thermo Fisher
Scientific Dharmacon, Lafayette, CO) (1: 4000 dilution in 1X TBST containing 5% BSA)
for 1 hr. After another wash, SuperSignal West Dura Extended Duration Substrate
(Pierce, Thermo Fisher Scientific Dharmacon, Lafayette, CO) was developed. Blot was
incubated with the substrate for 2 mins and the signal was detected with the x-ray
machine.
The blotted membrane could be re-used and re-blotted two to three times with
another antibody by stripping the previous primary antibody. Restore Plus Stripping
Buffer (Pierce, Thermo Fisher Scientific Dharmacon, Lafayette, CO) was used to strip
the primary antibody from the membranes. The membrane was washed and incubated
with the stripping buffer (4 to 5 ml per blot) for 45 mins. After washing, the membrane
was blocked with 5% BSA in 1X TBST for 1 hr. A different antibody at an appropriate
dilution was added for another round of blotting.
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5.5.9 Immunoprecipitation (IP)
Immunoprecipitation is a method used to pull down proteins using protein G
beads followed by SDS-PAGE and immunoblotting. Usually, 200 to 300 μg of nuclear
extract or upto 1 mg of whole-cell extract diluted in either RIPA buffer or NETS buffer
were used. 1-3 μg of primary antibody was added and incubated at 4°C for overnight.
After adding Protein G beads and washing with 1X RIPA buffer, the proteins captured
by the antibody-bead complex were eluted by denaturing with 2X sample buffer
containing β-mercaptoethanol for 10 mins at 95°C. The immunoprecipitated protein was
then detected by SDS-PAGE followed by immunoblotting.

5.5.10 Chromatin Immunoprecipitation (ChIP) Assay
Chromatin Immunoprecipitation is a technique used to identify DNA-protein
association. QuickChIPTM kit from Imgenex (Imgenex Corp, San Diego, CA) was used to
carry out the ChIP assay. Cells were grown till they were around 70 to 80% confluent.
The next day, the cells were fixed and crosslinked with formaldehyde. The crosslinking
process was stopped by adding glycine directly to the formaldehyde/media solution for 5
mins at RT with frequent swirling. The fixed cells after washing with 1X PBS
supplemented with 1X PMSF and 1X PIC were harvested in 1X PBS. Lysis of the
harvested cells was done with SDS lysis buffer. Sonication of the lysate was done on
the ice using a sonicator and centrifuged. To check if the shearing process generated
on an average 500 bp DNA fragments, 25 μl of the sheared chromatin was reverse
crosslinked and agarose gel electrophoresis was carried out. Next, 100 μl of salmon
sperm DNA/protein G beads was used to pre-clear the sheared chromatin for 1 hr. The
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precleared chromatin was then used for immunoprecipitation with the appropriate ChIP
grade antibody. Next day, protein G beads (60 μl) added to the complex were incubated
for 2 hrs. After washing the complex extensively with different wash buffers with
increasing salt concentrations to prevent non-specific binding, the immunocomplex was
eluted from the beads, reverse crosslinked and the released chromatin was purified.
The purified DNA was amplified by PCR and analyzed.

5.5.11 Immunostaining
For immunostaining, the cells were seeded on culture plates with coverslips or
chambered slides and either transfected or treated with the respective drug. Fixing of
the cells was done with 4% paraformaldehyde in PBS for 15 mins. Permeabilization was
done with 0.25% Triton X-100 in PBS after washing with 1X PBS. After blocking the
cells with 3% BSA in PBST, the cells were incubated with appropriate primary antibody
for 1 hr. Secondary antibody, either anti-Alexa Fluor 555 (orange, anti-rabbit) or antiFITC (green, anti-mouse) IgG antibodies in 3% BSA in PBST (0.1%) was added to the
cells and incubated at RT for 1 hr in the dark. After washing with PBS for three times
five mins each, Prolong Gold antifade reagent containing DAPI (Molecular Probes) was
used to mount the slides. The slides were cured overnight at RT and viewed using Zeiss
LSM Confocal Microscope or fluorescent microscope.
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5.5.12 Cell Proliferation Assay
5.5.12.1 MTT Assay
Cell viability was measured using MTT assay (Sigma, St. Louis, MO). 4000 cells
were seeded 24 hrs before knockdown and transfection of cells with vectors containing
p68 and the mutants. Subsequently, 24 hrs after transfection and different drug
treatment, reconstituted MTT-reagent (5 mg/ml MTT in RPMI-1640 without phenol red)
was added to the cells and left at 37°C for 2-4 hours. Formazan crystals were dissolved
with the MTT Solubilization solution (0.1 N HCl in isopropanol). Cell proliferation was
measured using a spectrophotometric plate reader (Victor 3TM; PerkinElmer Life
Sciences) by reading the absorbance at A570.

5.5.12.2 BrdU Cell Proliferation Assay
BrdU cell proliferation assay (Millipore, Billerica, MA) was used for measuring cell
proliferation. Briefly, 4000 cells were seeded, treated and incubated with the BrdU label
diluted in fresh cell culture medium at 37°C incubator. Cells were treated with
Fixative/Denaturing solution and subsequently, incubated with anti-BrdU primary
antibody (Millipore, Billerica, MA). After washing the unbound primary antibodies,
secondary goat anti-mouse secondary IgG (Millipore, Billerica, MA, peroxidase
conjugate) was used at RT for 30 mins. After incubation with the substrate and stop
solutions, the nuclei incorporation of BrdU was measured using a spectrophotometer
microplate reader (Victor 3TM; PerkinElmer Life Sciences) at a wavelength of 450nm.
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5.5.12.3 Caspase-3/CPP32 Colorimetric Assay
Cells plated on 6-well plates were treated with 10 μM oxaliplatin after p68
knockdown and transfection and caspase-3/CPP32 colorimetric assay (Biovision
Research Products, Milpitas, CA) was used to measure the activity of caspase-3.
Briefly, after apoptosis induction, the cells were lysed in Cell Lysis Buffer. Cell lysate in
Cell Lysis Buffer, 2X buffer and 4 mM DEVD-pNA substrate were incubated at 37°C.
They were read at A405 using a microtiter plate reader (Victor 3TM; PerkinElmer Life
Sciences).

5.6 Materials
Table 5.1 Cell-lines
Cell-line

ATCC Number

Origin

Culture Medium

HeLa

CCL-2

Human epithelial

MEM + 10% FBS + 1mM

cervical adenocarcinoma Sodium Pyruvate + 1mM
Non-essential amino-acids
HEK 293

CRL-1573

Human kidney epithelial

DMEM + 10% FBS

cells immortalized by
adenovirus
HCT 116

CRL-247

Human colorectal

McCoy’s 5A + 10% FBS

carcinoma
LN229

CRL-2611

Human glioblastoma

DMEM + 10% FBS

PC12

CRL-1721

Rat adrenal gland

DMEM + 10% FBS + 5%
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SW620

CCL-227

pheochromocytoma

horse serum

Human colorectal

L-15 Medium + 10% FBS

adenocarcinoma from
lymph node (metastatic
site)
T98G

CRL-1690

Human glioblastoma

MEM + 10% FBS + 1mM

multiforme

Sodium Pyruvate + 1mM
Non-essential amino-acids

U-87MG

HTB-14

Human glioblastoma,

MEM + 10% FBS + 1mM

astrocytoma

Sodium Pyruvate + 1mM
Non-essential amino-acids

Table 5.2 Bacterial Strains
Bacterial Strains

Company

BL21-CodonPlus (DE3)-RIL

Stratagene, Cedar reek, TX

JM109

Promega, Madison, WI

XL-1 Blue Supercompetent Cells

Stratagene, Cedar reek, TX

Table 5.3 Antibodies
Antibody

Animal of origin

Company

Acetylated tubulin

Rabbit polyclonal

Cell

Signaling

Beverly, MA

Technology,
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α-tubulin

Mouse monoclonal

Sigma Aldrich, St. Louis. MO

Caspase-3

Rabbit polyclonal

Cell

Signaling

Technology,

Beverly, MA
Cleaved-caspase-3

Rabbit polyclonal

Cell

Signaling

Technology,

Beverly, MA
FLAG

Mouse monoclonal

Sigma Aldrich, St. Louis, MO

GAPDH

Mouse monoclonal

Millipore, Billerica, MA

HA

Rabbit polyclonal

Georgia State University, Animal
center facility

HA, chip grade

Rabbit polyclonal

Abcam, Cambridge, MA

Lamin A/C

Rabbit polyclonal

Cell

Signaling

Technology,

Beverly, MA
P38

Rabbit polyclonal

Cell

Signaling

Technology,

Beverly, MA
P-p38

Rabbit polyclonal

Cell

Signaling

Technology,

Beverly, MA
P68

Rabbit polyclonal

Georgia State University, Animal
center facility

P68-rgg

Mouse monoclonal

Auburn

University

Hybridoma

Facility
P-threonine (14B3)

Mouse monoclonal

Calbiochem, Billerica, MA

TPPP

Rabbit polyclonal

Santa

Cruz

Santa Cruz, CA

Biotechnology,
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TPPP

Rabbit monoclonal

Abcam, Cambridge, MA

Table 5.4 Chemicals/Reagents
Chemical Name

Company

γ-32P] ATP

PerkinElmer, Waltham, MA

Acetic acid

VWR International, West Chester, PA

Acetone

VWR International, West Chester, PA

Acrylamide/bisacrylamide

Fisher BioReagent, Fairlawn, NJ

Adenosine triphosphate

Fermentas, Glen Burnie, MA

Agar

Sigma Aldrich, St. Louis, MO

Agarose

MP Biomedicals, Aurora, OH

Alcohol

VWR International, West Chester, PA

Ammonium persulfate

Sigma Aldrich, St. Louis, MO

Ampicillin

Sigma Aldrich, St. Louis, MO

Bacto Yeast Extract

BD Bioscience, Spark, MD

Bacto Tryptone

BD Bioscience, Spark, MD

β-Mercaptoethanol

Sigma Aldrich, St.Louis, MO

Bovine serum albumin

Promega, Madison, WI
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Bromophenol Blue

EMD Biosciences, San Diego, CA

Cell culture media

Mediatech, Herndon, VA

Coomassie blue

Sigma Aldrich, St. Louis, MO

Dithiothreitol

Shelton Scientific, Shelton, CT

Ethanol

AAPER Alcohol & Chemical,
Shelbyville, KY

Ethidium bromide

Sigma, St. Louis, MO

Ethylenedinitro-tetraacetic acid (EDTA)

Sigma Aldrich, St. Louis, MO

Ethylene glycol bis(2-aminoethyl
ether)-

N,N,N'N'-tetraacetic acid (EGTA)

Sigma Aldrich, St. Louis, MO

Fetal calf serum

Hyclone, Logan, UT

Formaldehyde

Calbiochem, San Diego, CA

FuGENE HD Transfection Reagent

Roche Applied Science, Indianapolis,
IN

Glycine

MP Biomedicals, Aurora, OH

Hydrochloric acid

VWR International, West Chester, PA

Imidazole

Sigma Aldrich, St. Louis, MO

Isopropyl-ß-D-thiogalactopyranosid

Sigma Aldrich, St. Louis, MO

Isopropanol

VWR International, West Chester, PA

Kanamycin

Sigma Aldrich, St. Louis, MO
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Lipofectamine 2000

Invitrogen, Grand Island, NY

Lipofectamine RNAimax

Invitrogen, Grand Island, NY

Lysozyme

Sigma Aldrich, St. Louis, MO

Magnesium/ATP Cocktail

Upstate, Charlottesville, VA

Magnesium Chloride

Fisher Biotech, Fairlawn, NJ

Methanol

VWR International, West Chester, PA

Methylene blue

Sigma Aldrich, St. Louis, MO

Molecular weight marker (DNA)

Fermentas, Glen Burnie, MA

Molecular weight marker (protein)

Fermentas, Glen Burnie, MA

N- (2-hydroxyethyl) piperazine-N`-(2-

Sigma Aldrich, St. Louis, MO

ethanesulfonic acid) (HEPES)
Nickel-nitrilotriacetic acid (Ni-NTA)

Qiagen, Valencia, CA

agarose
Nonidet P40

Roche Applied Science, Indianapolis,
IN

Oligonucleotides

Sigma-Genosys, Woodlands, TX

Penicillin-Streptomycin solutions

Mediatech, Herndon, VA

Phenol/Chloroform

Promega, Madison, WI

Phenylmethylsulfonyl fluoride

Fluka, Switzerland

Phosphatase inhibitor cocktail

Sigma Aldrich, St. Louis, MO

Phorbol 12-Myristate 13-acetate (PMA)

Promega, Madison, WI

Poly-L-lysine solution

Sigma Aldrich, St. Louis, MO

Ponceau S

Sigma Aldrich, St. Louis, MO
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2-Propanol

VWR International, West Chester, PA

Protease inhibitor cocktail

Sigma Aldrich, St. Louis, MO

Protein G agarose

Upstate, Charlottesville, VA

RNasin

Promega, Madison, WI

Sodium acetate

Promega, Madison, WI

Sodium azide

Fluka, Switzerland

Sodium bicarbonate

Sigma Aldrich, St. Louis, MO

Sodium chloride

Fisher BioReagent, Fairlawn, NJ

Sodium dodecyl sulfate

Fisher BioReagent, Fairlawn, NJ

Sodium fluoride

Fluka, Switzerland

Sodium hydroxide

Fisher BioReagent, Fairlawn, NJ

Sodium orthovanadate

EMD Biosciences, San Diego, CA

Sodium pyruvate

Cellgro, Herndon, VA

SYBR Green RT-PCR Master Mix

Applied Biosystems, Foster City, CA

Taxol

USB, Cleveland, OH

Tris base

Fisher Biotech, Fairlawn, NJ

Triton X-100

Sigma Aldrich, St. Louis, MO

Trypan Blue

Sigma Aldrich, St. Louis, MO

0.25% Trypsin-EDTA

Cellgro, Herndon, VA

Tween-20

Sigma Aldrich, St. Louis, MO

Urea

Fisher Biotech, Fairlawn, NJ

213
Table 5.5 Experimental Kits
Name of the kit

Company

Bio-Rad Protein Assay

Bio-Rad, Hercules, CA

BrDU Cell Proliferation assay

Calbiochem, Billerica, MA

ChIP-IT™ Chromatin Immunoprecipitation Kit

Active Motif, Carlsbad, CA

Improm-II Reverse Transcription System

Promega, Madison, WI

Nuclear Extraction Kit

Active Motif, Carlsbad, CA

RNeasy® Mini Kit

Qiagen, Valencia, CA

QIAprep Spin Miniprep Kit

Qiagen, Valencia, CA

QIAquick Gel Extraction Kit

Qiagen, Valencia, CA

QuikChange® II Site-Directed Mutagenesis

Stratagene, Cedar reek, TX

Kit
Quick-ChIP Kit

Imgenex, San Diego, CA

Wizard® plus DNA purification System

Promega, Madison, WI
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Table 5.6 Laboratory Equipments
Name of the Euipment

Company

AllegraTM 6R Centrifuge

Beckman Coulter, Fullerton, CA

C25 Incubator shaker

NewBrunswick Scientific, Edison, NJ

EpiChemi3™ Darkroom Bioimaging System

UVP, Inc., Upland, CA

Eppendorf Centrifuge 5415D

Eppendorf AG, Hamburg, Germany

Eppendorf Mastercycler

Eppendorf AG, Hamburg, Germany

Mini-PROTEAN® II Electrophoresis Cell

Biorad Laboratories, Hercules, CA

NuAire™ CO2 Water-Jacketed Incubator

NuAire, Plymouth, MN

Purifier Class II Biosafety Cabinet

Labconco, Kansas City, MO

Centrifuge

Thermo Electron Corporation,
Asheville, NC

Sonic Dismembrator 500

Fisherscientific, Fairlawn, NJ

UV-1700 UV-Visible Spectrophotometer

Shimadzu Corporation, Kyoto, Japan

Victor3V 1420 Multilabel Counter PerkinElmer

PerkinElmer, Waltham, MA

